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ABSTRACT 
 
The overall scope of this thesis is to consider the relationship between knowledge, space 
and technology in the „knowledge economy‟ by drawing upon biotechnology value 
chains as a case study of the knowledge economy. Central to this is the claim that 
although biotechnology is an internationally distributed sector, it is also concentrated in 
specific places because those locations provide an advantage through dynamic innovation 
processes. Such processes are embedded in places because those places have a particular 
set of knowledge inputs and provide access to other knowledge inputs outwith those 
places. In this sense, the knowledge economy can be seen as dependent upon different 
places and scales that all contribute to the innovation process and therefore necessitate 
relationships within and between different and diverse locations.  
 
The major contribution to knowledge that the thesis provides is the development of a new 
conceptual understanding of innovation processes called the knowledge-space dynamic 
that focuses on the knowledge and spatial features of the innovation process rather than 
assuming that the concentration of innovation necessarily entails specific knowledge and 
spatial characteristics. Consequently the thesis picks apart the current emphasis on certain 
types of knowledge (e.g. tacit and explicit) to explore the ways in which these are 
combined in the innovation process and embedded in particular places. Thus the research 
approach in the thesis adopts a new methdological framework to collect and analyse 
secondary and primary data that has not been previously undertaken. Overall the thesis 
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conclusion is that the knowledge economy – and especially the biotech industry – may 
not represent the best method for regional development. 
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CHAPTER 1 
INTRODUCING THE KNOWLEDGE ECONOMY 
 
“Most of us make our money from thin air: we produce nothing that can be 
weighed, touched or easily measured. Our output is not stockpiled at harbours, 
stored in warehouses or shipped in railway cars.” (Leadbeater 1999: viii). 
 
1.1 INTRODUCTION 
 
As the world economy has globalised through direct and indirect state support for global 
institutional bodies like the General Agreement on Trade and Tariffs (GATT) and the 
World Trade Organisation (WTO), local and regional economies have been presented as 
increasingly important sites of industrial research and production (see Scott 2000a, b; 
Dicken 2003; Scott and Storper 2003). These changes have been associated with 
declining manufacturing and industrial bases in advanced economies as 
deindustrialisation in such countries (see Williams 1992) has led to an increasing reliance 
on the service sector as well as the „new economy‟ and „creative‟ industries (e.g. 
Leadbeater 1999; Rifkin 2001). In the United Kingdom (UK), for example, the number of 
people employed in manufacturing jobs fell by over 1 million between 1996 and 2005 
and now represents less than 12% of total employment (Cumbers et al 2006). The long-
term trends are evident across much of Western Europe as Table 1.1 illustrates. 
However, perhaps more significantly, the changing economic structure of these countries 
is unevenly spread across regions. Some locations are witnessing higher rates of 
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deindustrialisation and lower levels of service sector growth compared with others which 
is reproducing and embedding uneven economic development.  
 
Table 1.1 Industrial Employment in Western Europe 1965-1995 
 Relative Industrial Labour Force (%) 
  1965 1975 1985 1995 
Austria 45 n.a. 38.1 35.4 
Belgium 46 39.9 31.8 28.3 
Denmark 37 31.5 27.9 27.1 
Finland 36 n.a. 31.9 27.9 
France 39 38.7 32.4 26.9 
F.R. Germany 48 46 41 36 
Greece 24 29.2 25.7 23.2 
Ireland 28 30.5 30 31.4 
Italy 42 39.1 33.5 32.1 
Luxembourg n.a. 46.3 32 25.5 
Netherlands 41 34.6 28.2 22.8 
Portugal 31 33.8 33.9 32.2 
Spain 35 38.3 31.8 30.2 
Sweden 43 n.a. 29.9 26.6 
United Kingdom 47 40.7 34.6 27.4 
EU15 n.a. n.a. n.a. 30.3 
 
Source: Adapted from Williams (1992: 51) for 1965 and Hudson (1999a: 33) for 1975-
1995. 
Note: n.a. means “not available”. 
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The changing economic structure of these societies has been variously described by a 
number of commentators over the last fifty years as a shift to „post-industrial society‟, 
„post-Fordism‟, „information society‟, „knowledge-based economy‟ and now the 
„knowledge economy‟ (see Webster 1995; Sokol 2003, 2004; Godin 2006). In these 
theories one characteristic stands out, namely the importance of knowledge and 
technology to economic change. For these „knowledge economies‟ the loss of 
comparative advantage to „newly industrialising‟ and emerging global centres of 
manufacturing in the Far East, South America and, more recently, Eastern Europe has 
centred on the lower labour costs in these economies. Consequently, the differences 
between „developed‟ and „developing‟ economies has produced a new international 
division of labour in which head office activities such as research and development 
(R&D), marketing and decision-making are performed in developed economies, whilst 
manufacturing and assembly is performed in developing economies (Simmie 2003). Thus 
in the 1990s the Organisation for Economic Co-operation and Development (OECD) 
argued that about half of its members‟ economies were now „knowledge-based‟ with the 
growth rate in such industries outpacing overall growth rates (OECD 1996, 1999b). 
Furthermore the World Bank contended that “knowledge has become the most important 
factor determining the standard of living” (quoted in DTI 1999c: 11).  
 
As mentioned above, the spatial distribution of the knowledge economy, in terms of 
specific industrial sectors and knowledge production sites (e.g. research organisations), is 
as uneven as in any other economic activity, including resource dependent industries, 
across both the world and national economies (Fagerberg 2005). Consequently to 
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understand the role of knowledge in economic development we need to consider its 
embedding in space. In classic formulations of knowledge as an economic input it is 
presented as both non-rivalrous and non-excludable in that it is difficult to stop others 
from using knowledge you produce and that the use of knowledge does not deplete it 
(Malecki 1997; Jessop 2000). Consequently there should be few barriers to the use of 
knowledge across different regions and countries, implying that an uneven distribution of 
knowledge industries should not occur. However, because such an uneven distribution 
does exist and persist, several authors have argued that we need to understand the 
different spatial embedding of different knowledge. Thus different forms of knowledge – 
usually identified on a continuum from codified (or explicit) to tacit (Polanyi 1973, 
Senker and Faulkner 1996) – can be seen as particular to specific places (e.g. Howells 
2002; Lever 2002; Gertler 2003; Asheim and Gertler 2005; Fagerberg 2005).  
 
The overall aim of this thesis is to address a number of these issues by exploring the 
relationship between knowledge, space and technology using the British biotechnology 
industry as a case study in the knowledge economy. The central hypothesis is that 
although the biotechnology industry is an internationally distributed sector, innovation is 
concentrated in specific places because those locations provide an advantage through a 
knowledge-space dynamic that features functional, relational and associational 
characteristics. The thesis seeks to explain the knowledge and spatial processes involved 
in biotechnology innovation as well as how and why they are concentrated in particular 
places (Chapter 5). It then considers how such place-specific processes operate across 
difference spaces and scales necessitating interaction both within and beyond these 
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concentrations of innovation (Chapter 6). Finally, it addresses the question of how the 
knowledge economy depends on different spaces and scales because of the positioning 
and embedding of innovative „assets‟ across and within these spaces and scales (Chapters 
4, 5 and 6).  
 
1.2 THE KNOWLEDGE ECONOMY 
 
Since the 1950s and the work of Robert Solow, knowledge has been recognised as an 
important driver of economic growth. Subsequent theories and concepts like the 
„information society‟, „knowledge-based economy‟ and „knowledge economy‟ reflect a 
growing concern with such issues as well as the growing importance of the production 
and utilisation of knowledge (Temple 1999; Brint 2001; Soete 2002; Simmie 2003; Sokol 
2003, 2004; Godin 2006). According to Cooke and Leydesdorff (2006) the concept of the 
knowledge economy originates in the 1950s and has a long pedigree that is perhaps 
obfuscated by more recent discussions. In the European Union (EU), the knowledge 
economy has been identified by regional, national and European governments as a vital 
element in economic development because of the structural changes in advanced 
economies; i.e. declining manufacturing employment and rising service sector 
employment (EC 2002). For example, in its 1998 Competitiveness White Paper Our 
Competitive Future the British government defined the „knowledge-driven economy‟ as; 
 
“…one in which the generation and the exploitation of knowledge has come to 
play the predominant part in the creation of wealth. It is not simply about pushing 
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back the frontiers of knowledge; it is also about the more effective use and 
exploitation of all types of knowledge in all manner of economic activity” (DTI 
1998) 
 
Several features of this knowledge economy were highlighted as particularly important 
including (a) the development of information and communication technologies (ICT), (b) 
the role of new scientific knowledge, (c) the growth in global competition, and (d) 
changing patterns of consumption based on increased incomes (DTI 1999c: 12). These 
four characteristics may appear arbitrary – they are also contentious for a number of 
reasons (Sokol 2004; Thompson 2004) – but they do illustrate the view that the factors 
relied upon by developed economies are different from those relied upon by industry 
dominated economies. These factors are largely presented as intangible, „weightless‟ or 
as Charles Leadbeater (1999: viii) contends we “make our money from thin air” (see also 
Rifkin 2001). 
 
The empirical definition of the knowledge economy has consisted of different metrics 
(e.g. employment, expenditure on ICT), but more generally concentrates on both high-
tech manufacturing and services sectors. These include aerospace, telecommunications, 
information technology (IT), pharmaceuticals, biotechnology, old and new media, 
advanced business services, and creative/cultural industries (Cooke 2004d), as well as 
education and healthcare and other public or non-profit services (see Malecki 2000; 
Cooke 2002c).  Such sectors are characterised as knowledge sectors because of the higher 
than usual research intensity (i.e. R&D expenditure as proportion of revenue) and higher 
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levels of scientific and technical employment, both of which are meant to indicate a 
higher level of innovativeness and creativity (Rifkin 1996; Malecki 1997; Florida 2002). 
However, there is little to distinguish the empirical definition of the knowledge economy 
from its theoretical use since so much of the discussion is based on technologically 
determinist concepts. The assumption that the definition of the knowledge economy is 
constituted by innovation and technological change can therefore be seen as problematic 
(Sokol 2004). 
 
Consequently, the central identifying feature of the knowledge economy concept is the 
role innovation plays in economic performance at a firm level and the role of innovative 
firms in economic performance at a geographic scale (Cooke 2002c; Simmie 2003; 
Asheim and Gertler 2005; Fagerberg 2005). Innovation can be characterised in a number 
of ways, as outlined below: 
 
 Schumpeter (1942) argues it is “new commodities, new technologies, new 
sources of supply and new types of organisation” (quoted in Simmie 2001: 
14). 
 European Commission (1996) defines it as “the commercially successful 
exploitation of new technologies, ideas or methods through the introduction of 
new products or processes, or through the improvement of existing ones.” 
(quoted in Simmie 2005: 790). 
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 Fagerberg (2005: 6-7) writes of “new products, new methods of production, 
new sources of supply, the exploitation of new markets, and new ways to 
organize business.” 
 Gordon and McCann (2005) suggest it covers “the successful implementation 
of a new product, service, or process, which for most activities entails their 
commercial success.” 
 
Distinctions are also made between product and process innovation (Malecki 1997) and 
between radical and incremental innovation that highlights the importance of diffusion 
(Freeman 1982). It is therefore evident that there are a number of different ways to 
conceptualise innovation, but that they all contain similar themes, such as an emphasis on 
„newness‟ and consequently uncertainty as well as learning (Malecki 2000; Cooke 2002c; 
Fagerberg 2005; Gordon and McCann 2005). However, this conceptual emphasis 
reinforces the perception that technological change directs economic change and 
reinforces the emphasis placed on innovation.  
 
Innovation is seen as central to the knowledge economy in that it represents the end point 
of economic development because it can be seen as “the transformation of knowledge 
into novel wealth-creating technologies, products and services through processes of 
learning and searching” (Asheim and Coenen 2006: 149).  Thus innovation is distinct 
from knowledge in that it concerns the production of economic value (e.g. wealth), 
whereas knowledge represents the capacity for and organisation of understandings about 
the world (see Nonaka and Takeuchi 1995). Thus, although the definition of the 
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knowledge economy is ambiguous, it can be usefully defined as the commercialisation of 
„new‟ understandings as a resource through the capture of existing and expected future 
knowledge by the adaptation of institutional systems like intellectual property (IP) (see 
Drahos and Braithewaite 2002, 2004). It therefore entails the production of both 
commodities (intangible and tangible) and markets through investments in R&D, 
organisational change, marketing etc. In this sense, technological change and innovation 
do not necessarily represent Schumpeterian „creative destruction‟, but rather the daily 
operation of the knowledge economy simultaneously across sectors rather than in the 
linear model of one sector superseding another. It is therefore too simple to argue that one 
set of structures produces advantages for some and disadvantages for others since 
innovation occurs across sectors and structures (Cooke 2002c). Thus technological 
change and innovation are continual processes (Nelson and Winter 1974, 1982; Dosi 
1988; Tödtling 1994). Alongside other sectors like IT, telecommunications and new 
media, the „modern biotechnology‟ industry is one in which innovation is constant. For 
this and other reasons it lends itself well to the study of the relationship between 
knowledge and space.  
 
1.3 THE KNOWLEDGE ‘BIO’-ECONOMY 
 
In discussions of the knowledge economy and innovation there are a number of sectors 
that are repeatedly cited as examples. One such example is the biotechnology industry. In 
the last few years, the industry has gradually been redefined as the „bioscience‟ industry 
and now „life science‟ industry as researchers and policy-makers have sought to 
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encompass a broader range of economic activity within it. Despite the greater breadth in 
these later definitions, the focus of attention is still on the scientific and technological 
derivatives of post-1953 research in genetics, molecular biology, biochemistry and more 
recent disciplines like bioinformatics, genomics and proteomics. These depend on 
discoveries in recombinant DNA, cell fusion, protein engineering, recombinatorial 
chemistry and other such technologies (House of Lords 1993; Woiceshyn 1995). In the 
UK the biotech industry was originally defined in terms of the application of the 
biological sciences to industrial production (see ACARD et al 1980) with later definitions 
conceptualised in “enabling” terms that have persisted (House of Lords 1993). In two 
important Department of Trade and Industry (DTI) reports, Biotechnology Clusters 
(1999a) and Genome Valley (DTI 1999b), biotechnology was similarly defined as “the 
application of knowledge about living organisms, and their components, to make new 
products and to develop new industrial processes” (DTI 1999a: 1).  
 
As an industry, biotechnology presents a useful example of the knowledge economy for 
two primary reasons; first, it relies on high levels of sophisticated scientific knowledge 
and, second, it relies on a highly educated workforce (Audretsch and Stephan 1996, 1999; 
Bartholomew 1997; Prevezer 1997; McKelvey et al 2004). It has always been unevenly 
distributed with major sites of activity in particular places like California and 
Massachusetts in the USA and Cambridgeshire in Europe, which have persisted as the 
industry has matured (Prevezer 2003; Cooke 2004a). Several authors have suggested that 
such concentrations persist because of the nature of the knowledge being used in the 
biotech industry; it is dependent upon people, especially „star‟ scientists (Zucker et al 
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1998) and relies upon a specific set of intellectual property rights (IPR) (Fuller 2001; 
Drahos and Braithwaite 2002). Without these aspects the knowledge used in 
biotechnology innovation would be available to every interested party, so innovators have 
to ensure that biotech knowledge is appropriable (Zucker et al 1998; Audretsch and 
Stephan 1999). Consequently the importance of scientists and IPR means that 
biotechnology can be commercialised, providing an incentive for private capital to invest 
in innovative activity (MacKenzie et al 1990; Heller and Eisenberg 1998; Hughes 2001). 
 
Although there has been a great deal of enthusiasm and expectation surrounding the 
biotechnology industry in the 1990s (e.g. DTI 1999a) and the early 2000s (e.g. Boulnois 
2000; BIGT 2003), more recent analyses have questioned the innovative and economic 
performance of the sector (see Arundel and Mintzes 2004; FDA 2004; Nightingale and 
Martin 2004; Joppi et al 2005). The innovativeness of biotech is therefore neither 
uncontested nor the simple technological progression of knowledge and its application. 
Rather there are a number of material and institutional features of the biotech innovation 
process that impact on and constitute the biotech industry producing both positive and 
negative effects on the direction of technology (see Arthur 1989, 1999; Cooke 2002c). 
Considering these systemic effects in dynamic terms through concepts drawn from 
evolutionary economics necessitates a consideration of path dependency and 
technological lock-in (Nelson and Winter 1974, 1982; Dosi 1988). However, in order to 
consider the role of knowledge we must add a spatial dimension to these systemic and 
dynamic features and this is something that evolutionary economics does not contain, 
although some authors have tried to theorise it (e.g. Boschma and Lambooy 1999; 
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Boschma 2004). Therefore it is important to consider the geographical basis of the 
knowledge economy, especially in terms that seek to explain how and why certain 
locations dominate certain sectors.  
 
1.4 THE GEOGRAPHY OF THE KNOWLEDGE ECONOMY 
 
The knowledge economy consists of organisations that need the capability to acquire, 
absorb, learn from, utilise and then unlearn knowledge (see Cohen and Levinthal 1990; 
Morgan 1997). These provide the means for organisations, particularly companies, to 
dynamically change and adapt as necessary with the „environmental‟ pressures (see 
Nelson and Winter 1974, 1982). However, such firms are also spatially embedded and 
this necessitates the consideration of the geography of organisational capabilities, 
particularly the inter-organisational linkages between different organisation types (e.g. 
firms, public research bodies). Without such capabilities and linkages these organisations 
would not be able to function because innovative activity relies upon (1) access to a 
diverse range of knowledge, (2) access to new knowledge in order to maintain continuous 
innovation, and (3) iterative interaction between knowledge sites or nodes (von Hippel 
1988, 1994; Scott 1998b). It is therefore possible to argue that the knowledge economy is 
spatially constituted because people in organisations rely upon access to and interaction 
with these different sites of knowledge. This necessitates an approach to knowledge that 
incorporates an understanding of the role of external organisations, institutions and 
agglomerations in providing people with the means to benefit from systemic relationships 
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that cut across different organisational types and geographical scales (Gibbons et al 1994; 
Audretsch and Stephan 1996).  
 
At a local level, organisations can gain access to other organisational knowledge through 
positive externalities such as „knowledge spillovers‟ whereby knowledge produced and 
used in one organisation escapes organisational boundaries through labour mobility and 
market interaction. Other organisations can then acquire and adapt this knowledge to 
their own organisational needs, but they need to be „open‟ to new knowledge (see 
Chesborough 2003) and therefore subject to knowledge escape themselves. Patent 
citations have been used as a means to track the geography of such spillovers with Jaffe 
and Tratjenberg (2002) showing that there is a distinct time and location lag between 
patent publication and citation by another patent. Other research in endogenous growth 
theory has also placed an emphasis on the importance of knowledge spillovers (e.g. 
Romer 1990, 1994; Grossman and Helpman 1994), although Acs et al (1991) have 
argued that spillovers cannot explain the process of knowledge transfer from universities 
to firms (see also Acs et al 1999). However, Krugman (1991) argued that spillovers are 
not the only factor that makes certain locations attractive meaning that they do not offer a 
full explanation for the geography of the knowledge economy.   
 
Instead of focusing on the organisational level, other authors have emphasised the 
importance of the institutional features of locations, whether at a global, national or 
regional scale. In the first case, the creation of specific global IPR regimes, such as 
TRIPS at the WTO (Drahos and Braithewaite 2002), and regulatory systems, such as 
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pharmaceutical regulations in the EU which are designed to enhance competitiveness 
(Abraham and Reed 2002, 2003), produce „institutional thickness‟ that promotes 
innovation (Amin and Thrift 1992, 1994; Keeble et al 1999). The national case has been 
explored in relation to both the „varieties of capitalism‟ (Hall and Soskice 2003) and 
national systems of innovation perspectives (Lundvall 1992). In the latter theory the 
importance of different national features to innovation is explored in reference to 
innovation with „social market‟ countries like Germany pursuing incremental innovation 
whilst „liberal market‟ countries like the USA pursue radical innovation (Gertler 1997, 
2001). At the local scale these analyses focus on the embeddedness of organisations in 
local institutions that promote the development of trust and social capital through the 
increasing probability and encouragement of interaction between co-located organisations 
(Amin and Thrift 1992; Amin 1999). Such embeddedness does not mean that 
organisations operate at an isolated scale, but rather that the local is constituted by its 
relationship to the global (Amin and Thrift 1994). 
 
The final set of theories emphasise the geographical basis of organisational activity in 
terms of concepts like agglomeration, which originated in the work of Alfred Marshall 
and Alfred Weber in the nineteenth century. Here specific activity is located in specific 
locations because of the benefits that accrue to those organisations in those places 
through economies of scope and scale. These can include shared local resources, shared 
local services and labour markets, as well as knowledge spillovers (Simmie 2001). Later 
theoretical work in agglomeration economies distinguished among internal returns to 
scale, as well as localisation and urbanisation economies (Hoover 1937). Thus on the one 
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hand, organisations that locate near similar organisations benefit from shared inputs, 
whilst organisations that locate near different organisations benefit from the diversity of 
inputs. There are numerous possible explanations of the benefits that accrue from co-
location that cut across material and relational factors. In terms of innovation and 
knowledge these could consist of the importance of „learning through interaction‟ 
through the difficulty of transferring knowledge across distance to the importance of 
face-to-face relationships in transferring knowledge and developing trust (Asheim and 
Gertler 2005). Several authors have built on the national systems theories to suggest that 
there are regional innovation systems (e.g. Cooke 2004d) or learning regions (Florida 
1995; Morgan 1997). Perhaps the most famous example is the work of Porter (1990, 
2000, 2003; Porter and Solvell 1998) on „clusters‟ of industrial activity, which 
emphasises the importance of local linkages both along the „value chain‟ and across local 
organisations. All these theories have been applied to the biotech industry in one form or 
another, although they have, in turn, raised a number of further issues and problems in 
explaining satisfactorily the spatial embedding of biotech innovation processes. 
 
1.5 CENTRAL THEORETICAL AND EMPIRICAL PROBLEMS 
 
Social science research on the biotechnology industry can be broadly split into a series of 
phases stretching from early work on management strategy through innovation systems to 
the more recent emphasis on knowledge spillovers (see Senker 2005). Throughout these 
phases there has been continuing interest in the political economy of biotechnology (e.g. 
Kettler and Casper 2000; Loeppky 2004, 2005; Lofgren and Benner 2005). Both strategic 
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management and innovation systems approaches focus on the acquisition and use of 
biotech knowledge by biotech and pharmaceutical firms. They also focus on the 
differential impact of internal firm capabilities and the complementarities of external firm 
collaborations (e.g. Deeds and Hill 1996; Prevezer and Toker 1996; Sharp 1996; Saviotti 
1998). Such analyses are not concerned with geographical aspects except at the broadest 
national scale. The more recent spillovers approach is oriented towards the regional scale, 
although because it adheres to a systems perspective it does not adequately address the 
relationship between different scales. The ongoing approach drawn from political 
economy obviously concentrates on national differences, although it also considers the 
important role of supranational and increasingly international governance as well (e.g. 
Loeppky 2004, 2005).  
 
In the strategic management literature, there is a focus on the importance and role of 
networks, collaboration and alliances to firms (see della Valle and Gambardella 1993; 
Powell et al 1996; Powell 1998; Chiesa and Toletti 2004; Powell et al 2004). Such 
interactions provide the means to access capabilities that firms and other organisations do 
not have like marketing and manufacturing particularly in the case of dedicated biotech 
firms (DBFs) (Woiceshyn 1995). They also mean that DBFs can avoid some of the 
uncertainty and offset their risks during innovation (Chakrabarti and Weisenfeld 1991). 
Furthermore they necessitate that firms remain „open‟ to external knowledge which helps 
to prevent lock-in (Cooke 2005a, 2005b, 2006) but may also entail a loss of proprietary 
knowledge. Ironically this means that knowledge excludability is particularly important 
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to DBFs in the form of either strong IP protection (May 2000) or tacit knowledge from 
scientists (Zucker et al 1998).  
 
Despite the range of the strategic management literature, there are a number of important 
gaps in the research. First, they concentrate on social networks rather than spatial 
networks, which downplays the importance of space in social interactions. A second gap 
results from the atomistic approach to understanding organisational activity in that there 
is little consideration of how innovation occurs systematically through the interaction 
among a range of organisations and not just those involved in a direct relationship. 
Finally, the understanding of innovation and knowledge is largely static consisting of an 
analysis of a single time-dependent relationship. In this thesis these issues are addressed 
with the first hypothesis, which is:  
 
H1: There are „knowledge economy‟ concentrations because successful 
innovation depends on dynamic (i.e. across time) and systemic (i.e. across 
organisations) processes embedded in and across specific places. 
 
The innovation studies literature presents a systemic approach to understanding 
innovation that draws upon work in evolutionary economics and science studies 
(Fagerberg 2005). Several authors argue that different national or supra-national scales 
entail specific innovation systems that benefit biotech firms operating within them. This 
provides a competitive advantage for certain locations such as the characterisation of the 
USA as a beneficial biotech environment compared with Europe (e.g. Senker et al 1996; 
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Sharp 1996; Acharya et al 1998; Saviotti et al 1998; Sharp and Senker 1999). One 
distinctive theory in this field is Etzowitz and Leydesdorff‟s (2000) Triple Helix model in 
which university, industry and government combine to produce a particular innovation 
system for biotechnology. Again there are a number of difficulties with this literature. 
First, such innovation systems remain loosely defined and when they are applied to 
specific locations they remain a „fuzzy‟ concept (Markusen 2003) that ignores national or 
global scale actors (Lovering 1999) and presents analytical explanations as descriptions 
that normalise local policy prescriptions (Lovering 1999, 2001). Second, the tendency to 
normalise explanations also leads to the reversal of causality in that the location of the 
system is argued to be the reason for innovative activity (Malmberg and Maskell 2002). 
At a regional scale, according to Frank Moulaert and Farid Sekia, this is because:  
 
“The conceptual superficiality of the TIM [territorial innovation model] literature 
is a consequence of several factors such as the immediate links with regional 
economic competition policy (many TIM were written to legitimize it)” (Moulaert 
and Sekia 2003: 295). 
 
Finally, the concentration on a system as the source of innovation leads to a supply-side 
focus that treats sources of demand as external or less significant than the endogenous 
qualities of the system or particular location. In this thesis these issues are addressed with 
the second hypothesis, which is: 
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H2: Successful innovation in the knowledge economy depends on place-
specific dynamic and systemic processes because different types of 
knowledge originate in different places and at different scales 
necessitating interaction both within and beyond concentrations.  
 
The final set of literature on biotechnology concerns industrial clusters. Porter (1990: 41) 
defines clusters as a “a network of activities, connected by linkages” that combine 
different activities within the firm and with external organisations (e.g. suppliers, 
customers). In his later work, Porter (2000) concentrates more on spatial clusters in 
contrast to his early focus on sectoral ones (see Malmberg 2003), which has been 
liberally applied as an explanation for the location of the biotech industry. Within this 
literature there is an emphasis on several common characteristics that derived from the 
importance of localised, informal and tacit knowledge exchange between cognate firms, 
supply/service firms, public sector and other organisations (see Ryan and Phillips 2004). 
Some common features include: 
   
 Concentrations of dedicated biotech firms (DBFs); usually small or medium 
sized enterprises (SMEs) 
 Concentrations of „upstream‟ and „downstream‟ competencies (e.g. 
universities, large pharmaceutical firms) 
 Local linkages between the organisations as well as with local service 
providers (e.g. lawyers, accountants, consultants) 
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 Local identity fostered by local government or through trade associations and 
networks 
 Local government involvement in the promotion of a „cluster‟ approach to 
economic development.  
 
These features are stylised representations of a number of different theories. Many of 
these also emphasise the importance of extra-local linkages, in contrast to Porter‟s cluster 
argument, in acquiring knowledge and knowledge workers (Lawton-Smith et al 2000; 
Cooke 2004b; Leibovitz 2004; McKelvey et al 2004). There are once again a number of 
problems with this approach. First, the focus on a particular location tends to not only 
limit the analysis of extra-local linkages, but also leads to a loss of comparative 
perspectives as research concentrates on one location to the exclusion of others. Second, 
the concentration on one location leads to the conceptualisation of that location as an 
agent in regional economic performance; i.e. local assets lead to successful outcomes. 
Finally then, the treatment of a location as an actor tends to produce descriptive research 
that concentrates on what happens in that location and not how processes function in that 
location (i.e. explanatory research). In this thesis these issues are addressed with the third 
hypothesis, which is: 
 
H3: The knowledge economy depends on different locations and scales of 
knowledge because different places have different locational assets that 
contribute to successful innovation in different ways and therefore 
necessitate linkages between locations. 
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1.6 CONCLUSION AND THESIS SUMMARY 
 
The overall aim of this thesis is to explore the relationship between knowledge and space 
using the British biotechnology industry as a case study of the knowledge economy. The 
main reason to do this is to synthesise different approaches in order to avoid a number of 
theoretical and empirical issues that existing research has encountered in understanding 
both knowledge and space and the relationship between them. In the next seven chapters 
I will develop and apply an approach that combines theories of knowledge and theories of 
space into a conceptual perspective that can be applied to understanding the knowledge-
space dynamic in terms that address existing theoretical and empirical concerns. This 
new conceptual approach will combine elements of existing functional, relational and 
associational theories drawn from a range of disciplines including economics, economic 
geography, regional studies, management studies, and economic sociology. The three 
core hypotheses raise questions about whether the biotech industry is concentrated in 
particular places and asks if so what are the specific features of these places. They also 
concern the nature of the relationship between different types of knowledge and different 
places. Finally they consider why different types of knowledge and places impact on 
innovation in different ways and how the relationship between places may affect this.  
 
The thesis explores how and why the knowledge economy is positioned and embedded in 
different places. This is achieved uniquely by focusing on the knowledge and spatial 
processes of biotechnology innovation, rather than by assuming that such concentrations 
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by necessity entail such processes. Consequently it highlights the processes that are 
traditionally accepted to underpin the concentration of „knowledge‟ industries like 
biotechnology. Furthermore, the thesis uses a new theoretical approach called the 
knowledge-space dynamic drawing from a diverse number of disciplines (Chapter 2). 
This directly impacts on the research design and methodological framework (Chapter 3). 
Using this theoretical and methodological approach, the thesis contains a set of 
background (Chapter 4), secondary data (Chapter 5) and primary data (Chapter 6) that 
have not been gathered toegther in one project before.  
 
The first section of the thesis (Part I) concerns the theoretical and methodological 
grounding of the research approach. The former is fully laid out in Chapter 2 bringing 
together theories of knowledge and space into a new conceptual approach that can 
address the knowledge-space dynamic inherent to the knowledge economy. This will 
draw on previous work in economics, economic geography and economic sociology as 
well as cognate disciplines. Chapter 3 follows directly on from this by outlining a 
methodological approach that incorporates secondary and primary data collection along 
biotechnology value chains. The core of the thesis (Part II) consists of background and 
data analysis chapters. Chapter 4 provides historical background and well as the global 
and institutional context of the British biotech industry. In Chapter 5 the data analysis 
concentrates on secondary data concerning the location of the British biotech industry, 
which includes a number of different variables that impact on innovation processes. 
Finally, Chapter 6 concerns the results of the primary research from a survey of actors 
drawn from biotech value chains. In the final section (Part III), the main findings and 
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conclusions are summarised in Chapter 7 before these are used to consider a number of 
policy implications.  
 
The major findings of the research show that the biotech industry is not as significant an 
industrial sector as many policy and popular discourses would suggest. For a start, the 
global industry has never been profitable (Ernst & Young 2003c; Lahteenmaki and 
Lawrence 2006) and the latest figures show global net losses of $4.39 billion (Lawrence 
2006: 603). Its impact on employment is also relatively small with less than 45,000 total 
employees and around 10,000 „knowledge workers‟ (i.e. those in R&D) in the UK. Since 
the UK only has around 430 firms no UK region, even at the relatively large NUTS1 
scale,
i
 has more than 105 firms; this implies that biotech „clustering‟ is limited. However, 
four regions (South East, East England, London and Scotland) have more than the 
average number of firms, university departments, public research organisations and 
service providers, and as such it could be argued that they represent clusters. Their 
significance for regional economic performance is another issue. In terms of the 
relationship between knowledge and space, there was little to indicate that innovators 
drew exclusively upon localised sources of either tacit or explicit knowledge, nor that 
they necessarily combined local sources with international ones. Overall the research 
showed that there was not a localised concentration of biotechnology knowledge, but 
rather that innovators and firms drew upon a variety of knowledge sources and types 
from a variety of places.  
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PART I  
Theory and Methodology 
 
This section of the thesis concerns the development of the theoretical and methodological 
approach used to construct the three hypotheses already outlined in Chapter 1 and how 
these have been addressed in the research design. The theoretical approach provided in 
Chapter 2 is centred on the concept of the knowledge-space dynamic, which concerns the 
spatial specificity of different types and forms of knowledge and how the spatial and 
scalar positioning and embedding of these knowledges impact on the innovation process. 
The methodological approach detailed in Chapter 3 builds on this theory in a framework 
that incorporates a number of features from different theories and concepts including a 
value chains, innovation systems and biotechnology innovation approaches. These all 
contribute to the research design that is discussed in the rest of the chapter. The 
framework is built upon a case study that uses biotech values chains (i.e. biotechnology 
products) as an example of the knowledge economy and enables the exploration of how 
knowledge and space relate to one another in the innovation process.  
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CHAPTER 2 
DEVELOPING THE KNOWLEDGE-SPACE DYNAMIC: 
THEORETICAL DISCUSSION 
 
2.1 INTRODUCTION 
 
As economic theories have developed throughout the twentieth century the role of 
knowledge has been positioned as an increasingly prominent driver of economic growth 
and development. Such emphasis is not a uniquely modern concern since Adam Smith 
(1723-1790) in the Wealth of Nations highlighted the importance of specialisation that: 
 
“…increases the competition of the producers, who, in order to undersell one 
another, have recourse to new divisions of labour and new improvements of art” 
(quoted in Best 2001: 61). 
 
Furthermore, Alfred Marshall (1842-1924), writing over a century later, emphasised the 
importance of knowledge as a driver of economic growth and the „fourth factor of 
production‟ that attracts producers to particular places (Freeman 1982; Best 2001). 
Despite such concerns with knowledge and especially Marshall‟s interest with its 
interdependence with place, knowledge has only really become a particular policy 
concern more recently and especially after World War II with the onset of industrial 
restructuring and globalising markets (see Howells 1997). Such policy interest has 
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developed through a number of different theoretical phases to the current focus on the 
„knowledge-based‟, „knowledge-driven‟ or „knowledge economy‟. Although there are 
terminological similarities between these concepts they do not necessarily mean the same 
thing (see Cooke and Leydesdorff 2006).  
 
In recent policy discourse at the national, supranational and international levels the 
knowledge economy has achieved hegemonic dominance despite a number of 
problematic concerns with the concept and its policy implications. For example, recent 
policy discourse (e.g. OECD 1996, 2005; DTI 1998; HM Treasury 2003; House of 
Commons 2003; Rodrigues 2003; Rosiello 2004; Scottish Enterprise 2004; EC 2005) 
emphasises the particular role of the public science base with academic research 
highlighted as crucial, especially in relation to government defence expenditure (Hall 
1997) and, more recently, health expenditure (Etzkowitz and Leydesdorff 2000). Implicit 
within the knowledge economy therefore is the connection between the public and private 
sectors. For example, in relation to biotechnology the National Health Service (NHS) has 
been championed as a nationally specific resource for the UK (BIGT 2003; DoH 2003 
Vince 2006). Furthermore the knowledge economy has been promoted in policies 
focused on the role of universities in regional economic development especially by 
Regional Development Agencies (RDAs) (Goddard and Chatterton 1999; Potts 2002). 
 
This Chapter outlines the analytical foundations for the thesis by developing a theoretical 
framework that underpins the thesis hypotheses and research questions. The Chapter 
starts (2.2) with a brief history of „knowledge economy‟ theory from the early work by 
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Machlup (1962) through to the current emphasis on the knowledge-based economy, all of 
which stress the role that knowledge and information have on economic development 
generally. Second it outlines (2.3) how innovation contributes to economic growth at the 
level of the firm. This sets the stage for the consideration of how both knowledge (2.4) 
and space (2.5) impact on the innovation process. These discussions then feed into the 
analytical perspective I have called the knowledge-space dynamic (2.6) which seeks to 
combine aspects of both knowledge and spatial theories of innovation. Subsequently this 
approach is used to develop a conceptual framework (2.7) that raises a number of 
research questions in pursuit of the central thesis hypothesis: 
 
Despite being an internationally distributed sector, biotechnology innovation is 
concentrated in regional nodes because these locations provide advantage through 
a knowledge-space dynamic that encompasses functional, relational and 
associational features. 
 
Finally, the conclusion will summarise the overall theoretical basis of the thesis before 
introducing the research design and methodology chapter (Chapter 3).  
 
2.2 THE KNOWELDGE ECONOMY 
 
Although both political economy and classical economics were concerned with the new 
division of labour in the industrialising society of the eighteenth and nineteenth centuries, 
they did not focus on it as a particular factor of production. As mentioned both Adam 
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Smith and Alfred Marshall had considered knowledge to be crucial, but it was first 
considered seriosuly in the work of Joseph Schumpeter (1883-1950). However, 
Schumpeter concentrated on the firm level whilst the early discussions on the knowledge 
economy tended to focus on the broader, societal scale. Schumpeter will therefore be 
discussed in the next section (2.3). The likes of Robert Solow illustrated the importance 
of knowledge in work on technical change in the 1950s although he conceptualised 
technology as exogenous to the market in contrast to Schumpeter who saw it as 
endogenous (Scherer 1999).
ii
 This work by Solow (e.g. Solow 1956) and others built 
upon earlier economic theories by introducing the concept of technical change as a key 
factor in economic growth. He argued that labour (L) and capital (K) could not 
sufficiently explain economic growth since there was a significant „residual‟ that was 
unaccounted for in the traditional production function (f) (see Nelson and Winter 1982; 
Coombs et al 1987; Cooke 2002c; Easterley 2002). Such technical change could be 
incorporated into earlier models of the production function as time (t): 
 
Q = f (L, K, t) 
 
By treating it as neutral, the production function can be split further between technical 
change (A) and labour and capital: 
 
 Q = A(t)f(L, K) 
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However, this „residual‟ is problematic because, apart from the assumption of neutrality, 
it covers a wide range of changes including those to organisations, knowledge and 
education that could impact on economic development (Coombs et al 1987). 
 
Once the role of knowledge, conceptualised as technological change, was highlighted it 
opened the way to the conceptualisation of economic development as knowledge-driven 
or knowledge-based.
iii
 This was especially relevant to countries whose relative industrial 
employment had peaked in the 1950s and 1960s like the USA and UK (Townsend 1997; 
Sadler 2000). The Organisation for Economic Co-operation and Development (OECD) 
was itself established in 1961 to help promote science and technology policies across its 
member countries (Cooke and Leydesdorf 2006) and subsequently played a crucial role 
in the promotion of the „knowledge economy‟ concept (Godin 2006). There have been a 
welter of concepts and definitions since the 1960s including the „information(al) 
economy‟, „information age‟, „post-industrial society‟, „post-Fordism‟, „service 
economy‟, „new economy‟, „weightless economy‟, and „post-capitalist society‟. In 
particular there was a proliferation around the theme of the „knowledge economy‟ such as 
the „knowledge society‟, „knowledge-driven economy‟, „knowledge-based economy‟ and 
the „learning economy‟ (Webster 1995; OECD 1996; Morgan 1997; DTI 1999c; Brint 
2001; Johnson and Lundvall 2001; Cooke 2002c; Rodrigues 2002; Sokol 2003, 2004; 
Thompson 2004; Godin 2006).
iv
 This changing debate raises two important points, 
namely that knowledge has become a „strategic resource‟ and that learning is crucial for 
the „competitiveness‟ of different places (Coenen and Asheim 2006).  
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As mentioned, one of the first people to define the „knowledge economy‟ was Machlup 
(1962) who identified 29% of the US GNP in 1958 as belonging to „knowledge 
industries‟: these were defined as those industries which were information centred and 
therefore make an impression on people‟s minds (Brint 2001).v As such it was a 
definition that included a broad range of knowledge sectors that included fields like 
education, research and development (R&D), media and communications, information 
services and information technologies (Cooke 2002c; Cooke and Leydesdorff 2006). This 
rather broad definition was not only inconsistent since it combined numerous diverse 
sectors (e.g. private and public), but also Machlup‟s expectations of the spread of the 
knowledge economy proved overly optimistic. For example, later studies of knowledge 
industries showed that the growth in proportion of GNP was fairly limited and reached a 
plateau of 34% during the 1970s (Brint 2001: 106). Despite some optimistic claims that 
the service sector will account for 80% of the UK economy by 2010 (Leadbeater 1998: 
376) – which in itself is an inadequate characterisation of the knowledge economy 
because it covers a vast array of activities – a number of other commentators are less 
positive. They suggest instead that the potential of the knowledge economy is and will 
remain limited – especially in some regions – to around a third of employment (Webster 
2001; see also Vallas 1999; Thompson et al 2001; Thompson 2004).  
 
Whilst Machlup sought to highlight specific sectors of the knowledge economy, the 
American social theorist Daniel Bell (1973) focused on the possible change from 
industrial to „post-industrial society‟. Here Bell‟s arguments built directly on the 
conceptualisation of knowledge as a productive resource by suggesting that societies 
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become increasingly dependent upon the service sector and science-driven, high 
technology industries (Brint 2001; Thompson 2004). In particular, Bell emphasised the 
importance of „theoretical‟ knowledge in order to distinguish the post-industrial epoch 
from earlier periods, which therefore leads to a focus on the university and „knowledge 
workers‟. This, in turn, leads to the idea that there is a „knowledge society‟ based on the 
application and production of intellectual knowledge such as the management practices 
promoted by F.W. Taylor (Osborne 1998; Fuller 2000; Rikowski 2000; Sokol 2004). 
Consequently, universities and academic credentials are considered as crucial 
prerequisites for the development of the knowledge society and are therefore increasingly 
capitalised and marketised in pursuit of specific forms of value (Brint 2001; Kleinman 
and Vallas 2001). The university and especially its relationship with industry therefore 
become a crucial concern in the knowledge economy (Delanty 2001). 
 
Later discussions in the Regulation School around the shift from Fordism to „Post-
Fordism‟ (Aglietta 1979; Webster 1995; Vallas 1999; Simmie 2001) follow on from the 
work of Bell as well as the „flexible specialisation‟ arguments of authors like Piore and 
Sabel (1984) in The Second Industrial Divide. In this school of thought a number of shifts 
can be identified in both the regime of accumulation and mode of regulation in Western, 
capitalist societies (Webster 1995). This can be characterised as a shift from mass 
production manufacturing (i.e. Fordism) towards a globalised, service-based society (i.e. 
Post-Fordism) reminiscent of Bell‟s earlier arguments (Webster 1995). Technology plays 
a central role in this movement as it enables increased „flexibility‟ or „flexible 
accumulation‟ (Vallas 1999), which was most evident in changing production practices 
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such as „just-in-time‟ or batch production (Murray 1985) as well as outsourcing (Webster 
1995). Again there are a number of discrepancies and contradictions in this perspective, 
not least of which is the somewhat optimistic contention of some authors (e.g. Piore and 
Sabel 1984) that „Post-Fordism‟ represented enormous opportunities for workers (see 
Webster 1995; Vallas 1999; Kleinman and Vallas 2001).  
 
Yet another concept developed around these ideas were those of Manual Castells (1996) 
and others on the „information society‟. Rather than focusing on shifting regimes of 
accumulation, Castells concentrates on changes to technologies, especially those that 
relate to the gathering, production, processing and exchange of information and 
knowledge (Sokol 2003; Thompson 2004). Centrally then, the information society is 
characterised by the application of knowledge to the production of knowledge (Cooke 
2002c), which means that information technology is positioned at a crucial juncture in 
economic activity. Others like Jeremy Rifkin (1996) present less uplifting analyses by 
arguing that the „new economy‟ represents The End of Work. More recent arguments 
about the „weightless economy‟ (Rifkin 2001) or „living on thin air‟ (Leadbeater 1999) 
were all written before the „dotcom crash‟ in 2000-2001 and perhaps illustrate the 
dangers of basing such theories on technologically determinist premises (see Sokol 
2004). However, it is useful to take away from this discussion the importance that 
intangible assets have to modern companies, especially those assets that are embedded or 
embodied in technical knowledge.  
 
 33 
The emphasis on technology and in particular on specific technological regimes or waves 
is reiterated in the firm-level theories derived from Schumpeter‟s work on innovation 
(2.3) discussed in the next section. More crucial to note here is that the preceding debates 
have led to the current interest in the „knowledge economy‟. It is possible to argue that 
the knowledge economy, as defined in policy at least (see DTI 1999c),
vi
 contains features 
of all four previous concepts with slight differences. Thus the knowledge economy is 
characterised by industries dependent upon knowledge, which means that knowledge 
workers are crucial to economic development. Furthermore, changing patterns of 
consumption entail changes to productive processes and regulations, which are, in turn, 
influenced by new technologies. Perhaps the most important difference is the emphasis 
on the individual knowledge capacities and capabilities of both workers and firms (Sokol 
2003), which is considered to be socially and iteratively reproduced rather than 
constrained by organisational boundaries (Cooke 2002c; Chesborough 2003; Cooke 
2006). In these terms, the knowledge economy can be characterised as both knowledge-
based and knowledge-driven because of the dual purpose of knowledge as both producer 
and product (Cooke 2002c).  
 
There has been a particular emphasis placed on both the investment in knowledge and the 
spread of knowledge industries, which combines the focus on learning in the „learning 
economy‟ (Lundvall 1992; Johnson and Lundvall 2001) with the concern with high 
technology industries in the „knowledge economy‟ (Morgan and Murdoch 2000; Godin 
2006). According to Godin (2006) these two concerns were wedded together in the work 
of the OECD during the 1990s in an updating of the original knowledge economy thesis 
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put forward by the likes of Machlup in the 1960s. It has since been taken up by a number 
of authors such as Charles Leadbeater (1999: 52) who in Living on Thin Air argues that: 
 
“…knowledge is not just one among many resources, it is becoming the critical 
factor in how modern economies compete and how they generate wealth and 
wellbeing”. 
 
Because knowledge work is considered to be inherently „creative‟ in that it involves the 
production, processing and transfer of knowledge (Leadbeater 1998; Thompson 2004), it 
has been positioned in highly positive terms as both a current social trend and potential 
outcome (Godin 2006). As such it represents a strongly policy-oriented concept that has 
been adopted across the current UK government from the Prime Minister downward (see 
Rikowski 2000).  
 
The vision offered in the knowledge economy thesis of the knowledge worker – 
independent, creative, innovative, entrepreneurial, learning, wealth producing – has 
provided a strong policy pull for the New Labour administration in the UK and its 
devolved regions (Thompson et al 2001). For example, the Prime Minister stated in 1999 
that: 
 
“To succeed in this new, competitive, global economy, Britain‟s businesses need 
to be knowledge-driven. That applies not just to high-tech business but to all 
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businesses in all sectors…Business must lead the way towards the knowledge 
economy. But government has a part to play” (quoted in Rikowski 2000: 164). 
 
Furthermore, the departments of Trade and Industry (DTI) and Education and 
Employment (DfEE) have expressed similar sentiments in documents like Building the 
Knowledge Economy and Learning Age respectively (Goddard and Chatterton 1999; see 
also Rikowski 2000; Thompson et al 2001). The British government‟s Competitiveness 
White Paper, drafted by Charles Leadbeater, defined the „knowledge-driven economy‟ as: 
 
“…one in which the generation and the exploitation of knowledge has come to 
play the predominant part in the creation of wealth. It is not simply about pushing 
back the frontiers of knowledge; it is also about the more effective use and 
exploitation of all types of knowledge in all manner of economic activity” (DTI 
1998). 
 
This aligns the production, processing and transfer of knowledge with its commercial 
exploitation and therefore legitimates the expansion of intellectual property (IP) regimes, 
usually following codification (Jessop 2000; Luque 2001; Roberts 2001). This contrasts 
somewhat with the promise offered by Leadbeater (1998, 1999) of the empowered 
knowledge worker.  
 
More widely the knowledge economy has come to dominate supranational and 
international policy-makers, especially the European Commission (EC 2000; Rodrigues 
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2003) and OECD (1996, 1999b). The knowledge economy‟s most recent incarnation 
originated in the latter and was especially focused on Europe rather than the USA (Godin 
2006). The importance of this agenda in Europe is most evident in relation to the 2000 
Lisbon Agenda (2000; also EC Enterprise DG 2002) and 2002 Sapir Commission (The 
Sapir Group 2005) although it also impacts directly on bioscience policy in relation to the 
more recent „knowledge-based bio-economy‟ project (EC 2004, 2005; see also 
Rosamond 2002). For the OECD, the knowledge economy concerns both investments in 
knowledge and their distribution through networks and is conceptually related to both 
„new growth theory‟ and „national systems of innovation‟ (OECD 1996; Godin 2006). 
Knowledge codification is particularly highlighted as crucial to the knowledge economy 
enabling knowledge to acquire “more of the properties of a commodity” (OECD 1996: 
13). Learning and tacit knowledge (see below), however, are still considered important, 
especially in relation to the „interactive learning‟ between firms and institutions, which is 
a key element to measure in dynamic systems (see Godin 2006). The EC has taken on 
board the OECD recommendations that governments need to adapt to this „paradigm 
shift‟ with an aim “To establish an inclusive, dynamic and knowledge based economy”, 
not only in terms of knowledge investment but also institutional „adjustment‟ (EC 2000: 
11; see also Rodrigues 2002).  
 
2.3 INNOVATION AND ECONOMIC DEVELOPMENT 
 
The knowledge economy theory focuses on broad economic trends and therefore it does 
not adequately address the processes through which knowledge impacts on economic 
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development. In order to consider the specific processes that impact on economic 
development it is useful to consider the studies of innovation inspired by Schumpeter and 
others. This research provides the means to explore the role that innovation plays in the 
knowledge economy and how this then impacts on economic change at the regional 
(Cooke 2004d), national (Lundvall 1992) and even international (Gereffi 1994) scale. 
Here innovation can be described as the “novel application of economically valuable 
knowledge” in relation to products, processes or organisations (Feldman 2000: 371), 
which, in the context of the knowledge economy, refers to the application of knowledge 
to itself as Peter Drucker emphasised in the 1960s (see Brint 2001). However, this 
conceptualisation implies that innovation represents both the means and ends of the 
knowledge economy and economic development.  
 
It is important therefore to distinguish between the knowledge economy and innovation 
in order to explore the role of the latter in the former. Perhaps the simplest way to do this 
is by first turning to the work of the Russian economist Nikolai Kondratieff (1892-1938) 
before considering Schumpeterian theories. In his work, Kondratieff outlined how 
capitalist economies progressed through long-term booms covering 40 to 60 years that 
were then followed by depressions (Hall 1981, 1985; Malecki 1997). Each boom 
represented a wave of technological change that revolutionised the economy. The first of 
these consisted of the power loom and steam power in the Industrial Revolution, whilst 
later waves included railways and steel, and electricity and chemicals (Malecki 1997). 
The eventual economic downturn stimulated the discovery of new inventions that then 
spread throughout the economy leading to the next upturn (see Figure 2.1). In the 1970s 
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Gerhard Mensch used the ideas of Kondratieff and Schumpeter to show that innovation, 
as opposed to invention, occurred in clusters over a short period of time that produced 
new processes, products and sectors (see Hall 1981).  
 
Figure 2.1: Kondratieff Waves 
 
 
 
 
 
 
 
Source: http://www.angelfire.com/or/truthfinder/index22.html 
 
The knowledge economy, as currently conceived, could be considered as the fifth 
Kondratieff wave representing innovative developments in areas like biotechnology, new 
materials and nanotechnology amongst other technologies. Such innovations represent 
potential contributions to economic development in the long-term, rather than assured 
outcomes, since they necessitate a range of complementary institutions and organisations 
that embed increasing returns to adoption (see Fagerberg 2005). This is why Schumpeter 
(1939, 1942) could refer to the „creative destruction‟ inherent in the innovation process as 
well as stress the importance of business cycles and long waves of innovation. Innovation 
not only leads to decline in some industrial sectors and the rise of other sectors, all of 
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which drives economic development (see Simmie 2001), but also to changes in 
surrounding institutions that relate to declining or rising sectors. Consequently, learning 
is a crucial aspect of the innovation process because it enables adjustment and adaptation 
to new circumstances through the interaction between institutions and organisations that 
stimulates innovation (Godin 2006).   
 
This work on innovation by Schumpeter can be split between two periods; Schumpeter I 
and Schumpeter II. The first consisted of his studies before World War I when he focused 
on the role of entrepreneurship marked by the separation of invention and innovation, 
whilst the second concentrated on innovation processes in large, oligopolistic firms 
(Simmie 2001; Cantwell 2002). In Mark I, Schumpeter emphasised the exogenous nature 
of invention and its appropriation by small firms that then drove economic development 
through „swarming‟ during new periods of technological change (Simmie 2001). Because 
there is no assurance of profit in a period of fluctuation or disturbance, innovation occurs 
in tranquil periods of the economic cycle precipitating booms and then slumps. 
Schumpeter argued that such innovations “tend to cluster” since they are not “distributed 
over the whole economic system at random, but tend to concentrate in certain sectors and 
their surroundings” (1939: 100-101). However, others have stressed the importance of 
diffusion in this process and the mutual interaction and co-ordination between firms and 
complementary organisations and institutions (Freeman 1982; Metcalfe 1994).  
 
In Schumpeter Mark II innovation was characterised by routinised innovation within 
large, oligopolistic firms with established industrial research programmes that combine 
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invention and innovation in one organisation (Malecki 1997). As Alfred Chandler (1977) 
identified some years later, the expansion of these large firms had a profound effect on 
the innovation process through the positive feedback produced by self-reinforcing and 
therefore path dependent cycles of change (see Simmie 2005). Schumpeter emphasised 
the dynamic processes surrounding innovation as an evolutionary system derived from 
profit-seeking rather than profit-maximisation (see Cantwell 2002). Of crucial 
importance, according to John Cantwell (2005: 561), is that the “capabilities created 
through innovation” can lead to a situation in which “a range of different actors may 
improve their competitiveness together”. Research in evolutionary economics provides a 
modern updating of Schumpeter‟s work with the likes of Nelson and Winter (1974, 1982) 
and Dosi (1988) providing the means to understand how different technological 
paradigms and trajectories are embedded in specific collective arrangements, rather than 
individual firms or organisations (see von Hippel 1988, 1994; Nonaka and Takeuchi 
1995).  
 
The resulting emphasis on „systems of innovation‟ has proved influential in debates 
around the knowledge economy in both policy and academic circles (see Godin 2006). 
There are a number of factors that influence innovation (and therefore economic 
development) in such systems, which Rosenberg (1976) splits between „inducement 
mechanisms‟ – as described by Albert Hirschman (b.1915) – and „focusing devices‟. 
These factors constitute the innovation system in terms of inter-related and self-
reinforcing features of the technological paradigm (see Dosi 1988). For example, Paul 
Nightingale (2000, 2003) argues that new gene sequencing technologies have led to a 
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shift from the original focus on single gene mutations to polygenetic diseases. Innovation 
diffusion is a central feature of such systems because they increase complexity and the 
professionalisation of R&D at the same time that they produce co-ordination issues 
between system actors (Freeman 1982). Thus the system is dependent upon the 
interaction between system actors that diffuses both commodities and demand throughout 
the system as the example of electrification illustrates (see Hughes 1983). The systems of 
innovation approach has proved highly influential across academic discourses, 
particularly with some of the more recent geographical theories as will be shown later 
(2.6). 
 
However, there are a number of issues with the systems perspective that necessitate a 
degree of caution. It is argued that the innovation process can „lock-in‟ to specific 
technological trajectories through „cumulative causation‟ or the “mutual reinforcement (a 
positive feedback) between a certain pattern of learning and a pattern of allocation of 
resources into innovative activities” (Dosi 1988: 1148). As a consequence, alternative 
trajectories become increasingly costly to undertake. Furthermore, as Arthur (1989, 1999) 
argues, returns to adoption can lead to the uptake of technologies that are not necessarily 
„superior‟ to other technologies because it is expensive to break such „path dependency‟. 
More importantly perhaps, we could argue that such lock-in and path dependence could 
affect technological paradigms as well as trajectories, embedding specific technological 
paradigms across networks, societies and cultures. Because the innovation process is 
collective, the consequence of this lock-in could be potentially ruinous as resources are 
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invested in particular technologies and people learn and adapt to their existence in a form 
of „groupthink‟ (Fagerberg 2005; see also Janis 1972). 
 
The last issue to address in relation to the innovation process is how knowledge is 
transferred across different actors in the overall system. One important argument 
highlights the role of knowledge spillovers. Such spillovers occur not just through direct 
collaboration, but also, and more crucially, as a consequence of learning from the 
interaction itself (von Hippel 1988, 1994). This means that knowledge is not 
unproblematically incorporated into innovation but entails distinct processes for its 
transfer and absorption. Patent citation studies have shown that there is a distinct time lag 
between publication and citation that peaks around 6-7 years after publication (Jaffe, 
Tratjenberg and Henderson 2002). Similar research has shown that there is „bi-
directional‟ knowledge transfer between specific countries like the USA and UK (Jaffe 
and Tratjenberg 2002). However, there are limitations to these studies because they do 
not show how such knowledge corresponds to innovative performance (Acs and 
Audretsch 1988) or how knowledge transfer actually occurs between different 
organisations (Acs et al 1991; Acs et al 1999). Research on biotechnology knowledge 
spillovers emphasises the role of „star scientists‟ in providing financial and not just 
scientific credibility to dedicated biotech firms (DBFs) (Audretsch and Feldman 1996; 
Audretsch and Stephan 1996; Zucker et al 1998, 2002). The interaction between such 
DBFs and university science remains ambiguous (Acs and Audretsch 1988) with a 
number of concerns about the appropriation and codification of biotech knowledge as 
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well as the impact of commercial considerations on academic research (Blumenthal et al 
1986; Krimsky et al 1991; Krimsky and Rothenberg 2001; Krimsky 2003).
vii
 
 
2.4 KNOWLEDGE AND INNOVATION 
 
In the knowledge economy discourse, innovation has been characterised as the driver of 
economic development where this consists of knowledge produced and exchanged 
through the interactions between organisations and institutions. The role of knowledge in 
the innovation process is fundamental to understanding how innovation can be 
considered as both systemic and dynamic. However, the definition of knowledge, even its 
distinction from information, is also central for understanding how it impacts on 
innovation processes and subsequently how such processes are embedded in space (2.5). 
For example, the knowledge necessary for „incremental‟ and „radical‟ innovation is 
dissimilar, as it is for „process‟ and „product‟ innovations, because different types and 
forms of knowledge are used in different circumstances (see Malecki 1997; Feldman 
2000). In the knowledge economy it is therefore possible to argue, as Lundvall (1992) 
and others from the „national systems of innovation‟ literature do, that innovation is 
dependent upon the „distribution‟ and „use‟ of knowledge (see Godin 2006). Or, as will 
be outlined later, that there is a need to distinguish between the „knowledge base‟ and 
„knowledge drive‟ of innovation, which entails further consideration of where different 
knowledge types and forms are located and embedded.  
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It is important to define and distinguish between information and knowledge so that they 
are not confused. One definition of information drawn from the mid-twentieth century is 
that information represents “messages possessing meaning for sender and recipient” 
(Cooke 2004d: xiv). It is also possible to argue that information is “the process of 
gathering and organizing data” (Rikowski 2000: 162), although this definition would 
seem to merely exchange „information‟ for „data‟ in the terminology and therefore 
appears somewhat tautological. Perhaps since Burton-Jones (1999: 5) defines 
„knowledge‟ as “the cumulative stock of information”, it is possible to define information 
as specific stocks of existing data, although this precludes its collection. However, 
arguably the collection of data is fraught with difficulties that arise around the subjective 
process of selection, collection and storage that make the „gathering‟ of data as 
problematic as its interpretation. Thus the clearest definition of information might be that 
information represents distinct tangible and intangible artefacts (e.g. posters, leaflets, 
statistics) that exist at any discrete point in time. Furthermore, information both conveys 
interpreted details and invites further interpretation.  
 
In contrast, knowledge has been defined as the process of interpretation, understanding 
and learning. These all present a number of issues in the clarification of its meaning 
because they are broad and amorphous descriptions. In relation to the knowledge 
economy concept, knowledge shifted from the information and technology fundamental 
to the „information society‟ thesis to focus instead on people and their embodied 
understandings and context (DTI 1999c; Rikowski 2000; Sokol 2003). Thus knowledge 
has been defined in a number of ways by different knowledge economy theorists; as 
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“impression-making information” by Machlup, as “the organization of understanding” by 
Drucker and Nonaka and as “economically-relevant systems of thought” by Bell (see 
Brint 2001: 110). Knowledge can be considered therefore as the means through which 
people collect, sort, absorb, interpret, and organise information, or “all cognitions and 
abilities that individuals use to solve problems, make decisions and understand incoming 
information” (Doring and Schnellenbach 2006: 377). However, it also entails the 
definition and identification of problems, although this means that it represents a „system 
of thought‟ in which particular concerns, agendas and interests are embedded or 
„architectural knowledge‟ as outlined by Pinch et al (2003). It is important to make this 
point because knowledge does not just represent the skills or learning of individual 
people, it is broader than that since it involves continuous accumulation that outlasts 
individual lives (Doring and Schnellenbach 2006).  
 
Broadly speaking and for ease it is useful to consider knowledge as “a dynamic 
framework or structure from which information can be stored, processed and understood” 
(Howells 2002: 872). There are many types and forms of such knowledge relevant to 
innovation, some of which overlap with definitions of information, whilst others are more 
difficult to codify or turn into information (Johnson and Lundvall 2001). One definition 
splits these between „know-what‟, „know-why‟, „know-how‟ and „know-who‟. The first 
represents information or facts; the second represents analytical principles; the third 
represents skill; and the fourth represents knowledge about people (OECD 1996: 12; also 
Morgan and Murdoch 2000). We can distinguish further between a number of these 
knowledge types; for example, know-what and know-why can be split between 
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„analytical‟, „synthetic‟ and „symbolic‟ kinds that refer to science, technical and creative 
knowledge respectively (Cooke and Leydesdorff 2006: 11; see also Faulkner 1994; 
Asheim and Gertler 2005). A more frequent distinction has been made between explicit 
and tacit forms of knowledge. Both forms feature strongly in the knowledge economy 
debate and are presented as crucial parts of the innovation process entailing an emphasis 
on „learning‟ as another characteristic of knowledge. The numerous types of learning 
have been usefully outlined by (Malecki 1997) (see Table 2.1).  
 
Table 2.1: Types of Learning 
LEARNING AUTHOR 
Learning by doing Arrow 1960s 
Learning by using Rosenberg 1980s 
Learning by operating, changing, feedback, 
training, hiring, searching 
Bell 1980s 
Learning by trying Rosenbloom and Cusumano 1980s; 
Fleck 1990s 
Learning by interacting Lundvall 1980s 
Learning by selling Thomson 1980s 
Learning from inter-industry spillover Malerba 1990s 
Learning to borrow David 1990s 
Learning by failing  Bahrami and Evans 1990s 
 
Source: Adapted from Malecki (1997: 59). 
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Because knowledge is so dependent upon learning, it is important to distinguish between 
„explicit‟ and „tacit‟ forms of knowledge. This was most famously explored by Michael 
Polanyi (1967, 1973) who identified explicit and tacit knowledge by the degree of 
fromalisation and articulation, which combines with the process of learning as well 
(Howells 1996, 2000, 2002). Rather than represent these two knowledge forms as 
dichotomous categories, Polanyi emphasised the continuum between explicit and tacit 
knowledge so that one could not be used without the other (Senker and Faulkner 1996; 
Maskell and Malmberg 1999; Howells 2000; Simmie 2002b). In the innovation process it 
is possible to argue that tacit knowledge is more closely aligned with know-how (OECD 
1996) and „synthetic‟ or technical knowledge (Cooke and Leydesdorff 2006) because 
they are both reliant on the application of practices rather than analytical principles (see 
Faulkner 1994; Howells 1996). However, others have argued that in certain industrial 
sectors, biotechnology in particular, the tacit dimension of „analytical‟ knowledge is just 
as important because there is a strong reliance on scientific knowledge held by certain 
„star scientists‟ (Zucker et al 1998, 2002; Asheim and Gertler 2005). Thus it would 
appear as though the tacit dimension of knowledge is not necessarily dependent upon the 
information content because different types of knowledge (what, why, how, who) all 
combine tacit and explicit forms. It is therefore possible to argue that tacit knowledge is 
actually highly context dependent, which distinguishes it from other forms of knowledge 
(Pinch et al 2003) and would help to explain why neoclassical economics “fails to 
account for the uneven distribution of knowledge” (Morgan and Murdoch 2000: 160). 
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However, it is important to note that Polanyi did not originally conceive of tacit 
knowledge as contextual, but rather experiential and cognitive (see Gertler 2003). 
 
The spatial dimensions of knowledge will be addressed later (2.7), but first tacit 
knowledge has to be clearly defined. It can be seen as a form of „direct experience‟ that 
impacts on the use of explicit knowledge so that it represents the skills necessary to use 
explicit or codified knowledge; i.e. it is individual and particular (OECD 1996; Howells 
2002; Simmie 2003). This means that it is implicated in a range of knowledge activities, 
not just knowledge production. It is necessary for the diffusion, distribution and transfer 
of knowledge, as well as its absorption, use and adaptation, along with forms of 
relearning or „unlearning‟ (Hassink 2005). This challenges the linear model of 
innovation, where basic research is seen to lead to technical development and then market 
demand (Howells 2002; Lever 2002). Instead, it can be argued that innovation is an 
iterative and interactive process in which explicit and tacit knowledge is cycled through 
different actors producing feedback on particular strategies, reinforcing certain activities 
and generally providing the means for learning and therefore more knowledge production 
(von Hippel 1988, 1994; Nonaka and Takeuchi 1995; Senker and Faulkner 1996; Bathelt 
et al 2004). Consequently the institutional environment can be seen as a crucial element 
in the innovation process since it ensures that tacit knowledge can cross organisational 
borders (Gertler 2003). 
 
More recently, Phil Cooke (2005a, 2005b, 2006) has argued that such „open innovation‟ 
entails a further type of knowledge, namely the „complicit‟ or „translational‟ knowledge 
 49 
of intermediaries who can convey tacit knowledge across epistemic boundaries (e.g. 
between scientists and investors) (see also Chesborough 2003). This chimes with earlier 
work by Gibbons et al (1994) distinguishing between the transition from Mode 1 to Mode 
2 knowledge production (see also Harloe and Perry 2004). The latter is characterised by 
its transdisciplinariity and social distribution, in that knowledge is diffused across 
multiple sites and contexts because it is embodied in people who organise themselves 
differently depending on where they are located (Gibbons et al 1994: 17). Consequently 
the elements in knowledge production consist of arrangements, interactions and 
relationships that are embedded in different spaces, different organisational forms and 
different institutional structures. Thus the role played by intermediaries can be seen as 
crucial. Even the relaxing of boundaries between different organisations and institutions 
can be seen as important as the Triple Helix model of innovation in the biosciences 
contends (Etzkowitz and Leydesdorff 2000). The Triple Helix model critiques Giddons et 
al (1994) by arguing that Mode 1 and Mode 2 knowledge are not distinct phases, but 
rather intimately tied to one another in the close relationships between government, 
industry and academia (Etzkowitz and Leydesdorff 2000).  
 
As shown above, the definition of knowledge in the innovation process is fraught with 
difficulty. It is easiest to distinguish explicit and tacit knowledge as elements on a 
continuum of knowledge that specifies explicit knowledge as codified intangible artefacts 
(e.g. information) (Howells 1996) and tacit knowledge as the processing, interpretation 
and use of codified knowledge. They are therefore „hybrid knowledges‟ that not only 
depend upon the cognitive understanding of knowledge, but also the social understanding 
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of the cultural context (e.g. norms, trust etc.) that facilitates knowledge production 
(Goddard and Chatterton 1999; Fagerberg 2005). Explicit and tacit forms are continually 
converted from one to the other and back again through the interaction of individuals, 
organisations and institutions (Nonaka and Takeuchi 1995; Morgan 2004). It is useful to 
consider the conceptualisation of these conversions by Ernst and Kim (2002) as outlined 
in Table 2.2.  
 
Table 2.2: Knowledge Conversion 
KNOWLEDGE CONVERSION TERM 
Tacit-to-tacit Socialisation 
Explicit-to-explicit Combination 
Tacit-to-explicit Externalisation 
Explicit-to-tacit Internalisation 
 
Source: Adapted from Ernst and Kim (2002: 1424-1425). 
 
Thus tacit knowledge can been externalised when it is articulated in the form of 
information or codified as an artefact, whilst explicit knowledge can, in turn, be 
internalised when it is absorbed into a particular system of thought (Ernst and Kim 2002). 
Overall then, tacit knowledge can be defined as the way individuals understand the 
world, which is highly contingent upon their context because they derive a significant 
proportion of their cognitive abilities and skills from people around them and their 
organisational and institutional base. In this way we can identify the role of knowledge in 
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the innovation process by distinguishing between the knowledge base and the knowledge 
driver of innovation. Since „knowledge‟ in the broadest sense is used in all economic 
activities, Cooke (2002c: 3-5) characterises the knowledge economy as dependent upon 
(1) new knowledge, (2) high value (i.e. scientific) knowledge, and therefore (3) new 
knowledge that is used to produce more new knowledge. Thus the knowledge base is 
central because it enables the production of new knowledge through the support provided 
by existing technological paradigms and trajectories (see Dosi 1988). In turn, the 
knowledge driver provides the impetus to produce new knowledge through collaboration 
and interaction with other individuals from diverse and dispersed sources. Without both 
the knowledge base and driver there would be little to stimulate the knowledge economy. 
 
2.5 SPACE AND INNOVATION 
 
The discussion above on the relationships between innovation, economic development 
and knowledge (2.3 and 2.4) illustrates the importance of spatial considerations to 
understanding the innovation process and consequently economic development. In 
particular it is evident that innovation and knowledge are unevenly spread across and 
within different countries for a variety of reasons, but all of which have a direct impact 
on the capacity of different locations to pursue economic development (Feldman 1999, 
2000; Fagerberg 2005). Consequently a central issue in economic geography, regional 
and urban studies and other cognate fields is to understand how and why this uneven 
development occurs across different places. Such differences are not static either, but 
rather dynamic changing over time as the uneven spread of industries leads to contingent 
 52 
processes of adjustment and adaptation (Hassink 2005; Hudson 2005). This interest with 
uneven development has a long history in the field, starting with academics concerned 
about de-industrialisation such as the seminal work of Doreen Massey (1995[1984]) and 
David Harvey (1999[1982]). However, the more recent interest has particularly focused 
on the territorial processes of innovation and knowledge. A number of reviews of so-
called „territorial innovation models‟ (TIMs) as Moulaert and Sekia (2003) term them 
have been undertaken in the last 10 years particularly as the „knowledge economy‟ has 
been promoted in policy circles (Malmberg 1997; Yeung 2000; MacKinnon et al 2002; 
Malmberg and Maskell 2002; Moulaert and Sekia 2003; Lagendijk 2006). A number of 
reviews have also raised a series of questions and problems with this types of research, 
not least of which is its orientation around policy concerns to the detriment of „critical‟ 
distance (Lovering 1999, 2001; although also see MacLeod 2001).  
 
The numerous TIMs that seek to explain spatial innovation processes have proliferated 
throughout this time as they have drawn in a broader range of theories from the work of 
the French Regulation School (e.g. Aglietta 1979) through to the economic sociology of 
Granovetter (1985) on „embeddedness‟. In his review, Lagendijk (2006) argues that there 
are three phases to the development of these conceptual approaches starting with 
„structuralist-organisational‟ phase (e.g. the California School) moving through „social-
institutional‟ (e.g. „institutional thickness‟) before ending with a „cognitive‟ model (e.g. 
„buzz and pipelines‟). These three phases crudely correspond to functional, relational and 
associational emphases in the various theories where functional concepts are more 
concerned with the material linkages in space, relational ones with the social and 
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institutional linkages and associational ones with individual and collective knowledge 
practices (MacKinnon et al 2002; Lagendijk 2006).
viii
 All such theories provide some 
useful analyses of the spatial embedding of the innovation process and contribute useful 
insights that all need to be taken into account. 
 
Firstly, the more functional models build upon work in economics on transaction costs 
and the evolution of technological paradigms and trajectories as well as Regulation 
theory. The early work of the California School in the 1980s is one example of this 
research agenda, focusing on the importance of transaction costs and flexible production 
enabled by a lack of existing Fordist production systems (Scott 1989; Storper and Walker 
1989). Such „new industrial spaces‟ (NIS) included areas like Silicon Valley in California 
(Scott 1998a, 1998b) where production was distributed across numerous firms so that 
external economies and economies of scope provide advantages to particular regions 
(Lagendijk 2006). In particular there was a focus on the region as a site of economic and 
social activity in a Post-Fordist world (see Storper 1995; Storper and Scott 1995), which 
placed greater emphasis on agglomeration economies and the work of Alfred Marshall 
(1890) on „industrial districts‟. Such agglomeration or concentration of industrial 
production produced “a widening of the social division of labor” meaning that knowledge 
and innovation were also distributed more widely as well (Scott 1998b: 387).
ix
 There are 
strong links and overlaps between the NIS concept and that of „flexible specialisation‟ 
propounded by Piore and Sabel (1984) and the work on „industrial districts‟ (ID) carried 
out in Italy by Bagnasco, Becattini and others. The ID approach again emphasised local 
production by small firms which each specialised in different parts of the production 
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process (Moulaert and Sekia 2003). However, increasingly, both the NIS and ID 
approaches stressed the importance of „untraded interdependencies‟ (Storper 1995) and 
the institutional structures in different regions especially in relation to the social 
embedding of networks in Piore and Sabel‟s (1984) work. Consequently they moved 
towards a more „relational‟ model. 
 
Secondly, the relational models build upon the growing interest in the social and 
institutional features of regional economies and particularly the impact these have on 
innovation processes. As such they build on work in economic sociology and institutional 
economics,
x
 as well as the institutional concepts from Regulation theory (see Kratke 
1999; Lagendijk 2006). The greater emphasis on the collective and therefore institutional 
basis of innovation and knowledge production helped to stimulate this approach. In 
particular, the interest in learning through interaction – whether at an individual or 
collective scale – provides an impetus for understanding how and why such processes 
occur (Nonaka and Takeuchi 1995; Malecki 2000; Asheim and Gertler 2005). Each 
location has different institutional frameworks that affect innovation, which then helps to 
explain the different and uneven development of regional (and national) economies. Thus 
it is possible to argue that certain regions embed knowledge and therefore innovation 
more successfully than others leading to „sticky places‟ (Markusen 1996) that attract and 
retain different, particularly tacit, forms of knowledge (see von Hippel 1988, 1994; 
Malecki 2000). Although there are a number of relational theories, they can be split, 
again crudely perhaps, between institutional and social approaches. The former includes 
the research of GREMI 
xi
 in France on the „innovative milieu‟ (e.g. Camagni 1995; also 
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Keeble et al 1999; Crevoisier 2004) as well as Amin and Thrift‟s work on „institutional 
thickness‟ in Neo-Marshallian nodes (e.g. Amin and Thrift 1992, 1994; Amin 1999, 
2004).  
 
In the innovative milieu approach, innovation and learning are considered as collective 
processes in a specific territorial context that is enabled by local networking and 
interaction between not only firms, but also supporting organisations (Plummer and 
Taylor 2001a, 2001b; Simmie 2005; Lagendijk 2006). A recent addition to this approach 
by Capello and Faggian (2005) has introduced the concept of „relational capital‟ 
representing a set of relationships that produces strong local culture. The Neo-
Marshallian approach stresses the region as a „relational‟ concept that is constituted by its 
relationship to the global; in these regions actors interact in pursuit of collective success, 
which leads to the development of a collective culture (Amin and Thrift 1994). In the 
more social models – e.g. „learning region‟ (Florida 1995; Morgan 1997) and „regional 
innovation system‟ (Cooke 1998, 2001a, 2004d; Cooke et al 1998; Park 2001) – there is a 
greater emphasis on the systemic, as opposed to institutional, basis of innovation and 
knowledge. Again, collective learning is central, but instead of it representing a „cultural‟ 
perspective, the social approach places the emphasis on the relationships between 
organisations or system members (Moulaert and Sekia 2003). Both are concerned with 
the effects of the knowledge economy on regional development and how „less favoured 
regions‟ (LFRs) can adjust to the changing economic climate (Morgan 1997). As such 
they can be considered evolutionary theories (Cooke et al 1998; Morgan 2004), but ones 
which place more emphasis on the interaction between system members than other 
 56 
theories concerned with the importance of internal knowledge do, especially regarding 
tacit knowledge (e.g. Faulkner 1994).    
 
Finally then, associational models can be aligned with what Lagendijk (2006) calls 
„cognitive‟ TIMs and includes „knowledge communities‟, „clusters‟ and „buzz‟. The 
general emphasis in such approaches is on the „associational capacity‟ that different firms 
have within a particular place to not only encourage co-operation within their 
organisation, but also across different organisations (Cooke and Morgan 1998). As such it 
may preclude the functional pursuit of market considerations (e.g. price) or the relational 
pursuit of social considerations (e.g. trust) for a concern with processes of knowledge 
collection, absorption and interpretation across organisations (Lagendijk 2006). Thus 
several authors have argued that regional innovation is constituted by knowledge 
communities or „communities of practice‟ representing a group of actors who co-operate 
across organisations and institutions (Henry and Pinch 2000; Pinch et al 2003). As such 
there can be entire systems of knowledge or „knowing‟ to which different actors adhere 
across a number of organisational boundaries, but embedded and bounded in particular 
places (Pinch et al 2003).
xii
 Such locations can be considered as „clusters‟ in that they 
incorporate a number of complementary and associated organisations in a particular 
geographical location (Porter 2000). They need to be distinguished from Porter‟s (1990) 
earliest conceptualisation of clusters as functional (e.g. sectoral) and instead be seen as 
spatial phenomena (see Malmberg 2003). Even though the cluster concept has proved 
popular amongst policy and some academic circles, it has also been widely criticised for 
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its simplicity and lack of empirical support (Malmberg 2003; Martin and Sunley 2003; 
Cumbers and MacKinnon 2004; Simmie 2004; Malmberg and Power 2005).  
 
In many cases such critiques have pointed out that local linkages and relationships are 
actually weaker than extra-local ones, which has led to the last associational concept of 
„local buzz and global pipelines‟ (Bathelt et al 2004). This approach acknowledges that 
both explicit and tacit knowledge are spatially embedded because both entail search and 
acquisition costs, and explicit knowledge, even though it is supposedly „ubiquitous‟ 
(Maskell and Malmberg 1999), still requires the existence (or production) of tacit 
knowledge (Bathelt et al 2004). The first feature is the „buzz‟ from local interaction, 
which is crucial in producing group trust and solidarity and thereby enabling both the 
access to new knowledge and knowledge of how to access such knowledge (see Pinch et 
al 2003; Storper 2003). However, buzz originates and is perpetuated by particular 
knowledge communities, rather then by individuals, firms or regions. Consequently it is 
dependent upon the „ecology of communication‟ produced through personal, face-to-face 
contact and therefore the co-location of people in similar places (Grabher 2001; 
Lagendijk 2006). The second feature is the „global pipelines‟ consisting of the extra-local 
linkages, specifically global ones, connecting different places to one another (Bathelt et al 
2004). Again they can consist of global communities of practice (Asheim and Gertler 
2005), although this would not necessarily entail the same type or level of interaction as 
the local level, and therefore a similar approach to knowledge search, acquisition and 
absorption (see Bathelt and Gluckler 2005). However they are constituted, they provide 
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an analytical approach that addresses a number of concerns highlighted around the cluster 
concept (see Malmberg and Power 2005).  
 
There are a number of conceptual and methodological issues with all the TIMs outlined 
above, particularly because there is a tendency in each to define the particular processes – 
functional, relational or associational – as the dominant factor in regional innovation 
processes. In contrast it is worth arguing that spatially-bounded innovation entails a 
combination of all three processes to a varying degree depending upon the specific 
location. There is no reason why regional innovation across the world need be constituted 
by exactly the same set of processes; rather, it would seem logically to assume that they 
are not because each region will have different knowledge bases and drivers. Thus one 
region may have a public-funded university that encourages collaboration between its 
academics and regionally-based firms, whereas another regional university (privately or 
publicly funded) may encourage global collaborations in pursuit of global status. The 
impact of this simple policy pursued by one organisation could significantly impact upon 
regional innovation. More importantly perhaps, it could have no impact at all for regions 
in particular circumstances. Such spatial specificity of the innovation process and, in 
particular the importance (or not) of knowledge, is considered in the next section by 
outlining a theory called the knowledge-space dynamic. 
 
2.6 THE KNOWLEDGE-SPACE DYNAMIC 
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The theory of the knowledge-space dynamic hinges on a number of propositions drawn 
from the preceding literature review of the knowledge economy (2.2), innovation and 
economic development (2.3), innovation and knowledge (2.4), and innovation and space 
(2.5). The central proposition is that regional economic development and performance in 
the „knowledge economy‟ – whether we accept that knowledge drives wealth creation or 
vice versa (Sokol 2003, 2004) – depends upon innovation (Malecki 1997, 2000; Asheim 
and Gertler 2005; Fagerberg 2005; Simmie 2005).
xiii
 Secondly, it is premised on the idea 
that every spatial context is unique and consequently every concentration of economic 
activity – whether industrial, service-based or otherwise – entails a geographical 
specificity regarding the spatial positioning and embedding of knowledge production, 
search, acquisition and absorption in the innovation process (Cohen and Levinthal 1990; 
Howells 2002; Gertler 2003; Asheim and Gertler 2005; Cooke and Leydesdorff 2006). 
Thirdly, it is crucial to acknowledge the cross-scalar relationships and interaction that 
further embed these knowledge and innovation processes by strengthening the position of 
certain regions at the expense of others (Malmberg 2003; Bathelt et al 2004; Phelps 2004; 
Wolfe and Gertler 2004; Malmberg and Power 2005). However, in this framing of 
innovation and knowledge it is important to acknowledge that neither these inputs to 
regional development, nor technological change more generally, are necessarily 
„progressive‟ in that they automatically change to „superior‟ forms over time. Instead the 
returns to adoption (Arthur 1989, 1999) engendered by embedding knowledge and 
innovation processes in particular institutional frameworks – at the regional, national or 
any spatial scale – may lead to path dependency and lock-in to particular paradigms and 
trajectories (Dosi 1988; Hassink 2005; Hudson 2005).  
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The innovation process itself is dependent upon many different types of knowledge 
drawn from numerous sources, both internal and external to a firm, and involving a 
collective interaction and engagement in learning and knowledge production that 
iteratively crosses organisations in a feedback processs (von Hippel 1988, 1994; Nonaka 
and Takeuchi 1995; Bartholomew 1997; Chesborough 2003; Cooke 2006). This 
necessitates the combination of diverse knowledge „inputs‟ such as problem-setting to 
acquire funding in the first place (whether externally or internally), research and 
development, market-making and so on. Consequently the concept of innovation as an 
atomistic activity is problematic, especially the portrayal of entrepreneurs and investors 
as „heroic‟ individuals (Smelser and Swedberg 1994). Instead the systemic characteristics 
of innovation means that knowledge is derived from functional, relational and 
associational processes that cover a range of organisational and institutional capabilities. 
Such knowledge could come from specific commodities and products, industrial or 
production processes and inputs, marketing and market-making activities, organisational 
techniques and arrangements etc. (Fagerberg 2005). However, these knowledges are 
bounded by and embedded in specific sets of conventions and institutional rules that are 
social produced and sustained by individuals, organisations and other actors working 
within and across a particular system (Nelson and Winter 1982; Morgan 2004). 
Consequently such knowledges are constituted by the positioning and embedding of the 
system in a particular place because the geographical location of a system – i.e. its 
regional, national and global relations – produces particular social associations (see 
Whitley 1996, 2004 on national business systems for example).  
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A central feature of this spatial positioning and embedding of knowledge is the role of 
individual people as „knowledge workers‟ (Brint 2001), although more broadly conceived 
than an emphasis on „high technology‟ knowledge producers. Although knowledge is a 
central feature of innovation, it has to be produced, transferred and absorbed by 
individual people within the process who can then contribute to the collective system. 
This entails a number of important considerations. For example, it would seem evident 
that the positions of each person within the innovation process – i.e. their organisational, 
institutional, spatial etc. context – bears closer examination. Furthermore, there is a 
possibility that the greater the diversity and variation of people in the innovation process 
would lead to more diverse and varied knowledge that could provide the impetus for 
conflict that then stimulates innovation (Grabher and Stark 1997). Crucially then, because 
it is people who produce, exchange and absorb knowledge – whether or not it is then 
added to organisational memory (Nelson and Winter 1982) – their actions and 
interactions are important foci for studies of the knowledge economy (Cohen and 
Levinthal 1990).  
 
Even though people produce, transfer and absorb knowledge, they may be doing so 
unconsciously or through tacit avenues of learning. As such they are transferring the 
knowledge of a capability in the Penrosian sense (Penrose 1995[1959]; Ravix 2002; 
Richardson 2002), or how to do something, rather than know-what or know-why 
(Johnson and Lundvall 2001). Such knowledge transfer is therefore bound up with the 
issue of how easy it is to access the knowledge in question in the first place and 
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subsequently how easy it is to absorb and incorporate such knowledge in an existing 
collective system of thought. As Michael Polanyi argued, it is the tacit dimension itself 
that: 
 
“…decide[s] our adherence to a particular culture and sustains our intellectual, 
artistic, civic and religious deployment within its framework” (Polanyi 1973: 264-
5). 
 
So tacit knowledge is both the means of „knowing‟ and a crucial form of knowledge for 
innovation. It is more difficult to transfer because it cannot be „articulated‟, which also 
means it is more difficult to absorb (Senker and Faulkner 1996). Thus the closer someone 
is to another person‟s system of thought (i.e. way of knowing) the easier it will be to not 
only transfer and absorb tacit knowledge, but also exploit explicit knowledge from 
similar sources. Consequently, the spatial proximity between people may make it easier 
to access such „sticky‟ knowledge especially in face-to-face contact (von Hippel 1994; 
also see Boschma 2005). 
 
The specific system of thought within which people operate can be seen as an effect of 
their organisational and institutional membership in that people work within contexts that 
have established rules and conventions on how knowledge is acquired, used etc. that are 
specific to that setting (Nelson and Winter 1982; Johnson and Lundvall 2001). 
Furthermore, these rules and conventions need not be „efficient‟ or „optimal‟ (see Meyer 
and Rowan 2004), but instead represent patterns of capabilities that ensure the co-
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operation and trust of other people around them (DiMaggio and Powell 2004). The 
„embeddedness‟ of economic actors within such social relationships and institutions has 
been a research programme pursued by economic anthropologists, sociologists and others 
for some time (Polanyi 1957, 2001[1944]; Granovetter 1985; Dobbin 1994; Whitley 
1996, 2004; Krippner 2001; Grabher 2004; Peck 2005). Consequently, people will be 
affected by their context cutting across not only spatial, but also social, cultural, cognitive 
and organisational proximity (Morgan 2004; Boschma 2005). In particular, knowledge 
acquisition, production and use depends on a series of similarities to ease transfer as well 
as differences to ensure it is „useful‟ that are constituted by multiple types of proximity. 
 
Despite the suggestion that there are multiple types of proximity that impact on the 
operation of knowledge within the innovation process, it is important to point out that all 
forms of proximity entail some geographical basis. For example, people working in 
similar organisations (i.e. organisationally proximate) are also spatially situated in 
relation to one another; the same is true for social, cultural and cognitive proximity.  
Organisations are also socially, culturally and cognitively proximate. The extent of the 
proximity is crucial in determining the impact it has on knowledge and innovation, since 
too much proximity in one field may prove detrimental to innovation as would too little 
in another field (Boschma 2005). However, all such forms of proximity are spatially 
situated and therefore the spatial dimensions of knowledge and innovation processes are 
crucial to understanding regional development. Furthermore, although this knowledge-
space is geographically based, it does not mean that it cannot operate across scales. It is 
important to emphasise that the different knowledge types, forms and sources are 
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spatially delineated according to their specific features. Thus because tacit knowledge, 
for example, is allegedly difficult to transfer over distance it necessitates personal contact 
in a particular community of practice, which, in turn, will be spatially bounded, whether 
in certain types of organisations, institutions and locations. Overall this means that 
innovation dependent on knowledge will be located in specific sites because those 
locations have certain systemic (i.e. collective) and dynamic (i.e. historical) 
characteristics (functional, relational and associational) that are conducive to a particular 
innovation process. 
 
2.7 RESEARCH QUESTIONS AND CONCEPTUAL FRAMEWORK  
 
The over-riding aim of this thesis is to understand what is particular to the knowledge and 
innovation processes in the British biotechnology industry and, specifically, what the 
spatial dimensions are of such knowledge and innovation processes. There are a number 
of theoretical issues that need to be considered in order to construct a set of research 
questions that can adequately address this focus (see for example MacKinnon et al 2002; 
Malmberg and Maskell 2002; Markusen 2003). First there is the question of spatial scale 
and the difficulties that a particular focus entails; e.g. a local focus will not be able to 
address national or international dimensions. Second is the question of causation; e.g. do 
specific concentrations of industrial sectors indicate that local knowledge is important, or 
does local knowledge indicate that concentrating is important (Malmberg and Maskell 
2002). In the development of the theoretical framework outlined above (2.6) a number of 
these conceptual and methodological issues were considered in order to produce the 
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theoretical framework for the research agenda and methodology of the thesis. This draws 
upon a number of approaches, most specifically the following: 
 
 Value chains model 
 Systemic-dynamic (i.e. iterative-collective) innovation model, and 
 Biotechnology industry model. 
 
These approaches help to avoid a number of issues around space/scale. In particular the 
tendency for research on regional dynamics to focus on specific locations and especially 
„successful regions‟ (e.g. Silicon Valley) leads to a number of conceptual and 
methodological assumptions. First, that the region has some form of agency in that its 
regional assets or endowments create or cause success. Second, the regional focus 
encourages an interest in what regional actors do, rather that how they function. The 
former ends up being largely descriptive, whilst the latter aims for a more explanatory 
analysis (Maskell 2001). Finally, the regional emphasis discourages a comparative 
perspective by downplaying (or ignoring) the inter-connections between different 
locations and different scales. The first hypothesis seeks to address these issues:  
 
H1: There are „knowledge economy‟ concentrations because successful innovation 
depends on dynamic (i.e. across time) and systemic (i.e. across organisations) 
processes embedded in and across specific places. 
 
 66 
The spatial concerns are reinforced in the conceptualisation of causation also proving 
problematic. First, Ann Markusen (2003) has questioned the „fuzziness‟ of process 
language because it assigns causative agency to an „-ism‟ or „-ation‟, which hides the role 
and function of individuals and organisations. Second, the focus on „successful‟ regions 
can lead to „reversing causality‟ in that there is an assumption that a region is successful 
because of a certain regional asset or endowment, rather than that a specific asset leads to 
success (Malmberg and Maskell 2002). Finally, the concern with locational assets or 
endowments as causes of economic development emphasises supply-side factors and 
limits the importance given to demand-side ones. The second hypothesis seeks to address 
these issues: 
 
H2: Successful innovation in the knowledge economy depends on place-specific 
dynamic and systemic processes because different types of knowledge (including 
supply and demand) originate in different places and at different scales 
necessitating interaction both within and beyond concentrations. 
 
Finally, there are a number of broader conceptual and methodological concerns beyond 
those outlined above. The first of these is the need to avoid the static perspective of much 
regionally focused research (Malmberg and Maskell 2002). The second is the need to 
avoid focusing on a single actor (e.g. person, firm) because this ignores the collective and 
iterative innovation process. Finally, there is a need to identify knowledge exchange as a 
transfer process in which actors actively engage rather than simply being an automatic 
effect of certain types of proximity. The final hypothesis seeks to address these issues: 
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H3: The knowledge economy depends on different locations and scales of knowledge 
because different places have different locational assets that contribute to 
successful innovation in different ways and therefore necessitate linkages within 
and between locations. 
 
To examine and explore these research questions further, this thesis is designed around a 
conceptual and methodological approach that incorporates three different models for 
understanding the spatial dimensions of knowledge and innovation processes. The first of 
these is the value chains model popularised by Porter (1990) in his book The Competitive 
Advantage of Nations and other further research on industrial „clusters‟.xiv Without 
wishing to accede to the hyperbole around the cluster concept, it is still fruitful to utilise 
the value chain approach because it provides a useful means to avoid a number of the 
problems outlined above. In particular the value chains model enables the research to 
consider knowledge and innovation processes across organisations both within a location 
and with other locations, although the latter point is not a specific feature of Porter‟s 
(2000) later concept of the cluster (see Malmberg 2003; Malmberg and Power 2005). 
However, the emphasis on different and discrete features of the value chain, from 
logistics through operations to marketing, means that a diverse array of knowledges need 
to be included in the conceptual approach.  
 
The second approach is the „systems of innovation‟ model (Freeman 1982; Fagerberg 
2005), which emphasises the collective and iterative features of knowledge and 
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innovation processes. This avoids two conceptual problems, namely the assumption of 
linear progression in innovation (see Figure 2.2) and that individual people or 
organisations are the drivers of innovation. Instead the innovation systems approach 
enables research to consider the collective and iterative aspects of the knowledge and 
innovation processes.  
 
Figure 2.2: Linear Innovation Model 
 
 
This is illustrated in the work of von Hippel (1994) and Kline and Rosenberg (1986) who 
outlined a „chain-link‟ model of innovation (see Figure 2.3). In these models it is the 
relationship and interaction between actors (e.g. people, organisations) that represents the 
locus of innovation. There is an inherent spatial dimension to these innovation models 
because they position the process within the relationships and interactions between 
spatially embedded actors (e.g. organisations), which benefit from their location to 
differing extents (see Moulaert and Sekia 2003 for a summary).  
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Figure 2.3: Chain-Link Model of Innovation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Kline and Rosenberg (1986). 
 
The final approach is specific to the biotechnology industry and draws on the work on 
this particular sector. Early analyses drawing on strategic management and innovation 
studies approaches (see Senker 2005) emphasised a number of features of biotech 
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innovation that have since been incorporated into more spatial perspectives. To start with 
there was an emphasis on alliances and collaborations between firms and cognate 
organisations both „upstream‟ (e.g. universities) and „downstream‟ (e.g. large 
pharmaceutical firms) from biotech firms (see Hamilton et al 1990; Chakrabarti and 
Weisenfeld 1991; Dodgson 1991; Greis et al 1995; Deeds and Hill 1996). Later work 
drew on research in innovation studies and also highlighted the important role of such 
external collaborations. This research emphasised the particular advantage held by some 
firms because of their location in certain countries (e.g. the USA) as opposed to other 
parts of the world (e.g. Europe) (see Walsh et al 1995; Senker et al 1996; Acharya et al 
1998; Saviotti 1998; Saviotti et al 1998; Senker 1998, 2004, 2005; Acharya 1999; Senker 
et al 2000).  
 
In the more recent geographical analyses, there is a continuing emphasis on the 
importance of external knowledge, although this time there is a difference between 
adherents to Krugman‟s (1991) „new economic geography‟ (or more accurately 
„geographical economics‟) and existing economic geography or regional studies. The 
former largely emphasises the importance of local knowledge spillovers (see Prevezer 
1997; Audretsch 2002, 2003; Johnson and Mareva 2002; Fuchs 2003; Fuchs and Krauss 
2003). However, the latter tends to also stress importance of extra-local knowledge, 
sometimes to a greater extent than local knowledge (see Lawton-Smith et al 2000; Zeller 
2001, 2004; Coenen et al 2004; Cooke 2003a, 2004a; Leibovitz 2004; Ryan and Phillips 
2004). Throughout this literature there is a common set of characteristics that can be used 
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to represent a stylised biotech concentration (see Ryan and Phillips 2004 for example). 
These include the following, to varying degrees: 
 
 Concentrations of dedicated biotech firms (DBFs) usually comprising small or 
medium sized enterprises (SMEs) 
 Linkages to „upstream‟ (e.g. universities) and „downstream‟ (e.g.large 
pharmaceutical firms) organisations that provide complementary competencies 
 Linkages to specialised service organisations like lawyers, business consultants, 
and accountants 
 Local identity that has led to the generation of trade associations or networking 
organisations 
 Local and national government involvement in the promotion and encouragement 
of a territorial approach to economic development. 
 
Below Figure 2.4 provides a visual representation of the innovation system that is 
particular to the biotechnology industry (CRIC 2000). However, one important caveat 
needs to be made in regards to this representation: it does not include any of the spatial 
dimensions of the various actors included in the process. Consequently it is important to 
incorporate the spatial features of the innovation process into a biotech innovation model. 
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Figure 2.4: CRIC Biotech Innovation Model  
 
 
 
 
 
 
 
 
 
 
 
Source: CRIC (2000). 
 
2.8 CONCLUSION 
 
The start of this chapter showed how knowledge has become an increasingly important 
focus in economic analyses and policy-making, especially after the 1950s. In part at least, 
this concern has led to the discussion of the „knowledge economy‟ as first conceived by 
the likes of Fritz Machlup and others. Although such concepts have been through a 
number of transformations as Godin (2006) and Sokol (2003) both illustrate, they retain 
the central concern with how a society based on industry has gradually – or rapidly in 
some cases – shifted to one based on services, knowledge and creativity (Florida 2002). 
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The role played by innovation in this economic change is argued to be pronounced as 
firms have adapted to changes in society by competing on „quality‟ as opposed to „price‟ 
(Cantwell 2002). This has, in turn, led to an interest in the systemic nature of innovation 
since individual firms and organisations find it increasingly difficult to acquire and retain 
all the necessary knowledge and skills needed to successfully innovate. Such „open 
innovation‟, as it has been called, cuts across organisations and embeds innovation in 
networks of actors who all benefit from the deliberate and often accidental transfers of 
knowledge between organisations and people (Chesborough 2003; Cooke 2006). Thus 
learning has become a crucial factor in the pursuit of innovation, as has the ability to 
convert different types of knowledge between different organisational and network 
settings. 
 
Throughout such debates the importance of space is illustrated in relation to the enduring 
concentration of knowledge and innovation processes in specific locations. The number 
of „territorial innovation models‟ (see Moulaert and Sekia 2003; Lagendijk 2006) that 
seek to explain the relationship between these concepts has proliferated throughout the 
last three decades. Broadly speaking, such models can be split between „functional‟, 
„relational‟ and „associational‟ theories, all with their own set of characteristics 
highlighted as the determinative factor in explaining innovation. However, this chapter 
outlined an approach that seeks to incorporate aspects of all these types of theories into 
one concept called the knowledge-space dynamic. As outlined above it seeks to explain 
knowledge and innovation processes in terms of their spatial and scalar specificity that 
entails the acknowledgement of the impact of cross-spatial and cross-scalar connections 
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as well as functional, relational and associational features of particular places. Thus the 
positioning and embedding of different types and forms of knowledge in different forms 
of proximity represent particular sites of knowledge and innovation. As a consequence of 
this approach, the research process and methodology outlined in Chapter 3 have been 
designed to address these conceptual issues. 
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CHAPTER 3 
STUDYING THE KNOWLEDGE ECONOMY: 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 INTRODUCTION 
 
The last chapter (Chapter 2) outlined the theoretical framework that drives the thesis 
and its research design. In brief it shows how the knowledge economy is premised on 
the concept of economic development through the pursuit of innovation, which, in 
turn, depends on the inter-relationship between knowledge and space that produces a 
knowledge-space dynamic. This dynamic consists of functional, relational and 
associational features that are positioned and embedded in particular places and across 
different scales. Consequently, it is important to ask research questions that address 
these concerns and design the research and its methodologies around it (3.2.1). In 
particular there are a number of issues with the designation of space and scale as well 
as with causation that entail the adoption of a particular research framework (3.2.2).  
 
Initially the research was designed to explore these questions using case studies of 
specific products, akin to the work on global commodity chains or global production 
networks (Gereffi 1994, 1996; Coe et al 2002; Hess and Yeung 2006), but this 
approach proved unfeasible for three reasons. First and foremost, there are very few 
clearly identifiable „biotechnology‟ products that have been developed by UK firms, 
especially pharmaceutical products. Second, it would have necessitated an in-depth 
approach focused on only a few products that would have limited its explanatory 
 76 
power. Third, because of the limited number of products it would have depended 
upon a few key informants who may not have been willing to take part. Consequently, 
the research design was broadened to incorporate a range products that had been 
developed at a number of different sites around the UK and that drew upon a range of 
diverse knowledge inputs.  
 
The approach taken in this thesis is therefore designed to use the biotech industry as a 
case study of the knowledge economy drawing on particular informants to explore the 
relationship between space and knowledge. It especially focuses on what types and 
forms of knowledge that informants drew upon during the development of successful 
innovations (i.e. those that have been marketed or near market). This chapter explains 
this research design (3.2) and in particular the data collection (3.4) phase. First it 
returns to the research hypothesis and outlines a number of research questions that 
were raised by the three main hypotheses and details the overall research design (3.2), 
before briefly addressing some of the ethical issues involved (3.3). Next it outlines the 
main methodological approach (3.4) covering secondary and primary data collection 
before concluding with a summary of Part I.  
 
3.2 RESEARCH DESIGN 
 
3.2.1 Research Questions and Hypotheses 
 
The overall hypothesis of the research was derived from the literature review outlined 
in Chapter 2. It was particularly concerned with how and why certain locations 
produce successful innovation in the knowledge economy. The positioning and 
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embedding of innovation in processes of knowledge-space is considered to be the 
main defining feature of the theoretical approach. This can be broadly laid out as 
follows:   
 
 Regional development in the knowledge economy depends on innovation  
 Innovation comes from knowledge 
 People produce knowledge 
 People consciously and unconsciously transfer knowledge 
 People work within organisations 
 Organisations and people are spatially situated. 
 
This brief outline underpins the overall thesis hypothesis. The central aim of this 
hypothesis is the exploration of the particular knowledge and innovation processes in 
the UK biotechnology industry, especially in relation to the spatial dimensions of 
these processes. The main hypothesis is therefore: 
 
Despite being an internationally distributed sector, biotechnology innovation 
is concentrated in regional nodes because these locations provide advantage 
through a knowledge-space dynamic that encompasses functional, relational 
and associational features. 
 
The dynamic between these three aspects of knowledge-space leads to innovation 
outcomes, some of which succeed and some of which fail. It is therefore important to 
remember that the tolerance of uncertainty and possible failure is a significant part of 
the innovation process.  
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The central hypothesis is itself split between three hypotheses that entail specific 
methodological concerns themselves. In each case the hypothesis is derived from the 
theoretical and methodological frameworks. The first (H1) of these concerns the 
dynamic and systemic features of innovation and how such aspects of innovation are 
spatially embedded. This hypothesis is largely addressed using secondary data 
collected on the UK biotech industry (Chapter 5). 
 
H1: There are „knowledge economy‟ concentrations because successful innovation 
depends on dynamic (i.e. across time) and systemic (i.e. across organisations) 
processes embedded in and across specific places. 
 
The second hypothesis (H2) concerns the particular knowledge processes involved in 
innovation that originate in and across different spaces and scales thereby 
necessitating interaction both within and across different locations.  This hypothesis is 
largely addressed using primary data collected on the role of different types and forms 
of knowledge in the innovation process (Chapter 6). 
 
H2: Successful innovation in the knowledge economy depends on place-specific 
dynamic and systemic processes because different types of knowledge 
originate in different places and at different scales necessitating interaction 
both within and beyond concentrations. 
 
The final hypothesis (H3) relates to the specific features of different spaces and how 
these impact on the innovation process. This draws on a theoretical position that 
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emphasises the importance of geographical, organisational and institutional influences 
on the innovation process. It has been largely addressed throughout Part II from the 
discussion of the historical background and global context of the UK biotech industry 
(Chapter 4) through the secondary data analysis (Chapter 5) to the primary data 
analysis (Chapter 6). 
 
H3: The knowledge economy depends on different locations and scales of 
knowledge because different places have different locational assets that 
contribute to successful innovation in different ways and therefore necessitate 
linkages between locations. 
 
Ourlined below is the research and methodological framework derived from the 
theoretical discussion developed in Chapter 2 and incorporating a number of the 
concerns with existing research on innovation processes and their spatial dimensions.  
 
3.2.2 Research and Methodological Framework 
 
In the last chapter (Chapter 2) a number of concerns were raised regarding existing 
research in economics, economic geography, regional studies and other fields that 
focus on innovation. In particular, nine main issues were raised that need to be 
addressed in the thesis‟ methodological approach. These are outlined in Table 3.1 
below, which consists of the particular research „pitfalls‟ that the thesis seeks to avoid 
as well the methodological model used to avoid this problem and the theoretical basis 
of this methodological choice.  
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Table 3.1: Methodological Framework 
RESEARCH PITFALL METHODOLOGICAL 
MODEL 
THEORETICAL BASIS 
Assigning agency to 
location (i.e. it causes 
success) 
Focuses on a chain (or 
sector) and not a region 
People produce knowledge 
Focus on what actor‟s 
doing, not how they 
function 
Value chain concerns 
interaction over action 
People rely on interaction 
Limits comparative 
analysis in the 
understanding of space 
Value chain represents an 
industrial sector and 
therefore has a comparative 
basis. 
People work with different 
knowledge 
„Fuzziness‟ of process 
language 
Innovation is conceived in 
neutral terms – i.e. it is 
neither an advantage nor 
disadvantage 
Knowledge has no value by 
itself 
„Reversing‟ causality (i.e. 
something is important 
because a region is 
successful) 
Innovation is considered as 
dependent upon 
knowledge; i.e. a product of 
people in place 
Knowledge is produced in 
place  
Supply-side focus Knowledge conceived in 
terms of  explicit and tacit 
continuum, therefore not 
supply-side focused 
Knowledge comes from all 
aspects of production 
Static research design Unit of analysis is a biotech 
product or technology and 
the process of innovation 
over time 
Locations inter-relate 
across different space, time 
and scale 
Singular actor focus „Systems‟ approach avoids 
reliance on a singular actor. 
Locations have multiple 
actors 
Relational emphasis Knowledge focus means 
that relational perspective 
was not emphasised 
Locations have endogenous 
features 
 
With caveats, the value chains model used in Porter‟s (1990) earlier work proves a 
useful conceptual perspective because it enables the research design to focus not just 
on „successful regions‟, but also on other regions whose innovation processes may be 
more difficult to identify. Because the research design focuses on a value chain and 
not a region and because the value chain concentrates on interaction over action, the 
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research design also emphasises the functioning of actors over a description of their 
actions. Finally, because the value chain represents an industrial sector rather than 
particular location it provides the means to develop a comparative perspective.  
 
The conceptualisation of innovation as an iterative and collective process means that 
knowledge can be both the main focus of research and conceived as a product of 
different organisational environments. Successful innovation can therefore be seen as 
dependent upon interaction between such organisations. This conceptualisation means 
that the „causation‟ problem can be avoided. First, because innovation is conceived in 
neutral terms – i.e. it is neither an advantage nor disadvantage – it is not considered in 
„fuzzy‟ or normative terms. Second, because innovation is considered as dependent 
upon knowledge, which is, in turn, seen as a product of people – who interact within 
and through their organisational environment – there is a specific causative direction. 
Third, because knowledge is conceived in terms of Polanyi‟s (1967, 1973) explicit 
and tacit continuum the research did not only focus on the supply-side of the process. 
 
Finally then, the biotech innovation model means that the research incorporates the 
value chain and innovation models above in a specific sectoral model that avoids the 
final three methodological „pitfalls‟. First, by focusing on value chains the framework 
establishes the relevant unit of analysis as a biotech product or technology and the 
process of innovation. It therefore avoids a static research design. Second, by 
emphasising a „systems‟ approach in focusing on a process the research avoids 
emphasising a singular actor. Finally, because the research focuses on knowledge – in 
all its forms – it does not emphasise a particular relational perspective, but rather 
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takes account of the possible spatial characteristics inherent in knowledge production 
and transfer.  
 
3.2.3 The Case Study Approach 
 
The research design uses a case study approach because the research field – the 
biotech industry – covers a range of analytical units – e.g. product value chains. Each 
value chain is therefore an element of the case study, which seeks to represent the 
biotech industry as an example of the „knowledge economy‟. The case study approach 
suits the methodological framework because it seeks to be explanatory, which Yin 
(2003: 6) argues leads to “operational links needing to be traced over time”, rather 
than the more traditional focus of case studies on an „instance‟ (see Blaikie 2000: 
215). Each value chain is conceived as temporally as well as spatially contextual and 
thus each chain covers the whole of the innovation process from, crudely speaking, 
the initial „discovery‟ stages to product sales.   
 
Case studies are inherently dynamic because they concern more than a single point in 
time. Thus they can incorporate the dynamic elements of the methodological 
framework outlined above. However, because it needs to cover a specific context 
(Bryman 1996: 100) – which in this case is the UK biotech industry identified – and 
spatial research needs to avoid a location emphasis, the case study needs to be focused 
on an industrial sector. Furthermore, by focusing on value chains – constituting the 
overall case study – the research avoids the static, spatial focus on „what‟ 
organisations do and, in contrast, focuses on the more dynamic, organisational aspects 
of „how‟ they do it (i.e. function) (Maskell 2001).  
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In summary the theoretical and methodological concerns raised in Chapter 2 and in 
this chapter above encourage the adoption of a case study approach because a regional 
focus could not be used. The conceptualisation of innovation as systemic and dynamic 
also means that the biotech value chains are designated as the units of analysis and 
therefore necessitate a non-static and organisational perspective. The case study 
approach also enables the research to avoid one major issue with a focus on value 
chains. There is a possible issue here with the need for specific informants (i.e. people 
involved in a value chain) that may lead to problems with access to informants 
(Arksey and Knight 1999) and commercially sensitive data (O‟Neill 2003). However, 
the case study approach sufficiently broadens the research area and thereby alleviates 
the possible threat of low response rates and inaccessible informants. 
 
3.2.4 Initial and Revised Research Designs 
 
After choosing the case study approach it is important to consider how a sample 
population is to be identified for each unit of analysis (i.e. biotech value chain). The 
initial research design centred on a „product history‟ approach akin to the global 
commodity chains (see Gereffi 1994, 1996) or global production network (Coe et al 
2004) perspectives. This would have centred on a small number of products and 
analysed their historical development in depth. However, there were some crucial 
weaknesses with this approach. First, there were only a small number of clearly UK 
origin biotechnology products, which could have meant that data availability would 
be very low. Second, and following on from the last point, the small number of 
products would have meant that any research would have been highly reliant on 
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access to certain informants and data. This was a special concern with biotech because 
of the importance of commercially sensitive and confidential product data. Therefore 
informants may have been reluctant to take part. Third, the popularity of the biotech 
sector as a research site may also have been an issue because of the time and energy 
needed using a product history approach; interview or survey „fatigue‟ was therefore a 
particular concern (Healey 1991). Thus to broaden the sample size it was necessary to 
expand beyond a product history approach. 
 
The research design therefore focuses on the role and use of knowledge in the biotech 
industry using value chains as a means to identify the sites of innovation and 
knowledge processes, especially the transfer and acquisition of different types and 
forms of knowledge. The research design is oriented towards quantitative research 
techniques and in particular it uses a mixed survey methodology comprising 
standardised questions administered via structured telephone interview or as a 
questionnaire. Informants are identified through their involvement in a biotech value 
chain, which are, in turn, identified using secondary data. Thus the value chains 
themselves are part of the methodological framework rather than the point of the 
methodology itself. There is still an issue with access to secondary data – especially 
because of commercial confidentiality – and primary data – especially in access to 
„elite‟ groups – but these concerns are lessened using this approach (Stewart and 
Kamins 1993). However, both issues are still central concerns in the research ethics 
and design of the mixed method survey, which needed to ensure confidentiality and 
anonymity as well as reassure elite informants that taking part will not require 
excessive time or effort.  
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3.3 RESEARCH ETHICS 
 
3.3.1 Research Ethics 
 
During the research process, ethical approval was sought and received from the 
research ethics officer of the Department of Planning at Oxford Brookes University. 
Final approval was received on form SOPE1 in September 2003. Where relevant, the 
research design complies with the Oxford Brookes Code of Practice regarding the 
„Ethical Standards for Research involving Human Participants‟. At the same time I 
attended a University training session on the „Principles of Ethical Research for 
Studies involving Human Participants‟. 
 
The mixed methods survey had been based on informed consent with details on the 
project, its aims and initial motivations provided to informants when they were 
approached. Perhaps the most significant issue that has already been highlighted 
above is how to maintain and assure confidentiality, particularly commercial 
confidentiality, whilst administering the survey. During administration by either email 
or telephone each informant had been assured of anonymity and confidentiality. This 
is maintained in two ways. First, the standardised survey questions are worded in such 
a way as to avoid the need for a specific, self-identifying answer (see Appendix 3.1  
for the coding frame), whilst informants‟ responses to the open questions are 
anonymised. Secondly, during analytical coding of the survey responses the survey 
title page, containing personal information on the respondent, had been removed.  
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Where relevant potentially revealing comments recorded in the survey itself are also 
erased or deleted on electronic copies. The front pages have been disposed of, but an 
electronic record of the identities of respondents has been kept by the researcher and 
updated regularly. Once the final response had been completed the electronic files 
were deleted from the university computer although an electronic backup was kept in 
a secure location. All hardcopy survey responses have been kept in a locked desk 
draw until the analysis stage when the standardised questions were input into an SPSS 
data format and the open question responses were transcribed. Once this had been 
done, these survey hardcopies were disposed of. 
 
3.3.2 Researching Elites 
 
A secondary element that had to be taken into account during the research design is 
the special circumstances surrounding research on „elite‟ groups. Whilst the term 
itself is certainly ambiguous (see Woods 1998), the conceptualisation of an „elite‟ 
informants plays an important role in methodological design. There are several things 
that need to be taken into account in terms of a research design based on accessing 
biotech firm managers, academics and service provider personnel. First, approaching 
elite informants requires short, concise requests and administration because of time 
constraints (Kincaid and Bright 1957). Second, preparation is vital because informants 
are willing to argue, sometimes forcefully, their own point of view, especially where 
they do not see the point of the research emphasis. Therefore it is necessary to be 
prepared to defend this focus. Third, informants are not necessarily restricted to a 
clear set of organisational boundaries or locations (Cochrane 1998). Some informants 
move around frequently, both within and across organisations, whilst others spend a 
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considerable amount of time moving between locations, in meetings or tied up in their 
work. For example, over about eight months I attempted repeatedly, and in the end 
unsuccessfully, to interview one informant, who was a venture capital investor, even 
after they had agreed to participate.   
 
3.4 RESEARCH METHODOLOGY 
 
3.4.1 Sampling 
 
The sampling process was two phased. In the first phase a series of value chains were 
identified through the collection of secondary data on biotech products and processes. 
Although there had been several problems during this phase, usually concerning the 
difficulty identifying relevant value chains, eventually enough value chains were 
identified. The second phase consisted of the identification of individual informants 
drawn from value chains identified in the previous phase.  
 
3.4.1.1 Value Chain Identification  
 
The value chain sample was constructed from both biotechnology products and 
biotechnology processes in order to broaden the sample and account for technologies 
that are intangible (e.g. bioinformatics platforms) or designed for intermediate 
markets (e.g. drug delivery platforms). For ease these are all referred to as „products‟ 
throughout the thesis. In each case the product had the following four characteristics: 
  
 It had to be marketed, have been marketed or be near market (i.e. be successful) 
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 Its sale had to benefit a UK company (i.e. contribute to the UK economy) 
 Its R&D had to occur at least partially in the UK (i.e. derive from UK knowledge) 
 It had to involve biological science or be produced by a biotech company (i.e. be 
part of the „biotech industry‟). 
 
A sample population was created through the collection of secondary data on biotech 
products. This started with regulatory agencies like the FDA, EMEA, Canadian drug 
agency, and MCA (now MHRA). However, because the number of products 
identified this way was limited, covering pharmaceutical products only, it was 
necessary to broaden the approach. Consequently, biotech databases and consultancy 
reports were used to identify other products because they referred to the products / 
technologies of firms. Furthermore, after a database of firms had been created (3.5.1) 
it was possible to check their websites and identify any relevant products through 
such internet sources. Using these methods it was possible to identify around 250 
biotech firms (over half the total number) which sold some sort of product, although 
in most cases these were limited to research tools and techniques, components, and 
technology platforms.  
 
All biopharmaceutical products identified by the FDA and EMEA were included in 
the sample because these tend to be the products that are most often analysed in 
existing research. No agricultural crop products were included because of the 
moratorium on crop growing in the UK until 2004. There were other agricultural 
products, but these refer to products like feed enzymes or pest control products. A 
significant number of products were tools or techniques for use in the biological 
sciences (e.g. platform technologies) rather than products for general sale. It was 
 89 
necessary to include these types of products because of the limited number of 
products in the therapeutic and agriculture sectors. 
 
In order to identify the relevant informant for the mixed methods survey it was 
necessary to collect secondary data on the biotech products covering a number of 
characteristics. In particular it was important to identify where development had taken 
place and who had been involved in development. The exact information collected 
includes the following: 
 
 Type of product 
 Product sector: e.g. therapeutic, agricultural 
 Product launch or approval date 
 Product‟s marketer  
 Product‟s developer 
 Development collaborators. 
 
It is difficult to acquire this secondary data on biotech products, especially where the 
aim is to create an adequate sample population, because the number of marketed 
products is limited (as with therapeutics) or information is scarce (as with platform 
technologies). Despite claims to the contrary in the BIGT (2003) report on the UK 
biotechnology industry, there are few biopharmaceutical products that have been 
developed by UK firms. For example, BIGT (2003) provides a list of around 40 UK 
„biotech‟ products, which includes both chemical substances and products developed 
outside of the UK. However, the number is really nearer 10 biopharmaceuticals and 
even some of those are loosely defined, no longer marketed, or jointly developed with 
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non-UK firms. Furthermore, the secondary data on other types of biotech products 
was also limited meaning that only brief details for 107 biotech products could be 
acquired covering the 250 identified companies with products (see above). These 
products therefore do not represent a random sample per se, but rather a sample based 
on data availability that enables the identification of individual informants involved in 
the product‟s value chain (see Appendix 3.2 for a list and Appendix 3.3 for an 
analysis). 
 
3.4.1.2 Informant Identification  
 
The identification of biotech value chains enables the identification of informants who 
have been involved in the development of the particular product. These informants 
were initially separated into three distinct populations to cover the biotech innovation 
system: (1) company informants, (2) science base informants, and (3) service provider 
informants. These had been defined in terms of their organisational position within 
the value chain: 
 
 A company informant was someone in a company carrying out R&D on 
biotechnology 
 A science base informant was someone connected to a biotech company 
whether through their research or position (e.g. Science Advisory Board 
(SAB) member) 
 A „service provider‟ was a person in a non-biotech organisation that provided 
non-R&D services during development. It is a broad category that covers a 
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range of services, from the usual legal or consultancy services through to 
technology transfer offices to regional development agencies and regulators.   
 
However, this original three-way distinction had to be abandoned because of the poor 
response rate from science base informants. Instead, two categories were used: 
 
 Innovator: covering anyone involved in R&D anywhere throughout the value 
chain. 
 Service provider: covering anyone involved in a non-R&D function anywhere 
throughout the value chain, although still outside the firm.  
 
The reason for distinguishing between informant populations is to see whether there 
are any major differences in their responses in the mixed survey. Since all respondents 
are considered as members of the value chain, conceived in systemic terms, it is 
interesting to consider the differences between „innovators‟ and „service providers‟ to 
explore whether the innovation process can actually be conceived in such a systemic 
fashion. Any differences between the informants would also be useful in illustrating 
the different position of different actors with the innovation process and the particular 
knowledge that these different actors draw upon based on their role and function.  
 
Both sample populations were identified using the biotech value chains, defined as a 
particular product. The innovator informants were identified using two main methods. 
First, from a patent search for a relevant product and then an internet search of the 
company website for the relevant person. This proved to be a surprisingly successful 
method for a number of products, but usually only for smaller firms and therefore 
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another method proved necessary as well. Secondly, informants were chosen from 
firms themselves, either (initially, but later dropped) from SABs (for science base 
informants) or from management teams. The usual informant chosen was either the 
Chief Scientific Officer (CSO) or Chief Technology Officer (CTO), although where a 
manager‟s biography mentioned a specific product then they were chosen.  
 
The service provider sample was slightly more difficult to identify. They were chosen 
because of their position within an organisation that had some sort of connection to a 
particular value chain. For example, where a value chain firm was located on a 
science park then the science park manager might be approached, or if the firm had a 
particular investor then one of investment managers might be approached. More 
generic informants were also approached where they are part of organisations like 
Regional Development Agencies (RDAs) or government departments (e.g. the DTI 
Bioscience Unit). Because of the way that the methodological framework was 
constructed the experiences and perceptions of these „service provider‟ informants are 
treated the same as „innovator‟ informants. 
 
The main problems with this sampling process derives from the reliance upon 
identifying specific biotech value chains and then associated individual informants 
who played a part in it. Knowing whom to focus on is a problem in research, 
particularly with business informants whose „status‟ may prove ambiguous (see 
Cochrane 1998). In order to avoid this issue, the research design concentrates on 
specific individuals involved in the value chain. In a majority of cases these can be 
identified in the innovator sample population with over two-thirds (39 out of 58) 
directly associated (i.e. worked on research and/or development) with a particular 
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product. The other third (19 out of 58) were chosen according to job title and, where 
possible, relevance to R&D (see Markusen 1994 for problems with using occupational 
titles). A secondary problem is the low response rates from specific population types, 
in particular university academics. The initial three-way sample approach had to be 
adjusted because so few academics were willing to participate; usually for time 
reasons, but also because they did not associate themselves with a particular value 
chain. The use of SABs did not solve this problem because most SAB members are 
there to reflect financial credibility, rather than provide direct scientific and technical 
input (see Audretsch and Stephan 1996). Finally, the original approach to service 
providers had to be adjusted because of confusion over the questions in the mixed 
methods survey as identified during the pilot study phase as outlined below. 
 
3.5 DATA COLLECTION AND RESEARCH METHODOLOGIES 
 
A number of issues helped to influence the choice of methodologies. For example, the 
initial research design focused on „product histories‟ and had led to the collection of 
secondary data on biotech products (see Appendix 3.2, 3.3) and firms (see Chapter 
5). This data proved useful in the subsequent research framework. The research also 
largely followed a „realist‟ approach – in that it is concerned with the existence of a 
material world understood through particular social descriptions (Williams and May 
1996: 81-82) – and therefore focuses on causation rather than „refining‟ or 
questioning material descriptions. Consequently the research methodologies are 
concerned with the „representativeness‟ and „reliability‟ of the phenomenon under 
consideration (i.e. knowledge-space processes in innovation) over and above 
„validity‟ (Bryman 1996). This means that data collection has been split between the 
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collection of secondary data from primary sources (e.g. databases, websites) and 
primary data using a mixed methods survey administered through structured phone 
interview or as an email questionnaire.  
 
The first stage of the research had been the collection of secondary data on biotech 
products and firms. There were two main reasons for collecting data on biotech firms; 
the first was to generate a database on the UK biotech industry and the second was to 
identify a sample population for the primary data collection. Since the latter has 
already been discussed above, we will deal with the former here. The purpose of the 
secondary data on firms was to address the first hypothesis and thereby complement 
the primary data generated through the mixed methods survey that addressed the 
sedond hypothesis (Markusen 1994). Thus the secondary data provides the grounding 
for the primary data analysis through describing the UK biotech industry, especially 
in relation to the analysis of the spatial distribution and connections between different 
scales. 
 
3.5.1 Secondary Data Collection 
 
The secondary data on the biotech sector came from a number of primary sources (see 
Tables 3.2, 3.3, 3.4 and 3.5 below) and was used to construct a database in a number 
of electronic formats depending on the analytical use to which it was put. The 
database covers the whole UK biotech industry and details a number of firm-level 
indicators chosen because of their relevance to the theoretical and methodological 
framework. It also covers other organisations like public research organisations 
(PROs) and universities. The data is analysed on a territorial basis using software such 
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as Microsoft Excel and SPSS. In particular, the data is split between three scales 
based on Eurostat regional designations:  
 
 NUTS1 (equivalent to RDA designations) 
 NUTS2 (equivalent to two or three counties) 
 NUTS3 (equivalent to one county or city). 
 
These Eurostat designations were used because they are scalable in that one scale 
leads to another and the data is therefore easier to compare across scales. Second, it 
enabled the use of secondary data derived from Eurostat itself. Third, the data 
collected during the research would also be relevant beyond the confines of the UK. 
Finally, such scales are based on population, rather than administrative, boundaries 
which means they are relevant for population specific indicators. 
 
The first stage of secondary data collection involved identifying biotech firms, which 
necessitated a definition of „biotechnology‟ that could be applied to firm activities, 
especially their research activities. This definition follows previous ones used in 
policy circles (e.g. ACARD et al 1980; House of Lords 1993; DTI 1999a, 1999b) in 
order to make the research policy relevant. As a consequence it is a broad definition 
covering firms that primarily use biological production processes and / or produce 
biological products. However, since the thesis focuses on innovation processes only 
firms that carry out R&D were included. Overall this means that pharmaceutical 
companies, major corporations, and other specialist supplier and service firms are not 
included in the definition. Thus the database may not reflect the whole scope of 
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biotechnological activity within the UK although studies by the DTI (2005) and 
Critical I (2006) have used similar approaches.   
 
Firms were identified through regional biotechnology associations such as ERBI, 
OBN, and Scottish Enterprise, which means that they are largely self-selecting and 
therefore cover a number of unsuitable firms (e.g. reagent suppliers and service 
firms). Therefore it was necessary to filter the firms by refining the database 
according to the above definition particularly in relation to R&D activity. 
Furthermore, because regional associations are self-selecting it is necessary to search 
other biotech databases produced by private organisations such as Biospace and the 
BIA (free access) as well as BioWorld and BioCommerce (subscription service); the 
latter were accessed either through copyright libraries or on trial periods. This cross-
checking of firms between the regional associations and biotech databases helped to 
filter out unsuitable firms as well as provide information on those firms included in 
the database. 
 
The collection of data on firm indicators was determined by the theoretical and 
methodological concerns highlighted above.  They primarily cover „knowledge‟ 
factors such as the number of patents a firm has, the size of its R&D employment and 
the number of alliances it has. Data on the basic characteristics – e.g. location, 
foundation date, employee numbers etc. – was derived from two sources, either a 
biotech database or the FAME internet database of all UK firms,
 xv
 depending on 
which was most up-to-date. Data on the knowledge indicators came from a range of 
other electronic sources. For example, patent data came from searches of patent 
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offices. The sources of the basic secondary data on firms are outlined below in Table 
3.2, which also highlights the data coverage and type.   
 
Table 3.2: Secondary Data Sources: Firms and Products 
DATABASE ACCESS COVERAGE TYPE 
Bioworld  Pay (3-week trial) Industry  Firms, products, 
alliances, finances 
Biocommerce Pay (OBN copy) Firms Firms, statistics, 
Biospace Pay (part free) Products Marketed products 
are free access 
BIA Pay (part free) Firms  Firms, products 
Bioscorpio Pay (part free) Industry Firms, products 
Nature 
Biotechnology 
directory 
Pay (part free) Firms Firms, statistics 
Genetic 
Engineering News  
Pay (part free) Products, 
technologies, 
science 
Products, alliances 
BIO Free Industry  Firms, products, 
statistics 
Biotech Analytics Free Firms  Firms, histories and 
products 
Informagen.com Free Firms Addresses 
National Center 
for Biotechnology 
Information 
(NCBI)   
Free Products, 
technologies, 
science 
Products, histories 
Open Directory Free Information 
sources 
Databases, 
webpages  
Oxfordshire 
Bioscience 
Network (OBN) 
Free Firms Firms 
ERBI Free Firms Firms, products 
BioDundee Free Firms Firms 
Bio Sci North Free Firms Firms 
London 
Biotechnology 
Network 
Free Firms Firms, products 
Scottish 
Enterprise 
Free Firms Firms 
 
Once a list of products and firms had been compiled, secondary data on firm-level 
knowledge indicators was collected from the same secondary sources and from 
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relevant primary sources. Once this data was collected it was input into the database 
as well. The source of data on firm-level indicators is shown in Table 3.3 below. 
 
Table 3.3: Secondary Data Sources: Knowledge Indicators 
INDICATOR SOURCE 
Location FAME database, company website, 
biotech database 
Company type (e.g. public, private) FAME database 
Biotech sector (e.g.. therapeutic, agriculture) Company website 
Ownership (foreign) FAME database, company website 
Spin-out Company website, university 
technology transfer offices 
Foundation Date FAME database, company website 
Turnover 2001-03 FAME database, biotech database 
Employment 2001-03 FAME database, biotech database 
Employment R&D 2001 Biotech database 
Total Alliances 1997-2004 Bioworld database 
Total International Alliances 1997-2004 Bioworld database 
Total UK Alliances 1997-2004 Bioworld database 
R&D Spend $ www.innovation.gov.uk - R&D 
Scorecard, biotech database 
Number of Patents USPTO <2003 USPTO 
Number of Patents EPTO <2003 esp@acenet (patent database) 
Number of Articles <2003 ISI Web of Science 
 
As well as data on products and firms, secondary data on universities and public 
research organisations (PRO) was collected. The main secondary source for this data 
was the university department lists from the 2001 Research Assessment Exercise 
(RAE), but biotech the databases already used to identify firms were also used to 
identify PROs. Instead of merely identifying whole universities, separate university 
departments were identified based upon their relevance to biotechnology. The 
departments chosen corresponded to those selected in the DTI (1999b) Genome 
Valley Report and are outlined below: 
 
 99 
 Agriculture 
 Biological Sciences 
 Chemistry 
 Clinical Laboratory Sciences 
 Hospital-based Clinical Subjects 
 Other Studies and Professions Allied to Medicine 
 Pharmacology 
 Pharmacy 
 Veterinary Sciences 
 
Table 3.4: University Department Indicators 
INDICATOR SOURCE 
Location Website 
Department RAE 2001 
2001 RAE Score RAE 2001 
1996 RAE Score DTI (1999b) 
Staff Numbers 2001 RAE 2001 
Total Research Council PhD Studentships  BBSRC, NERC, MRC websites 
Wellcome Trust Funding 1980-2002 Wellcome Trust 
NERC Funding 2003 NERC 
MRC Largest Recipients 2001/02 MRC 
BBSRC Top 50 Institutions by Total Approved 
Funds 
BBSRC 
 
PROs were identified from research council (RC) websites (e.g. MRC, NERC, 
BBSRC), the Wellcome Trust website, two biotech databases (Biocommerce and 
Nature Biotechnology), and the Genome Valley Report (DTI 1999b). Once both 
university departments and PROs were identified, secondary data was collected on 
organisational-level indicators covering information related to their knowledge base. 
These data sources are outlined in Table 3.4 for university departments and Table 3.5 
for PROs. 
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Table 3.5: PRO Indicators  
INDICATOR SOURCE 
Location Website, RC websites, biotech 
databases 
Institute Type Website, RC websites, biotech 
databases 
Foundation Date Website, RC websites, biotech 
databases 
Total Research Council PhD Studentships  BBSRC, NERC, MRC websites 
Staff Numbers 2001 Website, RC websites, biotech 
databases 
 
3.5.2 Primary Data Collection 
 
A mixed methodology survey was used to collect primary data (see Lavrakas 1993). It 
covered a series of standardised questions administered via either structured telephone 
interview or email questionnaire. Around 60% of the surveys was carried out via 
telephone interview and 40% by questionnaire with three face-to-face interviews 
carried out during the pilot phase. The choice of telephone or email administration 
was driven by the location and choice of the respondent – e.g. all international 
respondents were asked to complete a questionnaire, whilst national respondents were 
asked for a telephone interview. All the face-to-face interviews were within 
Oxfordshire (i.e. local).  
 
The mixed method survey took place over a 10-month period starting in December 
2003 and was split between a pilot and main phase. During the whole period a total of 
302 people were contacted – 174 innovators and 128 service providers – either by 
email (usually) or phone (where email information is unavailable). Of these people 
101 were unavailable or denied their relevance to the particular product value chain 
(33%), whilst 90 rejected the approach (30%) and 109 accepted (36%).  
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3.5.2.1 Mixed Method Survey: Pilot Phase 
 
The pilot phase covered December 2003 to January 2004 and consisted of eight 
structured interviews with six innovators and 2 service providers. It was stopped at 
this point because of a number of ambiguities with the questions. The pilot phase 
therefore proved a crucial part of the research process because it enabled the testing of 
the survey design as well as the questions and their meaning and interpretation by 
respondents. Such testing of surveys and their questions using a pilot phase is 
emphasised as crucial throughout the methodological literature (see Schoenberger 
1991; Healey and Rawlinson 1993; Arksey and Knight 1999).  
 
The pilot phase revealed an ambiguity within the research design that treated all 
informants whether „innovators‟ or „service providers‟ as similar actors in the 
innovation process. Because the questions focused on specific value chains (i.e. 
products) service provider respondents found the questions irrelevant to their roles in 
the innovation system because they did not see their role as directly impacting on 
innovation per se. The research design therefore contained a conceptual slippage 
between sampling and question rationale, which needed to be removed. For example, 
when service providers were asked about their role in value chains they denied 
involvement, but when asked about generic innovation systems (without reference to 
a product) the sampling frame lost its rationale and their answers became irrelevant.  
 
As a consequence of the pilot phase a choice had to be made between three 
possibilities. First, to not sample service providers at all; second, to use generic 
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questions for all respondents; or third, to use generic questions for service providers 
and specific questions for innovators. The first of these would limit the sample size, 
making the survey even more dependent on one sample population and skewing the 
methodological approach (i.e. that multiple organisation are involved in innovation 
providing different inputs that are all valid and important to success). However, the 
second choice would have meant that the sampling frame lost its relevance altogether. 
Therefore, the sampling frame was not changed (i.e. informants were still identified in 
relation to a value chain), but rather the questions service providers were asked were 
changed to make them generic. Thus, for example, instead of being asked:  
 
„Please rate how often you read information from the following sources 
during development?‟ 
 
They were asked: 
 
„Please rate how often you read information from the following sources?‟ 
 
Innovators were still asked the specific questions. The pilot process not only provided 
the means to address this design fault, it also meant that several other elements in 
survey administration could be practised. Thus it provided the opportunity to improve 
the precision of questions (Healey 1991); it helped to develop the interpretative advice 
given to respondents (Frey and Oishi); it improved the initial request techniques (in 
emails and phone calls); and finally it revealed the questions that informants found 
particularly problematic (Arksey and Knight 1999).  
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3.5.2.2 Mixed Method Survey: Question Choice and Design 
 
The pilot survey included a total of 109 standardised questions and five open 
questions with a general comment at the end. All the questions were developed in 
relation to the theoretical and methodological framework that draws on the existing 
literature on knowledge and innovation processes and their relationship to space. A 
number of people also provided advice on refining the questions as well as the layout 
and the design of the survey itself.  
 
The decision to use standardised questions was primarily to reduce the time needed 
for completion of the survey and thereby increase the response rate. The questions 
were designed around the Likert-scale (1 to 5) where 1 always represented the 
„lowest‟ response (e.g. very unimportant) and 5 the „highest‟ (e.g. very important). 
The inclusion of open questions was designed to avoid restricting the respondents‟ 
„voice‟ (Arksey and Knight 1999) and reduce any possible frustration at being limited 
to a certain set of responses; a particular concern with elite respondents (Schoenberger 
1991).   
 
The questions themselves were split between three sections (Relationships, Location, 
and External Influences) each of which was designed to cover an aspect of the 
methodological framework and the subsequent research questions. The sections 
covered the following issues:   
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 Relationships: these questions focused on the main interactions of each 
respondent and the source and types of explicit and tacit knowledge they 
access 
 Location: these questions focused on the location of each respondent in terms 
of the regional „assets‟ and importance of different labour markets 
 External Influences: these questions focused on the importance of external 
influences on the biotech industry, such as location of demand or government 
interventions. 
 
After the pilot phase the number of questions was reduced for two reasons. First, 
some of them were considered superfluous, whilst second the length of the telephone 
interview was considered to be too long by some respondents. Consequently, the 
number of questions was reduced to 79 standardised questions, three open questions 
and the general comment. The actual form of the questions was not changed except 
for the service provider sample population so the responses received during the survey 
phase could be used in the primary data analysis. The coding frame for the survey is 
contained in Appendix 3.1. 
 
3.5.2.3 Mixed Method Survey: Main Phase 
 
During the main phase of the survey the national-based informants were sent a prior 
request via email asking for an interview with the attached survey in Microsoft Word 
format. The survey included an introduction outlining the aims of the research as well 
as an Oxford Brookes logo and contact details to provide credibility. Because the 
introduction is an important tool for raising response rates, it was designed to identify 
 105 
myself and my university affiliation as well as explaining my research purpose and 
assuring confidentiality and anonymity (see Lavrakas 1993). In particular and taking 
Healey‟s (1991) suggestion into account the introduction also included information on 
the usefulness of the research by referring to the benefits it might have in relation to 
„regional economic growth strategies‟. The emailing of the survey questions prior to 
interview also proved useful because they then acted as a „flashcard‟ during the 
interview itself, which proved particularly useful with the standardised, Likert-scale 
questions (see Frey and Oishi 1995: 74-5). It also enabled respondents to raise 
preliminary issues. 
  
The email interview request included a comment stating that it would be followed up 
with a telephone call in the next two weeks to allow for time delays caused by 
holidays or other events and so that informants did not simply ignore the request. This 
also meant that the sample members could forward the email to another person within 
their organisational hierarchy, which happened several times during the research 
process (see Healey and Rawlinson 1993). Those informants with no identifiable 
email address were contacted directly by telephone to ask for an interview or to 
complete a questionnaire, but were given a similar introduction as that in the email 
(Lavrakas 1993). All internationally based informants were sent an email although in 
these cases they were only asked to complete the attached survey. Instead of emails or 
telephone calles large firms were sent letters addressed to either the „director of 
research‟ or „company secretary‟ asking if they would allow interviews of personnel 
involved in a particular product‟s development. This was usually necessary because of 
the added difficulty identifying a relevant sample member from such large 
organisations since they restrict the amount of published information on employees 
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and have complex hierarchies (O‟Neill 2003). Consequently it was a less successful 
than email approaches and more difficult to follow-up because of access difficulties. 
 
Only a limited number of informants chose to respond immediately to emails, which 
meant that most were also contacted by telephone. This was expected and the email 
pre-warning was designed to increase response rates (Healey 1991). The initial 
approaches were directed towards asking for an interview rather than administering 
the interview at that time as were the „cold-calls‟ to informants with no identifiable 
email address. This meant that interviews could be properly prepared and structured 
before administration. It also made it more convenient for the informant and hoepfully 
increased their response rate, especially because business informants may not wish to 
answer questions during work hours (Gilham 2000).  
 
On several occasions informants were willing to complete the interview at the 
approach stage, which necessitated a degree of preparedness before cold-calling. 
However, it was more usual for informants to either reject the request (for a variety of 
reasons) or accept and agree to arrange a time for the interview. Some also agreed to 
complete the questions and return them via email. The number of phone calls 
necessary to reach each informant was usually between one and six, although in some 
cases it was as high as 10. Where possible messages were left with each unanswered 
call stipulating the next time they would be contacted (e.g. tomorrow). 
 
3.5.2.4 Telephone Interviewing  
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The usual reason for choosing to use telephone interviewing is that it reduces the 
incidence of interviewer bias because the administration of questions can be tightly 
controlled thereby limiting any „interviewer effects‟ because an interviewer can be 
trained and supervised before and during interviewing (Fowler and Mangione 1990; 
Frey and Oishi 1995). Telephone interviewing is also seen as “well-suited to random 
and structured sampling” (Arksey and Knight 1999: 79) because there are electronic 
means to select respondents, such as „computer-assisted telephone interviewing‟ 
(CATI) and „random-digital dialling‟ (Lavrakas 1993; Frey and Oishi 1995). 
However, these concerns were not as important during the thesis‟ research process 
because each informant was individually selected in relation to their specific role or 
duties, which meant that each informant had to be treated differently.  
 
According to Lavrakas (1993) little is lost between face-to-face and telephone 
interviews, meaning that the former is not necessarily more relevant than the latter. 
However, it was hard to test this claim during the research because there were so few 
face-to-face interviews. Those that I did undertake invariably took longer, taking 
between 30 and 60 minutes, and the standardised format was less suitable than during 
telephone interviews. This aside, telephone interviewing had the following benefits:   
 
 It took less time than face-to-face interviewing (Frey and Oishi 1995) 
 It was cheaper than either face-to-face interviewing or a postal survey (Gilham 
2000) 
 There was a quicker response than a postal survey (Arksey and Knight 1999) 
 The social etiquette of telephone usage meant that termination was less likely 
(Lavrakas 1993). 
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Despite these benefits there were still several problematic aspects to telephone 
interviewing. First, they still took a lot of time because of the need to make multiple 
calls to initiate the request, the callback and then the interview (Arksey and Knight 
1999). The usual number of phone calls to conduct the interview was between two 
and 10, which was fairly reasonable in comparison to other studies ranging between 
five and 20 calls (see Frey and Oishi 1995). Second, because the sample population 
consisted of elites they were more difficult to tie down to a single location during the 
initial approach (Cochrane 1998). It was therefore necessary to call mobile phones as 
well as landlines, which could have interferred with the concentration of respondents. 
Third, although the short length of the interview was beneficial, it also meant that 
there was limited time to collect data. The suggested length of a telephone interview 
ranges between 10 minutes (Healey 1991) through 20-30 minutes (Lavrakas 1993), to 
a high of 50 minutes (Frey and Oishi 1995). During the initial approach informants 
were told that it would take around 15 minutes to do the interview, which was 
designed to encourage participation. Overall, the average (mean) time taken was 18 
minutes. Finally, the interviews were surprisingly tiring despite their short length 
because they required considerable concentration and sometimes detailed 
explanations. Overall, these issues meant that the complexity of the interview 
questions had to be limited, which in some ways created its own problems in that 
respondents often required interpretative advice (Lavrakas 1993; Arksey and Knight 
1999). 
 
3.5.2.5 Standardised Questions    
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As with telephone interviewing, the use of standardised questions is meant to avoid 
interviewer bias. However, the thesis‟ research design entailed a focus on the 
experience of informants rather than „factual‟ information about their organisation 
(Healey 1991; Healey and Rawlinson 1993). Therefore during the administration of 
the survey I played an important role interpreting the questions for respondents. 
Because I was the sole interviewer this did not affect the interpretative advice given to 
respondents and therefore avoided some aspects of „interviewer bias‟. It was apparent 
that interpretative assistance was almost a necessity with standardised questions 
because respondents often have very different understandings of terms or apply 
different meanings to concepts from the interviewer (Schoenberger 1991: 180-1).  
 
The main reasons to use standardised questions was to enable quality control of data 
collection through the easier construction of questions in relation to specific research 
aims (Lavrakas 1993). Second, because they increase time efficiency by taking 10-
20% less time (Groves 1989 in Arksey and Knight 1999), standardised questions 
enabled a larger respondent sample. During the thesis the average time per interview 
was 18 minutes, which was three more that claimed at the email or telephone requests 
stage (i.e. 15 minutes). Overall 83% of the telephone interviews took less than 20 
minutes. Third and most importantly, standardised questions improve response rates 
(Healey 1993), which Healey (1991) argues can vary considerably between 
methodologies. Frey and Oishi (1995) argue that a 70% response rate is reasonable for 
standardised questions for the general population, although this is lower for specialist 
populations. During the primary data collection phase a total of 174 innovators and 
128 service providers were approached over a 10-month period. After discarding 
those informants who were „not relevant‟ – e.g. they had no involvement with the 
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product in question or could not be contacted after repeated callbacks – the final 
response rate was 53% across the whole sample. There was little difference between 
the two main sample groups (innovators and service providers) and it would appear 
that the use of standardised questions with a mixed methodology helped to ensure the 
reasonable response rate. 
 
3.6 CONCLUSION 
 
The research design and methodological approach outlined in this chapter are meant 
to address the thesis hypotheses presented earlier in the chapter (3.2.1). The approach 
has been built upon a conceptualisation of the innovation process that incorporates 
three conceptual models identified in the last chapter (Chapter 2). These are the value 
chains model, the systems of innovation model and the biotech innovation model. All 
three represent crucial elements in the methodological framework (3.2.2). They are 
designed to address the central questions and issues that the knowledge-space 
dynamic raises regarding innovation processes in the knowledge economy and 
particularly in the biotech industry.  
 
First, the secondary data collected (3.5.1) during the research is meant to address the 
first hypothesis covering the question of whether knowledge economy concentrations 
are dynamic systems embedded in space. This is detailed in Chapter 5, which explores 
these issues by identifying a number of possible biotech concentrations in the UK and 
their particular characteristics that distinguish them from other concentrations. It then 
considers what types of proximity can explain such concentrations and how exactly 
the knowledge-space dynamic operates across different scales.  
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Second, the collection of primary data (3.5.2) is designed to address the second 
hypothesis on how the place-specific dynamic and systemic processes can be seen as 
originating in a number of different places, both within and across concentrations. 
This is explored in Chapter 6, which considers what different types, forms and 
sources of knowledge actors in the innovation process access. From this it is possible 
to argue that knowledge is positioned and embedded across different spaces and 
scales that are all necessary for successful innovation to occur. 
 
Finally, the collection of primary and secondary data alongside the exploration of the 
changing global and institutional context of the UK biotech industry is meant to 
enable the analysis of how different locational assets provide different advantages 
during the innovation process that therefore necessitate the formation of linkages 
within and across different locations. This analysis runs throughout Part II being 
incorporated in the next chapter on the background and context of the biotech industry 
(Chapter 4) as well as the secondary data analysis (Chapter 5) and primary data 
analysis (Chapter 6) in later chapters.  
 
Overall the research design and methodology adopts two distinct features. It reverses 
the causality of previous research by considering the knowledges – in all types, forms 
and sources – that actors use in the innovation process. It also adopts a specific spatial 
dimension, in that it considers each location as distinct from each other and therefore 
the site of geographical specificities. Consequently, the analysis of the biotech 
industry portrayed here concerns how different and distinct spaces of knowledge 
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position and embed different types and forms of knowledge that are then accessed by 
actors across and within different spatial scales.  
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PART I 
 
SUMMARY 
 
This section deals with the theoretical and methodological basis of the thesis, in 
particular outlining the core issues and problems that the thesis seeks to address. In 
particular these concern the spatial positioning and embedding of knowledge and 
innovation processes in the knowledge economy using the UK biotechnology industry 
as a case study. Chapter 2 provided a theoretical analysis of existing literature on the 
knowledge economy as well as theories addressing the importance of innovation to 
economic development and both knowledge and space to innovation. In so doing it 
provided the basis for a new approach called the knowledge-space dynamic that led 
directly to the construction of the methodological framework and research design 
outlined in Chapter 3. This entailed a case study approach using biotech value chains 
to produce an informant sample who were then questioned about the knowledge 
processes during the development of successful biotech innovations. As such the 
theory and methodology enabled the avoidance of reversing causality by addressing 
the importance of spatially-situated knowledge processes rather than assuming that 
such processes are important simply because of the success of particular locations.  
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PART II  
Background and Data Analysis 
 
The term „biotechnology‟ was first coined by the Hungarian Karl Ereky in 1917 to 
describe his work on the industrial fattening of pigs for the Austro-Hungarian war 
effort (Bud 1998: 7). Since then it has been defined in terms of three historical periods 
covering early biological processes like those undertaken by Ereky as well the 
industrial fermentation of the nineteenth and early twentieth century. More recently 
this definition has included „modern biotechnology‟ following the work of Crick and 
Watson on the double helix of DNA and later work in recombinant DNA techniques. 
It is during the modern period that biotechnology has assumed commercial 
importance and consequently come to represent a distinctive and perhaps even 
paradigmatic example of the knowledge economy. In this section the thesis outlines 
the historical development of biotechnology in the UK and the world as well as the 
global context of the current UK sector (Chapter 4). Subsequently the section consists 
of analyses of the secondary (Chapter 5) and primary (Chapter 6) data collected 
during the research process in response to the hypotheses developed in the last section 
of the thesis (Part I). In each of these chapters the primary focus of analysis is on 
understanding what the particular knowledge processes in the spatially embedded 
innovation system are and how these contribute to successful innovation. 
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CHAPTER 4 
PLACING THE BIOECONOMY: HISTORICAL 
BACKGROUND AND GLOBAL CONTEXT OF THE UK 
BIOTECHNOLOGY INDUSTRY 
 
4.1 INTRODUCTION 
 
As the discussion of knowledge-space dynamic in Part I shows, it is as important to 
ground any research on the knowledge economy in an analysis of the institutional 
environment and historical change as to focus on specific innovation processes. This 
is particularly important for the biotech industry because of the crucial role that 
institutions (e.g. intellectual property rights) play in promoting and encouraging the 
sector as well as the high expectations that are perceived to be necessary for its 
success (May 2000; Walsh 2002; Drahos and Braithewaite 2002, 2004). Such 
expectations can actually be seen as a constitutive element of the sector itself (Rajan 
2006) because of the important role they play in encouraging investment (Walsh 
2002). Thus it is possible to argue that the biotech industry is „socially constructed‟ 
through very deliberate legal, policy and legislative changes made by a number of 
governments in their pursuit of competitiveness in biotechnology over a number of 
years (Wright 1993; Loeppky 2004; Birch 2007). Overall the chapter concerns the 
particular institutional characteristics of the UK biotech industry in the wider global 
context in order to ground the later analyses in Chapters 5 and 6 as well as illustrate 
and address the third hypothesis that: 
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H3: The knowledge economy depends on different locations and scales of 
knowledge because different places have different locational assets that 
contribute to successful innovation in different ways and therefore necessitate 
linkages between locations. 
 
To do so this chapter provides an historical background for the discussion and 
analyses as well as positioning Britain within the global context. Although there are 
several thorough histories of developments in molecular biology and biotechnology, 
there are no histories of the biotechnology industry from its inception in the mid-
1970s until the present. Three examples of the former include: 
 
 Daniel Kevles‟ (1995 [1985]) In the Name of Eugenics which concerns the 
development of genetics from its origins in eugenics to the subsequent shift to 
molecular biology in the 1930s.   
 Robert Bud‟s (1993) The Uses of Life which is subtitled A history of 
biotechnology and concerns the development of biotechnology specifically 
from „zymotechnology‟ (i.e. fermentation) in the nineteenth century through 
chemical engineering to modern biotechnology.  
 Herbert Gottweis‟ (1998a) Governing Molecules which focuses on changes in 
the regulatory environment, particularly in Europe, covering modern 
biotechnology and how its subsequent development. 
 
However, these histories are limited and therefore it is necessary to provide at least a 
brief history of both modern biotechnology and the early development of the biotech 
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industry in the UK. This provides the historical background to the discussion of the 
global context in which the thesis has been undertaken. This is presented later in the 
chapter and covers two main issues. The first is the global context of the biotech 
industry, its comparative strength in different countries and especially the dominance 
of the USA. The second issue is the institutional environment in which biotechnology 
has developed both globally and in the UK, especially the changes in intellectual 
property rights (IPR). This discussion will ground the analysis of the secondary and 
primary data collected during the thesis in broader issues focused on the institutional 
changes particular to the biotech industry and how they have contributed to the 
development of the sector.  
 
4.2 HISTORICAL BACKGROUND 
 
4.2.1 Biotechnology Definition 
 
Biotechnology tends to be defined in terms of the application of the biological 
sciences to industrial production. In 1980 the Spinks Report used a definition of 
„modern‟ biotechnology (see later on difference between old and new) as “the 
application of organisms, systems or processes to manufacturing and service 
industries” (ACARD et al 1980: 7). The European Federation of Biotechnology (EFB) 
– founded in 1978 with the goal of promoting the development of biotechnology in 
Europe (Dibner 1986) – defined biotechnology in 1981 as the: 
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“…integrated use of biochemistry, microbiology, and engineering sciences in 
order to achieve the technological application of the capacities of micro-
organisms, cultured tissue cells and parts thereof” (quoted in Bud 1998: 9).  
 
Over a decade later in 1993, the definition of biotechnology remained broadly 
equivalent with the House of Lords Select Committee on Science and Technology 
defining it in “enabling” terms, which has persisted in later UK policy discourse. The 
Select Committee defined biotechnology as “the use of biological processes to make 
useful products (organisms, substances and devices)” (House of Lords 1993: 12). 
They argued that biotechnology is “not a single discipline”, but rather “it is a 
collection of quite different enabling technologies” such as recombinant DNA, cell 
fusion techniques, micro-infections, „biolistics‟, viruses and fermentation of cell 
cultures (ibid.: 14-15). The „enabling‟ concept was again emphasised in both the 
Biotechnology Clusters (DTI 1999a) and Genome Valley (DTI 1999b) reports which 
defined biotechnology as the “the application of knowledge about living organisms, 
and their components, to make new products and to develop new industrial processes” 
(DTI 1999a: 1). Interestingly, the latest government-sponsored report produced by the 
Bioscience Innovation and Growth Team (BIGT) in 2003 failed to provide a 
definition of biotechnology in its executive summary.  
 
The use of an „enabling‟ definition means that biotechnology is very broad covering 
many biological processes and not just those that occurred after the advent of either 
recombinant genetic engineering (1973) or cell fusion (1975). Consequently 
biotechnology has also been characterised in generational terms, such as “old 
biotechnology” – based on brewing and fermentation – and “new biotechnology” – 
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based on post-1973 or even 1953 developments (Bud 1993: 200). Another 
generational typology splits biotechnology between “first”, “second” and “third” 
generations. The first generation was characterised by the experimental application of 
biological processes in foodstuffs (e.g. brewing) and animal breeding. It can be traced 
back thousands of years to the beginnings of agriculture in the Fertile Crescent, which 
explains why biotechnology is often characterised as both old and new. Second 
generation biotechnology involved the industrialisation of biological production 
processes derived from greater scientific understanding and largely originated in the 
late nineteenth and early twentieth century. Finally, third generation (or „modern‟ 
biotechnology) dates from the 1953 discovery of the double helix structure of DNA 
and the subsequent breakthroughs in molecular biology and genetic engineering that 
followed this event (Acharya 1999; Brink et al 2004). Since 1953 there have been 
numerous „discoveries‟ and „inventions‟ that have led many commentators to 
proclaim a future „biotech age‟ (Oliver 2000) or „biotech century‟ (Rifkin 1999), even 
though there have also been a number false new dawns during this period (Glassman 
and Sun 2004).  
 
4.2.2 History of Biotechnology 
 
Whilst biotechnology, defined as the application of biology in technical form, has 
existed for millennia, modern techniques have their roots in the late nineteenth and 
early twentieth century, especially in genetics and eugenics (see Kevles 1995, 1997). 
A new “age of biology” was even proclaimed by the US geologist Clarence King as 
early as 1892, whilst the term “biotechnology” itself was fist coined in 1917 by the 
Hungarian Karl Ereky (Bud 1993). Later in 1936 Julian Huxley claimed that 
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“biotechnology will in the long run be more important than mechanical and chemical 
engineering” (quoted in Bud 1998: 6). Despite such early support, modern 
biotechnology was derived from molecular biology, which was at least partially a 
response to the decline of eugenics as a discipline, if not a movement.  Eugenics had 
been a dominant approach across many developed countries from the nineteenth 
through to the twentieth century, but was increasingly sidelined from the mid-1930s 
as molecular biology superseded it (see Kevles 1995; Gottweis 1998a, 1998b).  
 
Molecular biology research was initially funded by private and charitable 
organisations like the Rockefeller Foundation and Volkswagen Foundation, but after 
World War II the state became increasingly involved as science policy was aligned 
with national goals (see Yoxen 1981; Gottweis 1998a). The USA government in 
particular supported „big science‟ projects with Vannevar Bush, head of the Office of 
Science Research and Development, contributing to the rise of the National Institutes 
of Health (NIH). In Europe equivalent changes took place with the European 
Molecular Biology Organization (EMBO) originating in the 1950s (Yoxen 1981; 
Gottweis 1998a). The role of private foundations has not declined in importance since 
then. Today they still contribute significantly to the research effort as illustrated by 
the role played by the Wellcome Trust in the UK science base where its annual 
expenditure of $1 billion contributes enormously to basic research (Cooke 2004b). 
However, state investment remains a central plank in the development of basic 
science and its application as the recently completed Human Genome Project (HGP) 
shows (Loeppky 2005).  
 
 121 
The first major break with the molecular biology focus was the development by James 
Watson and Francis Crick of the „double helix‟ model of DNA in 1953 at the Medical 
Research Council (MRC) funded Laboratory of Molecular Biology in Cambridge 
(Bud 1993). Prior to this, in 1944, researchers at the Rockefeller Institute in New 
York had established that it was DNA and not proteins that bore genetic information 
thereby encouraging the subsequent mapping of DNA (Dutfield 2003). However, the 
research by Crick and Watson as well as later work on both DNA and proteins in the 
1950s and 1960s did not lead to major commercial developments. There was a thirty-
year gap before modern biotechnology produced its first major commercial   
commodity.  
 
In 1973 Stanley Cohen, Herbert Boyer and their colleagues at Stanford University and 
the University of California developed a recombinant DNA (rDNA) technique which 
provided the means to insert foreign genes into microorganisms (Rifkin 1999; 
Dutfield 2003). The commercial application of rDNA and, shortly afterwards, the 
development in 1975 of hybridoma techniques by Georges Köhler and Cesar Milstein, 
who both worked at the MRC Laboratory of Molecular Biology (Cambridge), 
heralded the start of the „biotech industry‟ proper. The latter technique enabled the 
fusion and multiplication of monoclonal antibodies (Sharp and Senker 1999). Several 
subsequent discoveries have also proved to be important elements in the expansion of 
commercial applications, or at least were presented as such. For example, Kary 
Mullis, working for Cetus Corporation, developed the means to amplify (i.e. replicate) 
large quantities of DNA through polymerase chain reaction (PCR) technology 
(Dutfield 2003; Bergeron and Chan 2004). Throughout the 1980s such genetic 
engineering techniques were expanded beyond microorganisms to other living 
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organisms; initially with plants where the first cross-plant species gene insertion 
occurred in 1983, then animals where a cancer-causing gene was inserted into a 
mouse, patented in 1988 (Dutfield 2003).  
 
Whilst genetic techniques were expanding, a new focus in biotechnology arose around 
genomic research. In 1990 the multi-national Human Genome Project (HGP) was 
instigated, largely funded from public sources such as the NIH and Department of 
Energy in the USA, but also with funding from private foundations like the Wellcome 
Trust in the UK (Bud 1993; Dutfield 2003). The HGP relied upon the earlier 
discoveries and inventions in DNA sequencing by Frederick Sanger and others at 
Cambridge in the 1970s and automated sequencing machines of Leroy Hood and 
others at the California Institute of Technology in the early 1980s (Dutfield 2003). 
Subsequently, several living organism genomes have been sequenced such as H. 
Influenzae (1985), C. elegans (1988), and Arabidopsis thaliana (2000) (Cooke 2001c; 
Dutfield 2003). Finally, in February 2001 the HGP and the company Celera 
Genomics, which from its establishement in 1998 had been competing with the HGP, 
both announced the completion of a draft human genome sequence (Dutfield 2003). 
 
Whilst biotechnology had a range of potential applications – as evident in Table 4.1 
below – the first commercialisation of molecular biology actually involved a firm 
called Cetus founded in 1971 in California before the discovery of rDNA. Cetus 
sought to apply new techniques in the engineering of bacteria for therapeutic purposes 
and had been founded with the support of the venture capital (VC) firm Kleiner 
Perkins, which had previously been heavily involved in the development of Silicon 
Valley (Bud 1998; Owen 2001).  
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Table 4.1: Timeline of Important Biotech „Discoveries‟  
DATE INNOVATION OR DISCOVERY SCIENTISTS COUNTRY 
1953 DNA structure Watson/Crick UK 
1968 Chromosome identification Caspersson/Lech Sweden 
1973 In vitro recombinant DNA Cohen/Boyer USA 
1975 Monoclonal antibodies Milstein/Kohler UK 
1977 DNA sequencing of a virus Sanger et al UK 
1981 Automated gene sequencing machine Hood et al  USA 
1983 First plant gene inserted in gene of 
another species 
Various USA, Belgium 
1985 DNA profiling Jeffreys UK 
1985 Polymerase Chain Reaction 
amplification 
Mullis (Cetus) USA 
1995 Genome of first free-living organism 
sequenced: H. Influenzae 
Venter, Smith 
 
USA 
1997 Clones and transgenic sheep Wilmut UK 
1997 Stem cells cultured for first time (Gerhard) USA 
1998 Nematode worm sequenced: C. elegans Waterston, Sulston USA/UK 
2000 First plant genome: Arabidopsis 
thaliana  
Davis, Federspeil USA 
2001 Human genome sequenced in draft HGP/Celera 
Genomics 
USA/UK/Other 
 
Source: Rifkin (1999); Cooke (2001c); Dutfield (2003); BIO website. 
 
However, after the mid 1970s Cetus faced strong competition from the newly 
emerging dedicated biotechnology firms (DBF) based on rDNA research. The first of 
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these was Genentech established in 1976 on the basis of the work of Cohen and 
Boyer, who had sought to patent their rDNA discovery under advice from Robert 
Swanson who was a partner at Kleiner Perkins (Hughes 2001).
xvi
 
 
Whilst the rDNA patent was not finalised until after the conclusion of the Diamond 
vs. Chakrabarty case in 1980 (dealt with later), Genentech still managed to gain 
credibility through a 1978 contract with the pharmaceutical multinational Eli Lilly for 
the production of recombinant human insulin (Bud 1993; Owen 2001). Recombinant 
human insulin subsequently became the first widely commercialised modern 
biotechnology product; it was launched in 1982 and reached annual sales of $5,340 
million by 2002/03 (Acharya 1999; Nightingale and Martin 2004). Following 
Genentech two other firms were founded in the 1970s – Biogen and Genex – before a 
burst of activity in 1980 led to the foundation of 26 new firms (Bud 1993: 193). In the 
same year Genentech had floated on the NASDAQ exchange and raised $35 million 
by doubling its market value in one day (Owen 2001; Dutfield 2003). Genentech was 
also the first biotech firm to market a new biotech pharmaceutical product (rDNA 
human growth hormone), which was approved in 1985 in record time (McKelvey 
1996; Dutfield 2003). Despite achieving these milestones, Genentech was 
subsequently acquired by Hoffman-La Roche in 1989, although it retains a significant 
level of independence (Bud 1993).  
 
4.2.3 History of the UK Biotech Industry 
 
Whilst the biotech industry was starting to develop in the USA, the Labour 
government in the UK sought to establish an equivalent industrial base and to this end 
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it commissioned an inquiry into biotechnology in 1978 (Gottweis 1998a, 1998b). 
Alfred Spinks, an ex-research director at ICI (Imperial Chemicals Industry), headed 
the commission, and the eventual report produced in 1980 became known as The 
Spinks Report (ACARD et al 1980). The report was the result of a working party set 
up to assess the “existing and prospective science and technology relevant to 
industrial opportunities in biotechnology” by the Advisory Council for Applied 
Research and Development (ACARD), Advisory Board for the Research Councils 
(ABRC) and The Royal Society (ibid.: foreword). According to Herbert Gottweis 
(1998a: 196) the composition of the „Spinks Working Party‟ indicated a “new 
orientation for the political coding of the new biology” towards a concern with the 
commercial applications and benefits of biotechnology as opposed to concerns with 
health and safety. A dominant theme throughout the report was the fear of lost 
commercial opportunities, which resurfaces throughout later assessments by UK 
policy-makers (see House of Lords 1993; BIGT 2003). However, the fear of lost 
advantage was not new, but had been evident much earlier in relation to molecular 
biology. For example, a 1962 Royal Society ad hoc committee argued that the UK 
would lose its “place in international research” without “major changes in the 
organisation of biology departments” (quoted in Yoxen 1981: 98). Even earlier, in the 
aftermath of World War I, the UK had established research councils, such as the 
Medical Research Council (MRC) (established in 1920), in response to a perceived 
“scientific and technological crisis” (Yoxen 1981: 84).  
 
After the publication of The Spinks Report in 1980, the new Conservative government 
in the UK produced a White Paper (1981) response that broadly claimed that 
biotechnology could be left to market forces and did not require government 
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intervention (Sharp 1985). Despite such claims, several important public initiatives 
were undertaken between 1980 and 1982 to encourage biotechnology research and 
commercialisation.
xvii
 First, in 1980 the government founded a new firm called 
Celltech, which had special rights to commercialise research funded by MRC (Bud 
1993; Owen 2001). Second, in 1981 the Science and Engineering Research Council 
(SERC) established a Biotechnology Directorate to support applied research in 
biotechnology (see Dunnill and Rudd 1984 for an assessment). Finally, in 1982 the 
DTI set up a Biotechnology Unit to support the commercialisation of research and 
included staff seconded from industry to help in this endeavour (Sharp 1985; OECD 
1988).   
 
Despite these changes Herbert Gottweis (1998a: 203, 205) argues that the new  
Conservative government “failed” to properly follow up The Spinks Report‟s 
recommendations, and took 10 years to “find a suitable organizational structure for 
funding decisions in biotechnology”. In contrast, Margaret Sharp (1985) suggests that 
the government strongly promoted biotechnology across a range of schemes including 
the funding of basic and applied science and the encouragement of public-private 
partnerships. However, there was a move away from a central strategy with a 
reorganisation of the National Research Development Corporation (NRDC), which 
had a monopoly over the commercial exploitation of government-funded research. 
The NRDC was merged with the National Enterprise Board (NEB) in 1981 to form 
the British Technology Group (BTG), which finally lost its overall monopoly in 1985 
(Owen 2001).  
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Whilst the public sector was reorganising the funding of biotechnology in the UK, the 
private sector was taking an active role in the establishment of more biotech firms. 
One such firm was British Biotech, which two scientists from the subsidiary of the US 
firm Searle founded in 1986; it has since merged with and been renamed Vernalis plc 
in 2003. Perhaps incidentally, the first research director of Celltech, and several other 
staff, had also come from Searle (Owen 2001). A new type of science entrepreneur 
was also evident with the likes of Christopher Evans founding Enzymatix in 1987 
after returning from working in the USA at Genzyme. Subsequently, he spun off a 
number of other companies like Celsis International and Chiroscience (merged with 
Celltech plc in 1999, which has since been bought by the Belgium firm UCB) (Owen 
2001). Evans is now chairman of the biotechnology venture capital firm Merlin 
Biosciences, which he founded in 1996.
xviii
 One major change that benefited the 
expansion of the private sector was the 1993 decision by the London Stock Exchange 
(LSE) to alter its listing rules so that firms could raise public investment without 
requiring revenue, profitability and trading experience (Gottweis 1998a; Owen 2001). 
There were still specific requirements that firms had to meet, such as £20 million 
market value and three-year record of R&D operations, but it still enabled UK firms 
to pursue public investment. As a consequence of such changes, firms began to 
publicly launch on the stock market so that by 1995 twenty-five firms had gone public  
(Owen 2001: 14-15).  
 
4.3 GLOBAL CONTEXT OF THE UK BIOTECH INDUSTRY 
 
4.3.1 The Global Biotech Industry  
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To gain some understanding of the global context in which the UK biotech industry 
operates it is useful to draw upon secondary data from market and consultancy 
reports. The most commonly used reports are those produced by Ernst & Young each 
year. These are particularly popular sources in the academic and policy literature on 
biotechnology, where they have been used extensively (e.g. DTI 1999b; van Reenen 
2002; Casper and Murray 2004). The reason to use these data is that it provides a 
consistent and comparative view of the global biotech industry. It also means that the 
data collected during the thesis could be contrasted with a broader view of the biotech 
industry. A final reason is that even though there are strong reservations about their 
veracity, the market and consultancy reports also tend to be more conservative than 
government estimates about biotechnology and therefore less subject to exaggeration.  
 
Table 4.2: Global Biotech Industry 2005 
 GLOBAL BIOTECH % CHANGE 2004-2005 
Revenues ($b) 63.16 18 
R&D Expenses ($b) 19.54 4 
Net Loss ($b) 6.27 -30 
Public Companies 645 4 
Private Companies 3,522 0.3 
Total Companies 4,167 1 
 
Source: Adapted from Lawrence (2006). 
 
In 2005 Ernst & Young reported that the global biotech industry had reached revenues 
of $63.16 billion for public companies (see Table 4.2), which is lower than an earlier 
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DTI forecast for the year 2000 of £70 billion (DTI 1999b). Another forecast, made in 
1997 for the European biotechnology trade association EuropaBio, predicted four 
possible scenarios for 2005 ranging from „fast‟ to „failed‟ development; the forecasted 
revenue projections ranged between €250 billion for the former and €25 billion for the 
latter (see DTI 1999b: 23-4). It is evident that current revenues are considerably closer 
to the „failed development‟ figure, especially when we consider that the EuropaBio 
figures refer to Europe alone. According to Ernst & Young (2005), the 2004 revenues 
in Europe were only $7,729 billion. Even though this refers to public companies only, 
a report by Critical I (2006) showed that the European biotech industry still only had 
revenues of €21.5 billion in 2004 for the whole sector. It is evident that the size of the 
biotech industry is well below the expectations of some policy-makers, especially 
when considering that the global biotech industry has never been profitable.  
 
Figure 4.1: Global Biotech Industry Change between 2001 and 2005 
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Source: Adapted from Ernst & Young (2003a, 2003b, 2005); Lawrence (2006). 
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Even public biotech companies have, as yet, to return positive revenue figures 
(Lahteenmaki and Lawrence 2006). Ernst & Young figures, which are based on data 
from public companies, show that between 2001 and 2005 revenues in the global 
biotech industry have increased by 75%, or nearly 15% per year. R&D expenditure 
also rose between 2001 and 2005, but only by 18.7% (see Figure 4.1). The impressive 
rise in revenues, however, has had only a marginal effect on net losses, which actually 
rose by 8.7% in the same period. As significant perhaps was the fall in global 
employees by 21% between 2001 and 2004. The number of firms remained relatively 
static with a 2% decline between 2001 and 2005.  
 
Table 4.3: Comparing the US and European Biotech Industries 2004 
 GLOBAL USA EUROPEAN EURO as 
% of USA 
Revenues ($b) 54.61 42.74 7.73 18.09% 
R&D Expenses ($b) 20.89 15.7 4.15 26.43 
Net Loss ($b) 5.3 4.14 0.48 11.59 
Employee Numbers 183,820 137,400 25,640 18.66 
Public Companies 641 330 98 29.70 
Private Companies 3,775 1,114 1,717 154.13 
Total Companies 4,416 1,444 1,815 125.69 
 
Source: Adapted from Ernst & Young (2005). 
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Although the global biotech industry provides a useful context in which to position 
the thesis, it is also helpful to compare the size of the US and European industries to 
show the difference in size of both and the dominance of the US globally. Again, 
Ernst & Young provide a useful secondary data source for the reasons outlined earlier. 
The data here concerns 2004 rather than 2005, primarily because the secondary and 
primary data collected during the thesis was only up until 2004. Therefore data from 
2004 provides a more relevant context for the rest of the thesis, even though the above 
discussion provides as up-to-date information as possible. The main indicators used 
by Ernst & Young to portray the biotech industry are revenue, R&D expenditure, net 
loss, employee numbers, and the number of public, private and total companies (see 
Table 4.3).  
 
Table 4.4: Biotech Industry Change 2003-2004 
 GLOBAL  USA EUROPEAN 
Revenues 17.31 % 19.22 % 3.48 % 
R&D Expenses 12.07 15.70 -1.89 
Net Loss 16.48 27.78 -12.73 
Employee Numbers -6.13 -5.95 -21.03 
Public Companies 4.91 5.10 2.08 
Private Companies -2.20 -3.88 -2.72 
Total Companies -1.23 -1.97 -2.47 
 
Source: Adapted from Ernst & Young (2005). 
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This data shows how small the European biotech industry is in comparison with the 
USA. In terms of both revenues and employee numbers, Europe represents around 
18% of the US; less than a fifth. For R&D expenditure this is slightly higher at 26% 
or a quarter and for number of public companies 29%. Net losses are only around 
11%, which indicates that Europe may be more sustainable, if significantly smaller. 
However, Europe does perform well in terms of number of companies with over 50% 
more private firms and 25% more total firms than the USA. Overall this would 
suggest that the European industry is made up of much smaller firms with lower 
revenues and levels of employment, although also significantly lower losses. This 
analysis is borne out in the change between 2003 and 2004, which show that although 
the USA is increasing its revenues significantly (and far more than Europe), it has 
also witnessed large rises in net losses over the same period, higher than revenues (see 
Table 4.4).  
 
Table 4.5: US and European Biotech Industry Growth 1998-2003 
 USA EUROPE 
Revenues ($m) 115 % 754 % 
R&D Expenses ($m) 101 556 
Net Loss ($m) 71 58 
Employee Numbers 38 184 
Public Companies -1 41 
Private Companies 16 59 
Total Companies 12 58 
 
Source: Adapted from Ernst & Young (2004a). 
 133 
 
There appears to be a growing divergence between the USA and Europe as the former 
continues to invest heavily in the biotech industry as evident in the 15.7% increase in 
R&D expenses between 2003 and 2004 compared with a 2% fall in Europe, whereas 
the European sector stabilises in search of profitability. However, by taking a longer 
period of data it is possible to show that European biotech is outperforming the USA 
in relative terms (see Table 4.5). Between 1998 and 2003 the growth in European 
revenues was 754%, over six times higher than for the US during that period. There 
are similar figures for the growth in R&D expenses where the European change 
between 1998 and 2003 was over five times the US. There also appears to be a 
fivefold difference in the growth of companies between Europe and the US, although 
most significantly perhaps is the huge difference in growth of public companies, 41% 
growth in Europe and 1% decline the USA. Despite the comparatively strong growth 
of the European sector, however, it is still obvious that there is a massive difference in 
economic and technological performance between the two geopolitical regions. 
 
4.3.2 Global Biotech Performance 
 
The difference between the US and European sectors can be split between market and 
technological performance. The market performance of the US biotech sector can be 
shown using data on the market capitalisation of US companies. This was $189.5 
billion in 2002 for the US – a decline of 34.7% from 2001 – and €21.8 billion for 
Europe, or a decline of 52% from 2001. However, to put this last indicator in 
perspective ir is worth noting that in 2001 the market capitalisation of the US 
company Amgen was $61.5 billion whilst for the whole European sector it was only 
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$51 billion (all data from Ernst and Young 2003a, 2003b, 2003c). More recent data 
shows that the market capitalisation of the San Francisco Bay Area – the heartland of 
biotechnology – was around $162 billion in 2005 (Lawrence 2006). The main reason 
for these differences is that US companies dominate product development particularly 
in relation to biopharmaceutical products, which represent the highest earning 
products in the biotech industry. The difference in technological performance between 
the US and Europe can be shown in relation the number of biopharmaceutical 
products each has produced and the strength of their product pipelines. A note of 
caution must be raised here, however. It is important to acknowledge a number of 
recent critical analyses of both pharmaceutical and biopharmaceutical development 
(see Horrobin 2003; NRDD Editorial 2003; FDA 2004; Nightingale and Martin 2004; 
Joppi et al 2005; Martin et al 2006). These will be dealt with below, but first it is 
useful to consider the strength of different national product pipelines. The different 
phases of these pipelines are outlined in Table 4.6. 
 
Table 4.6: Clinical Development Phases 
PHASE PROCESS 
Pre-clinical  In vitro and animal testing 
Phase I Toxicity testing on healthy volunteers 
Phase II Efficacy testing on patient volunteers 
Phase III Efficacy and statistical significance testing on large number of patient 
volunteers 
Phase IV Post-marketing surveillance 
 
Source: Eaton (2004). 
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Product pipelines are useful for illustrating the strength underpinning a country‟s 
biotech industry because they represent actual commercial possibilities as opposed to 
expectations. In Table 4.7 below there is data on the 2002 pharmaceutical pipelines of 
a number of countries which details the number of products in various phases of 
development and testing.  
 
Table 4.7: National Biotech Product Pipelines 2002 
 PRECLINICAL PHASE I PHASE II PHASE III TOTAL 
UK 65 50 56 23 194 
Switzerland 45 12 11 11 79 
Sweden 14 8 10 0 32 
France 16 8 6 1 31 
Denmark 14 5 5 4 28 
Italy 9 0 4 3 16 
Israel 2 3 6 4 15 
Germany 7 4 3 1 15 
Norway 8 2 2 3 15 
Netherlands 9 1 1 0 11 
Finland 9 1 0 0 10 
Ireland 2 0 2 3 7 
Belgium 2 0 1 0 3 
EUROPE 202 94 107 53 456 
USA 584 96 148 44 872 
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Source: Adapted from BIGT (2003). 
 
It is obvious that the USA dominates national pipelines with a total of 872 products in 
development and 44 in Phase III testing and therefore closest to the market. Phase III 
testing does not mean that a product will automatically make it to market, but there is 
a higher possibility than for the previous Phases (see Nightingale 2000; FDA 2004).  
 
Figure 4.2: European Biotech Product Pipelines  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from BIGT (2003). 
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A comparison of European and US pipelines shows that the USA has a significantly 
stronger pipeline with almost double the number of products in development than the 
whole of Europe; 872 and 456 respectively. Out of the European countries, the UK 
had the strongest pipeline with 23 products in Phase III development alone, a number 
that is over half the number that the USA has (44). The UK pipeline is obviously very 
strong, especially in Europe where it represents 43 percent of the European total (see 
Figure 4.2) and 42 percent of Phase III products. The UK and Switzerland accounted 
for nearly two-thirds of all European Phase III products. 
 
By 2003 the UK proportion of total products had fallen to 41 percent, although the 
proportion of Phase III products remained the same (Ernst and Young 2004). The 
overall number of European products in development had also fallen from 456 in 
2002 to 392 in 2003, with the most significant fall in Pre-clinical development where 
numbers fell from 202 to 147. The decline in products in development was not 
necessarily because products were successfully marketed since the United States Food 
and Drug Administration (FDA) only approved 25 new biotech products in 2003 
(Ernst and Young 2004), most of which had been developed and marketed by US 
companies.  
 
The first major reason that the US dominates biopharmaceutical development is that 
North America represents the largest market for both pharmaceuticals – 50% of global 
sales (Thayer 2004) – and biopharmaceuticals – 60% of global sales (Bibby et al 
2003). The current US dominance is evident in a number of recent analyses (e.g. 
Reichert 2000; Ashton 2001a; Arundel and Mintzes 2004; FDA 2004; Nightingale 
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and Martin 2004). Such research also shows how dominant the blockbuster model of 
development remains (Bergeron and Chan 2004), despite scientific and technological 
discoveries (e.g. pharmacogenomics) that make it possible to target pharmaceuticals 
to specific subgroups more effectively. The blockbuster model has, however, meant 
that the US biotech industry receives enormous revenues each year from its marketed 
products, although a significant proportion accrues to only two firms; Genentech and 
Amgen with 30% of revenues (Lahteenmaki and Lawrence 2006). Furthermore the 
top six biotech drugs launched during the 1980s and 1990s were all launched first in 
the USA (by US companies) where total biopharmaceutical sales represent $19 billion 
per year or 58% of global sales in 2002 (Bibby et al 2004: 5). 
 
The second major reason for US dominance is that the US has more marketed 
products and therefore higher revenues than Europe. The US Bio Industry 
Organisation (BIO) estimated that there were 197 approved „biotech‟ products in 
2003, although due to definitional ambiguity this figure may be significantly lower. 
For example, IMS Health estimates that there were only 119 biopharmaceuticals in 
2004, whilst Arundel and Mintzes (2004) put this even lower at only 60 
biopharmaceuticals. Despite the different claims, there is one uncontentious fact; US 
firms have more approved products than other firms. For example, data produced by 
Ashton (2001b: 23-26) shows that of the 66 „biotech‟ products introduced between 
1982 and 1998 exactly half were marketed by US firms compared with around a third 
by European firms, including one from the UK, and a fifth by Japanese firms.
xix
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Table 4.8: Top 10 Biopharmaceutical Products in 1993 and 2002/03 
PRODUCT DEVELOPER MARKETER 1993 SALES  
($ m) 
2002/03 SALES 
($ m) 
LAUNCH 
DATE 
1993 POSITION 
(top 10) 
Epogen (erythropoeitin) Amgen Amgen / Johnson and Johnson 587 8880 1989 (US) 2 
Humulin (recombinant human insulin) Genentech Eli Lilly 560 5340 1982 (US) 4 
Intron A (interferon) Biogen Roche and Schering-Plough 572 2700 1986 (US) 3 
Neupogen (GCS factor) Amgen Amgen 719 2520 1991 (US 
and EU) 
1 
Betaferon (interferon B) Berlex (Schering AG) Berlex (Schering AG) - 2200 1993 (US) - 
Protropin (recombinant human growth 
hormone) 
Genentech Genentech 217 1760 1985 (US) 9 
Remicade (infliximab) Centocor Centocor - 1730 1998 (US) - 
Rituxan (rituximab) Genentech/IDEC Genentech/IDEC - 1490 1997 (US) - 
Follicle stimulating hormone Serono/Organon Serono/Organon - 1000 1995 (EU) - 
Synagis (palivizumab) MedImmune MedImmune/Abbott - 850 1998 (US) - 
 
Source: Sharp and Senker (1999); Ashton (2001a, 2001b); Nightingale and Martin (2004). 
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As the total number of pharmaceutical product approvals has declined, these biotech 
products have assumed an increasingly important position in pipeline of multinational 
pharmaceutical companies. However, the number of biological license applications 
(BLA) to the FDA has also fallen from 25 in 2000 to 14 in 2003 suggesting that the 
biotech industry has also suffered from a similar „productivity crisis‟ to the 
pharmaceutical industry (FDA 2004; Martin et al 2006). Furthermore, this trend is 
global with the FDA reporting in 2004 that since 2000 there has been a marked 
slowdown in the number of new drug/biologic submissions to all worldwide agencies.  
 
Despite these trends, a number of biological treatments and products have produced 
enormous returns for their developers and marketers.
xx
  For example, the main reason 
that Amgen has such a high market capitalisation is because it not only developed the 
2003 top-selling biotech drug – Epogen – with sales of $8.9 billion, but also the 1993 
top-seller – Neupogen xxi – which still had sales of $2.5 billion in 2002/03 (Sharp and 
Senker 1999; Nightingale and Martin 2004). In contrast European companies only had 
four of the 15 highest selling biotech drugs in 2002/2003, all ranked 9
th
 or below and 
only two top 10 biotech drugs were originally launched in Europe, one of which was 
Neupogen produced by Amgen (Nightingale and Martin 2004) (see Table 4.8).  
 
4.4 INSTITUTIONAL CONTEXT OF THE UK BIOTECHNOLOGY 
INDUSTRY 
 
4.4.1 Global Institutional Change 
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Considering the major differences between the US and European biotech sectors, it is 
important to explain why, aside from „first-mover‟ advantage, the former so 
thoroughly dominates the biotech industry. In this regards it is useful to explore the 
different institutional environments in the two geopolitical regions, especially in 
relation to intellectual property rights (IPR). Some of the most important global 
changes to intellectual property (IP) are outlined in Table 4.9 below. These 
concentrate on the USA and Europe, although they also illustrate the growing 
importance of international standards such as the development of TRIPS at the World 
Trade Organisation (WTO). 
 
The main reason that IP is so important is that property rights are necessary for the 
delineation of new markets, especially in relation to markets based on „knowledge 
economy‟ products exemplified by the biotech industry (Green 1991, 2002). Tait et al 
(2006) argue that IP is necessary for private investment in biotechnology and that 
because there was weaker protection in Europe the USA had a competitive advantage. 
One major difference between Europe and the USA was that in a number of European 
patent offices awarded patents to inventors and not organisations like universities, 
which therefore provided few incentives for such organisations to commercialise 
basic and applied research involving biotech (Senker et al 2000). 
xxii
 Furthermore, Tait 
et al (2006) argue that US IP laws enable small and medium-sized enterprises (SMEs) 
to develop products by undertaking risky research that means large companies can 
avoid liability for failure, which encourages large firms to fund these SMEs. In turn 
though, such SMEs remain dependent upon the large companies because SMEs do not 
have the capabilities or financing to fulfil regulatory requirements (ibid.). 
 142 
Table 4.9: Intellectual Property (IP) Changes affecting the Global Biotech Industry  
YEAR POLICY/EVENT DETAILS 
1873 Pasteur patent Pasteur awarded patent claiming yeast as an “article of 
manufacture”. 
1911 Parke-David & Co. vs. 
H.K. Milford & Co. 
Purified and slightly modified natural product (adrenaline) 
considered patentable.  
1973 EPO established European Patent Convention established European Patent Office 
(EPO) and harmonised patent law.  
1980 Diamond vs. 
Chakrabarty 
US Supreme Court ruling on patenting living matter. 
1982 CAFC established Court of Appeals for the Federal Circuit (CAFC) established as 
final patent appeal court in the USA.  
1985 USPTO Decides that plants, seeds and plant tissue culture are patentable. 
1987 USPTO Decides that non-human living organisms are patentable.  
1988 EPO Grants first plant patent 
1994 WTO (TRIPS) Article 27 relates to biotech, which ensures that patents on genes 
etc. are covered by all signatories.  
1995 In re Brouwer CAFC rules that „novelty‟ is based upon the final product and not 
the process, therefore allowing process patents. 
1995 Biotech Patent Act Protected process patents in the US. 
1995 EPO Declares that DNA is not life but a chemical and therefore 
patentable. 
1998 EU Parliament Life Patent Directive adopted. 
2001 USPTO Changed concept of utility to cover theoretical uses. 
 
Source: Maebius (1996); May (2000); Coriat and Orsi (2001); Mowery et al (2001); 
Drahos and Braithewaite (2002, 2004); Ossorio (2002); Coriat et al (2003); Dutfield 
(2003); Laurie (2003).  
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Technology transfer in the USA was also encouraged, facilitated and promoted by 
successive government policies that shifted ownership of public sector research 
outcomes, in the form of patents and other IP, to the research organisation rather than 
central government (see Malinowski 2000: 19). Thus the critical Bayh-Dole Act 
(1980) reduced restrictions on licensing and allowed universities to retain IP on 
federally funded research. This policy was subsequently extended to small businesses 
carrying out federal research in 1983 (Poyago-Theotoky et al 2002). The US 
government also enacted a number of other pieces of legislation deliberately designed 
to promote the exploitation of basic and applied research. These included the 
Stevenson-Wydler Technology Innovation Act (1980), Economic Recovery Tax Act 
(1981), Small Business Innovation Development Act (1982), Orphan Drug Act 
(1983), Patent Term Restoration Act (1984), National Cooperative Research Act 
(1984), Federal Technology Transfer Act (1986), and, more specifically to 
biotechnology, the Biotechnology Process Patent Act (1995) (Kuhlman 1996; 
Slaughter and Roades 1996; Loeppky 2004; Birch 2007). The Bayh-Dole Act is seen 
as particular important with many national governments following suit with their own 
versions, although often some years later (Howard 2004; Senker 2004). 
 
Aside from this flurry of legislation, IP rights were also changed in the USA as a 
consequence of the desire to commercialise biotech research, including allowances for 
the patenting of living material (e.g. microorganisms, animals). Prior to 1980 there 
had been several patent cases concerning living material (e.g. Pasteur in the 
nineteenth century and adrenaline in 1911), but it was not until the 1980 Diamond vs. 
Chakrabarty (DvC) ruling by the US Supreme Court that such patent claims were 
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formalised (see Iwasaka 2000; also Kevles 1998). The ruling upheld a “broad patent” 
in biotech specifically (Mowery et al 2001: 103) deriving its judgement from a 1952 
US Supreme Court judgement that patentable matter could include “anything under 
the sun made by man” (quoted in Krimsky 1999). After DvC the US Patent and 
Trademark Office (USPTO) also shifted its position so that by 1987 it was allowing 
“nonnaturally non-human living organisms, including animals, to be patentable” 
(Coriat and Orsi 2001: 18). A year later the US Patent and Trademark Office 
(USPTO) granted Harvard a patent for their Oncomouse.  
 
4.4.2 National Institutional Change in the UK  
 
Whilst other countries changed their institutions, a succession of UK governments 
sought to counter the (perceived) threat of the USA to UK competitiveness in 
biotechnology. There has been a continual policy concern with the advantages of the 
US regulatory environment in UK policy discourse (see ACARD et al 1980; House of 
Lords 1993; BIGT 2003). There were at least two major reasons for this perception of 
the US. First, there were “powerful interests emerging in the late 1970s [in the USA] 
to promote deregulation of industry” (Wright 1993: 81), which cast regulation as an 
impediment to innovation. Policy-makers in the US quickly moved from concerns 
about regulation of biotechnology to its commercial exploitation (e.g. US Congress 
1981), whereas other countries mostly took their lead from US policies (see Wright 
1993; Gottweis 1998a). Second, public acceptance was also cast as an impediment 
(see Gottweis 1998b), seen as threatening the competitiveness of the emerging biotech 
industry (House of Lords 1993; US Congress 1981). However, the US government, 
through the NIH, launched public campaigns early on to persuade the US public that 
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there were low risks associated with biotechnology (Wright 1998). Thus although the 
UK had a different initial regulatory framework than the USA, it gradually adjusted to 
US policy because of the fear that „stronger‟ regulation might lead to lower 
competitiveness (Wright 1993, 1998). Thus the risks involved in the biotechnology 
industry came to be defined in terms of lost commercial opportunities rather than 
safety (Wright 1998). 
 
In the UK the 1980 Spinks Report heralded an increased concern with biotechnology, 
characterised by direct government intervention in terms of the foundation of Celltech 
and the establishment of biotechnology directorates at SERC and the DTI (Gottweis 
1998a; Owen 2001). However, alongside these specific policies the government also 
instigated a series of complementary policies designed to encourage hi-tech 
innovation generally and biotechnology specifically. These policies are outlined in 
Table 4.10 and Table 4.11 below, which specify the schemes pursued by both 
Conservative (1979-1997) and Labour (1997-Present) governments respectively.  
 
The broader schemes enacted by the Conservative government like Enterprise Zones, 
Small Firms Loan Guarantee Scheme and Business Expansion Scheme, were 
supplemented by policies designed to promote hi-tech growth. These included the 
1988 decision to privatise the British Technology Group (BTG) and its earlier 
emergence from the NRDC and NEB. Furthermore, in the same year universities were 
given greater scope to exploit their inventions (Robinson 2001) embedding the 1985 
decision to end the BTG monopoly on government-funded research, which sought to 
replicate the impact of the 1980 Bayh-Dole Act in the USA (Casper and Kettler 2001; 
Owen 2001).  
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Table 4.10: UK Government (Conservative) Policy 1979-97 
YEAR POLICY/EVENT DETAILS 
1979 – 
1997  
General 
government 
schemes 
Enterprise Zones: firms exempt from local tax and some planning 
controls are relaxed. 
Business Expansion Scheme: tax incentives for people investing in 
small firms which allowed investors to claim tax relief on equity 
investments up to £40,000 and pay no capital gains on sums 
invested for 5 years or more. 
1981 BTG NEB and NRDC merged to form BTG. 
1984 Agricultural 
Genetics Co. 
AGC founded to commercialise results of Agriculture and Food 
Research Council. 
1985 BTG lost monopoly BTG lost monopoly on government-funded research: reform based 
on Bayh-Dole Act (1980). 
1985 Support for 
Business 
Programme 
Rationalisation of various schemes that support SMEs by DTI. 
Includes SMART awards which are competitive system to win 
awards for product development  
1988 BTG privatised  BTG was privatised and universities were allowed to exploit their 
inventions. 
1994 BBSRC Biotechnology and Biological Sciences Research Council founded.  
1995 EMEA Pan-European medical regulatory agency founded. 
1995 Venture Capital 
Trusts (VCT) 
VCTs started to encourage people to invest in higher-risk SMEs 
that are not on recognised stock exchanges. Income tax relief and 
Capital gains tax relief on VCT shares 
1996 Pharmaceutical 
Price Regulation 
Scheme 
Companies in the UK allowed to set UK launch price of drugs 
 
Source: Walsh et al (1995); Casper and Kettler (2001); Owen (2001); Robinson 
(2001); PICTF (2003); Senker (2004). 
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In 1994 the government also established the Biotechnology and Biological Sciences 
Research Council (BBSRC) dedicated to funding academic research in the 
biosciences. A year later the government set up venture capital trusts (VCT) to 
encourage people to invest in high-risk SMEs that were not on recognised stock 
markets. Such policies were supported by the early 1990s decision by the London 
Stock Exchange (LSE) to allow companies to claim their IP as assets during the 
process of listing on the LSE (Gottweis 1998b). 
 
With the accession of the „New‟ Labour government in 1997 the number of policies 
specifically oriented towards encouraging the biotech industry multiplied 
considerably. The DTI, for example, established numerous schemes designed to assist 
biotech firms, such as Biotechnology Exploitation Platforms (BEP), Biotechnology 
Mentoring and Incubator (BMI) challenge, Biotechnology Finance Advisory Service 
(BFAS) and the Manufacturing for Biotechnology initiative (DTI 1999b). 
Furthermore the government introduced a Third Funding Stream for universities in 
1999 designed to encourage technology transfer from universities (HM Treasury 
2003). There was even a specific policy to encourage the development of business 
clusters with the 1999 Planning Policy Guidance (PPG) 11 and PPG12 requiring 
support for cluster development at a regional level (ODPM 2004). Corporate 
venturing, regional venture funds and lower capital gains tax were also all adopted 
and encouraged (DTI 1999a, 1999b, 2003). Such policies sought to stimulate high-
tech sectors, especially the biotech industry, as well as SMEs more generally.  
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Table 4.11: UK Government (Labour) Policy 1997-present  
YEAR POLICY/EVENT DETAILS 
1997+ DTI schemes BEP, BMI, BFAS, MBI and Bio-Wise. 
1997+ Corporate tax Lowest in Europe and reduced lower rate from 10% to 0%. 
1999 Third funding 
stream  
University funding: Science Enterprise Challenge, Higher 
Education Innovation Fund (HEIF), University Challenge Funds. 
1998 RDA Regional Development Agencies (RDA) established. 
1999 PPG Note 12 and 
PPG11 
Planning guidance issued to encourage planning bodies be more 
responsive to land-use implications of clusters. 
1999 Capital Gains Tax Taper relief to introduce lower rates. 
1999 RVC Funds Regional Venture Capital (RVC) Funds set up to invest in SMEs. 
2000  EMIS Enterprise Management Incentive Scheme (EMIS): allows tax-
privileged share options for key employees of small firms. 
2000 Corporate tax New rate 10% for SMEs. 
2000 R&D tax credits For SMEs, increased from 100% to 150%. 
2001 SBRI  Small Business Research Initiative (SBRI): target 2.5% of 
purchasing for govt departments from SMEs by 2004/05. 
2001 Regulatory Reform 
Act 
Allows govt to amend primary legislation such as business 
regulation. 
2001 Health and Social 
Care Act 
Enables inventors to participate in commercialisation of NHS 
research and allows NHS to take shareholding in spin-out 
companies. 
2001 Criminal Justice 
and Police Act 
Provisions to allow company directors to apply for confidentiality 
orders so their home address is not publicly available. 
2002 R&D tax credits Extended to all companies of 125%. 
 
Source: DTI (1999a, b; 2002; 2003); Owen (2001); van Reenen (2002); HM Treasury 
(2003); House of Commons (2003); ODPM (2004). 
 
 149 
The general support for SMEs is evident in the lowering of corporate tax for small 
firms in 2000 and the increase in R&D tax credits from 100% to 150% for SMEs in 
the same year (DTI 1999b; Owen 2001). Subsequently, in 2002, R&D tax credits 
were extended to all companies, although at 125% (Owen 2001). In 2001 the 
government also introduced the Small Business Research Initiative (SBRI) to 
encourage government departments to dedicate 2.5% of their purchasing from SMEs 
by 2004/05 (DTI 2003): this copies the Small Business Innovation Development Act 
(1982) in the USA (Walsh et al 1995). In the same year, the introduction of the Health 
and Social Care Act (2001) enabled inventors in the NHS to participate in 
commercialisation and shareholding in spin-out companies from NHS research 
(House of Commons 2003). 
 
4.5 CONCLUSION 
 
This chapter provides an historical and contextual grounding for the rest of the data 
analysis in Part II by showing how the development of biotechnology as a commercial 
endeavour and its current state of the industry has been not been straightforward nor 
linear. As a country the UK, for example, played a central role in the history of 
molecular biology and genetics with a number of important early discoveries made 
here (e.g. DNA structure) as well as more recent contributions to current research 
(e.g. Human Genome Project). However, whereas the UK has contributed to the 
„advancement of science‟ for a number of years, the lack of commercial exploitation 
of these ideas has been in marked contrast to the USA. Thus whilst Cohen and Boyer 
patented rDNA techniques leading to the foundation of the biotech giant Genentech, 
Milstein and Kohler chose not to do so, which, in its own way, led to the foundation 
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of Celltech, the UK biotech bellwether that was bought in 2004 by the Belgium 
phamaceutical firm UCB Pharma.  
 
These two contrasting examples illustrate the dominance of the US in economic 
terms, if not also in scientific ones. As mentioned above, there are a number of 
reasons for this dominance. Notably, the US industry has a considerable first-mover 
advantage as a consequence of early support and encouragement for the biotech 
industry, both by the US government, but also, more importantly perhaps, by private 
investment from VC (Bud 1998; Loeppky 2005). Currently the US represents three-
quarters of global revenues according to Ernst & Young (2006: 5). Furthermore, US 
firms dominate both (bio)pharmaceutical product pipelines and markets, although 
British firms do proportionately well in relation to both of these.  
 
The US dominance is marked in relation to the European sector, although there are 
possible reasons for this dominance; namely the focus of market and industrial 
assessments on the healthcare sector. Thus the majority (53%) of US biotech firms 
operate in the Human healthcare sector as opposed to 37% of European firms (Critical 
I 2006): see Figure 4.3. This means that the US dominance of pharmaceutical 
pipelines and products ensures that US firms reaped the highest revenues. However, 
perhaps problematically for US firms there are concerns about the viability of both the 
„blockbuster model‟ of development (Thayer 2004) and the innovativeness of biotech 
drug products (Arundel and Mintzes 2004; Joppi et al 2005). The UK has the 
„strongest‟ biotech industry in Europe with significantly more pipeline products than 
any other country and 43% of the European total (BIGT 2003). 
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Figure 4.3: US and European Biotech Sectors 
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Source: Adapted from Critical I (2006). 
 
It also has around a fifth all European biotech R&D employees and biotech R&D 
spend (Critical I 2006: 39). It is important to consider the institutional changes that 
both the US and UK have instigated over the past three decades to account for the 
dominance of each country, globally for the US and in Europe for the UK. The US 
has been especially pro-active in introducing legislation and policies that encourage 
and support the biotech industry, a trend that the UK has followed as a consequence 
of the fear of losing competitive advantage to the USA. What this means is that the 
outline of any analysis of the biotech industry, as will be covered in the next two 
chapters, has to bring such institutional concerns into this approach. This entails an 
appreciation of the different scales at which firms and organisations operate, as well 
as the influence and impact that different institutional structures have on decision-
making regarding the acquisition, production, use and commercialisation of 
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knowledge. Thus the national context, especially in terms of institutional changes, can 
be seen as central features of the biotech industry. Consequently it is vital to 
understand how such national (and also global) factors play out in the biotech 
innovation system, rather than simply assuming that firms operate within countries 
conceived as market environments. National governments and international actors 
play a vital role and represent central sources of knowledge for those involved in 
innovation, which necessitates an external orientation and focus in relation to 
knowledge acquisition. 
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CHAPTER 5 
EXPLAINING THE BIOECONOMY I:  
THE CONCENTRATION AND DISPERSAL OF 
INNOVATION PROCESSES IN THE UK 
BIOTECHNOLOGY INDUSTRY 
 
5.1 INTRODUCTION 
 
Although institutional change cuts across multiple scales it affects UK regions 
differently because these changes impact upon particular locations in relation to the 
existing regional context. For example, changes in public science funding or 
intellectual property rights (IPR) have different affects on regions because each region 
has different existing public science infrastructure (e.g. number of universities, public 
research organisations etc.). This very basic point means that it is important to 
identify the dynamic (i.e. changes over time) and systemic (i.e. complementarities) 
features of UK regions in relation to the biotech industry. This includes identifying 
not only the number of firms and when they were founded, but also the number of 
relevant university departments, public research organisations (PROs) and service 
provides such as financiers (Kenney 1998; Powell et al 2002). 
 
Recent literature on the biotech industry emphasises the importance of local sites or 
„nodes‟ of knowledge production that are linked to global knowledge networks (e.g. 
Wolter 2003; Coenen et al 2004; McKelvey 2004; Ryan and Phillips 2004). This 
 154 
literature argues that although biotechnology is concentrated in specific sites 
innovation is not constituted by spatial proximity, but rather through knowledge 
proximity that may necessitate embedding in a range of external, sometimes global, 
linkages. This provides a more sophisticated analysis of agglomeration economies 
than the „cluster‟ literature derived from the work of Michael Porter (1990, 2000), 
which has encoutered criticism for the lack of empirical support (see Malmberg 2003; 
Malmberg and Power 2005). The more recent literature is built into the first 
hypothesis: 
  
H1: There are „knowledge economy‟ concentrations because successful innovation 
depends on dynamic (i.e. across time) and systemic (i.e. across organisations) 
processes embedded in and across specific places. 
 
This chapter concentrates on this hypothesis by first analysing the organisational 
concentrations of the biotech organisations and their knowledge components in 
particular places. Although four distinct locations can be identified as concentrations 
of biotechnology, it is difficult to characterise a general trend that covers all such 
places. Instead it appears as though each location has a different set of knowledge 
characteristics – both in terms of bases and drivers – that help to explain the different 
paths each region has taken. It would also be difficult to support the notion that these 
UK biotech concentrations reflect similar locations in other countries, especially the 
USA where, for example, the San Francisco Bay Area alone has twice the revenue of 
Europe (Lawrence 2006). The next objective of this chapter is therefore to consider 
what effects different types of proximity – social, spatial and organisational – have on 
the concentration of the biotech industry (Boschma 2005). Of these three types, only 
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organisational proximity appears to have an important relationship. Thus the final 
objective is an exploration of the strength of different scalar relationships between 
knowledge (bases and drivers) and concentrations to determine the importance of 
these scales in relation to knowledge and innovation processes.  
 
5.2 UK BIOTECHNOLOGY CONCENTRATIONS 
 
The identification of UK biotech concentrations is mainly based on the number of 
research-driven firms in each NUTS2 region. This provides the means to identify both 
the commercial exploitation and creation of modern biotech knowledge, the two 
central features of knowledge economies identified by Phil Cooke (2002c: 3-5), that 
can be used to identify the specific characteristics of each concentration.  However, 
because biotech knowledge is also derived from extra-company sources, such as 
universities, and successful exploitation is dependent on non-science knowledge, such 
as financing, it is necessary to consider a wider array of organisations. Therefore the 
organisations included are:  
 
 Biotech firms 
 Service providers 
 University departments 
 Public research organisations (PROs). 
 
Alongside the consideration of the organisational characteristics of regional 
concentrations, it is also necessary to consider what types of knowledge exist in 
particular places, how this knowledge is manifested and transferred, and the linkages 
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both within and across different locations (McKelvey et al 2004). Amongst others, 
these knowledge indicators include: 
 
 Public science investment 
 Intangible knowledge (e.g. patents, articles)  
 Employment levels 
 Firm sizes and types. 
 
These indicators provide the means to consider some of the complexity of knowledge 
economies, especially in terms of exploring the importance of inter-regional relations 
and different knowledge types (Cooke 2003a; Wolter 2003). They also help to situate 
each biotech concentration within a series of regional, national and international 
relationships and therefore cut across different spatial scales. 
 
All these data were collected using the European Union NUTS2 region as the main 
spatial designation. There are 37 NUTS2 regions in the UK, most of which cover an 
area of approximately three counties or one large city. This means that, first, 
administrative boundaries are not used as arbitrary sites of research because NUTS2 
regions crossed several borders. Second, it provides a means to compare different 
spatial levels using a consistent scale that could be expanded upwards to NUTS1 or 
downwards to NUTS3 scales. Finally, it also means that the research is relevant at a 
European rather than just national level should anyone wish to pursue further 
comparative research. 
 
5.2.1 Organisational Concentrations 
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Four major concentrations of the biotech industry can be identified in the UK from 
available secondary sources; „major‟ means that they represent double the average 
(mean) number of all four types of organisation outlined above (except Eastern 
Scotland for service providers and East Anglia for university departments). These four 
main concentrations were, using NUTS2 categories:  
 
 East Anglia: consists of Peterborough, Cambridgeshire CC, Norfolk and 
Suffolk. 
 Berkshire, Buckinghamshire and Oxfordshire: consists of Berkshire, 
Milton Keynes, Buckinghamshire CC and Oxfordshire.  
 Inner London: consists of Inner London West and Inner London East. 
 Eastern Scotland: consists of Angus and Dundee City, Clackmannanshire 
and Fife, East Lothian and Midlothian, The Scottish Borders, City of 
Edinburgh, Falkirk, Perth and Kinross and Stirling, and West Lothian.  
 
There were also three regions with above average concentrations of all four 
organisations; Greater Manchester, Surrey, East and West Sussex, and South Western 
Scotland. However, considering that Surrey, even though it had the most, had only 22 
biotech firms, these regions were not considered to be concentrations. No other region 
in the UK had more than the average (mean) number of all four organisations and, 
more importantly, no other region had more than the average (mean) number of 
biotech firms (11.8 firms). So, out of 37 regions only seven contained any significant 
biotech presence (see Appendix 5.1 for full list of regional biotech).  
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5.2.1.1 Biotech Firms 
 
The main variable used to identify British biotech concentrations was the number of 
research-driven biotech firms in a region. As explained in Chapter 3, these were firms 
engaged in biotech R&D, which means that they are the main producers of new 
biotech knowledge for commercialisation. In 2003 there were 436 British biotech 
firms with an average (mean) of 11.78 per NUTS2 region (median of 6). Only seven 
regions had more than the mean number (see Table 5.1). 
 
Table 5.1: Regional Concentrations of Biotech Firms 2003 
REGION NUMBER OF BIOTECH FIRMS 
Berkshire, Buckinghamshire and Oxfordshire 68 
East Anglia  65 
Inner London 62 
Eastern Scotland 39 
Surrey, East and West Sussex 22 
South Western Scotland 18 
Greater Manchester 14 
 
Source: Various (see p.97). 
 
Only four of these regions had more than double the mean number (23.66) and these 
four regions represented over half of all British biotech firms with the two main 
regions (Berkshire et al and East Anglia) representing around 30% of all biotech 
firms. Historically these biotech firms have also been concentrated in these two 
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regions; of the 42 firms in 1983, around a third were concentrated in these two 
regions.  
 
Figure 5.1: Map of Biotech Firm Concentrations 2003  
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5.2.1.2 Service Providers 
 
Another important organisational variable is the concentration of service providers, 
representing complementary knowledge for biotech firms such as legal and financial 
services, financial investment, networking opportunities and technology transfer 
(amongst others). Secondary sources for 2001 showed that there were a total of 470 
relevant service providers across the UK with an average (mean) of 12.70 per region 
(median of 5). There were only three regions with twice the mean (see Table 5.2). 
 
Table 5.2: Regional Concentrations of Service Providers 2001 
REGIONS 
NUMBER OF SERVICE PROVIDERS 
Inner London 149 
Berkshire, Buckinghamshire and 
Oxfordshire 
50 
East Anglia 49 
 
Source: Biocommerce (2001). 
 
The highest concentration of service providers was in Inner London where nearly a 
third of them were located. There were another seven regions with above average 
(mean) numbers of service providers, but the three main regions represented over half 
of all these organisations. The dominance of these three was also evident historically 
with nearly half of the service providers located in Inner London in 1983 (49.6 %).  
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Figure 5.2: Map of Service Provider Concentrations 2001 
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5.2.1.3 University Departments 
 
Because of the important role that public science plays in the biotech industry, the 
next organisational variable considered is the concentration of „biotech‟ university 
departments (e.g. biological sciences, chemistry, pharmacology) in the UK. These 
totalled 255 departments in 2001 with an average (mean) of 6.89 per region (median 
of 6). In contrast to the two previous organisational variables, university departments 
were more evenly distributed across the UK. Consequently there were nine regions 
with more than 10 departments, although only three with twice the average (i.e. 14). 
The regions are outlined in Table 5.3 below. 
 
Table 5.3: Regional Concentrations of University Departments 2001 
REGIONS NUMBER OF UNIVERSITY 
DEPARTMENTS 
Inner London 46 
Eastern Scotland 14 
Berkshire, Buckinghamshire and Oxfordshire 14 
East Anglia 13 
Greater Manchester 12 
Leicestershire, Rutland and Northamptonshire 12 
West Midlands 12 
Gloucestershire, Wiltshire and North Somerset 12 
South Western Scotland 11 
 
Source: RAE 2001 (see p.99). 
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Inner London alone represented around 18 % of all „biotech‟ university departments, 
whilst all nine regions represented nearly half of the UK total. The historical data on 
this organisation type is less clear, but it does show that in 1996 there were similar 
concentrations with Inner London again dominant.  
 
5.2.1.4 Public Research Organisations 
 
The final organisational variable is the concentration of biotech public research 
organisations (PROs), which represent public investment in applied research. These 
were the least prevalent with 106 such PROs in 2003; the regional average (mean) 
was 2.86 per region (median of 1). The spread of these organisations was fairly 
limited with nearly 50% concentrated in just four regions, each with over 10 PROs. 
These regions represented extreme concentrations with three-times the average 
number (Table 5.4).  
 
Table 5.4: Regional Concentrations of PROs 2003 
REGIONS 
NUMBER OF PROs 
East Anglia 15 
Eastern Scotland 13 
Inner London 12 
Berkshire, Buckinghamshire and Oxfordshire 12 
 
Source: Various (see p.100). 
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Figure 5.3: Map of University Departments 2001 
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Figure 5.4: Map of PROs 2003 
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Information on foundation dates showed that in 1983 these PROs were concentrated 
in Eastern Scotland (8) and Inner London (5), which means the highest proportional 
investment in applied public research appears to have been in East Anglia (fivefold 
increase) and Berkshire, Buckinghamshire and Oxfordshire (fourfold). This might 
indicate that the PROs in these latter two regions were more oriented towards new 
research projects and programmes, such as biotechnology, whilst the PROs in the 
former two regions were less so.  
 
5.2.2 Knowledge Concentrations 
 
It is evident from secondary data sources on knowledge indicators that the four main 
organisational concentrations also represent significant concentrations of knowledge 
from levels of public science investment through to the number of large and medium 
enterprises. However, a number of other regions also feature strongly across these 
indicators, especially in relation to public science, which raises a number of questions 
about why there were only four main concentrations. These issues will be dealt with 
in the subsequent section when the specific knowledge bases and drivers are used to 
differentiate between different types of biotech concentration.  
 
5.2.2.1 Public science investment 
 
Throughout the literature on the biotech industry the role of public investment in basic 
science is repeatedly emphasised as crucial (Woiceshyn 1995; Senker et al 1996; 
Acharya et al 1998; Cooke 2003a; Bagchi-Sen et al 2004). Such public investment 
can be split between research funding and research training. In the UK these can be 
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represented by the total research council (RC) funding and RC-funded doctoral 
studentships of the Medical Research Council (MRC), Natural and Environmental 
Research Council (NERC) and Biotechnology and Biological Sciences Research 
Council (BBSRC). The latest available data for each council was collected covering 
2001/02 for the MRC and 2003 for the NERC and BBSRC. The average annual RC 
funding per region was around £19 million, although there were a number of major 
regional concentrations as shown in Table 5.5. However, some concentrations have a 
higher RC spend per university department than others, which suggests that whilst 
absolute spend may be important, relative spend may also be significant for 
determining regional knowledge capacity. 
 
Table 5.5: Regional Concentrations of Research Council Spend  
REGIONS RESEARCH 
COUNCIL SPEND 
SPEND PER 
DEPARTMENT 
Inner London c.£102 million £2.22 million 
East Anglia c.£85 million £6.54 million 
Berkshire, Buckinghamshire and 
Oxfordshire 
c.£60 million £4.29 million 
Eastern Scotland c.£58 million £4.14 million 
Greater Manchester c.£50 million £4.17 million 
 
Source: MRC; NERC; BBSRC. 
 
The concentration of RC-funded doctoral studentships was similar, although there 
were two regions with significantly higher proportions than other regions. In total 
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there were 879 RC-funded doctoral studentships in 2003/04 with an average (mean) 
of 23.76 per region (median of 15). The main regional concentrations were the same 
as the top four regions for research council spending (see above) as Table 5.6 shows. 
Again, the average number of studentships per university department reveals a 
different picture since the dominant region (Inner London) in absolute terms was also 
the weakest in relative terms.  
 
Table 5.6: Regional Concentrations of Research Council Funded Doctoral 
Studentships 
REGIONS RC-FUNDED 
DOCTORAL 
STUDENTSHIPS 
STUDENTSHIPS 
PER 
DEPARTMENT 
Inner London 164 3.57 
East Anglia 133 10.23 
Eastern Scotland 87 6.21 
Berkshire, Buckinghamshire and 
Oxfordshire 
73 5.21 
 
Source: MRC; NERC; BBSRC. 
 
As the data above shows, public knowledge investment is strongly concentrated in a 
few regions of the UK. These concentrations map onto the earlier organisational 
concentrations supporting earlier research highlighting the important role that public 
science investment has in relation to the biotech industry. However, there is not a 
clear relationship between such investment and the exploitation of biotech knowledge, 
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characterised as the number of firms in a region since some regions perform better 
relatively on some indicators (e.g. Greater Manchester and RC funding) than other 
regions with more firms (e.g. Inner London in relation to RC spend). 
 
5.2.2.2Private Knowledge Investment (i.e. patents, articles)  
 
As with public investment in knowledge, the private investment of biotech firms is 
crucial to production and exploitation of new biotech knowledge. Such investment 
can also represent the organisational capabilities of biotech firms in terms of their 
stock of knowledge, its scalar dimension (e.g. national or international) and the extent 
to which it is freely appropriable (e.g. articles) or not (e.g. patents). The different 
stocks and capabilities highlighted below include the number of USPTO patents and 
EPO patents (2003 and before) held by firms, where the former represents 
international codified knowledge and the latter more „local‟ codification. Next is the 
number of articles (2003 and before) held by firms, which represents the freely 
appropriable knowledge stock of firms. Finally, the number of UK and international 
alliances (1997-2004) that firms have represents the organisational inter-linkages and 
ties to local and international nodes of biotech knowledge, rather than firm-level 
stocks of knowledge or capabilities.  
 
In total there were 944 USPTO patents, 804 EPO patents and 4209 articles across all 
UK biotech firms up until 2003. The respective regional average (mean) were 25.5, 
21.7 and 113.8. All three types of knowledge were, once again, regionally 
concentrated with USPTO patents concentrated in two main regions (representing 
over half of all USPTO patents), with three secondary regions, whilst EPO patents 
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were more evenly spread across UK regions, although still concentrated in five 
regions. Finally, articles were concentrated in two main regions, but like USPTO 
patents there were three secondary regions (see Figure 5.5). 
 
What this data show is that such knowledge stocks and capabilities are largely 
concentrated in the same regions as biotech firms, for obvious reasons. However, 
there is an interesting anomaly in that Eastern Scotland has lower levels than at least 
two other regions with significantly lower numbers of biotech firms; Greater 
Manchester and Surrey, East and West Sussex. It is possible that these two regions 
have one or more large firm that produced this higher number. It is also worth noting 
that East Anglia, with more articles than Inner London, has more freely appropriable 
knowledge stocks, whilst Inner London has more USPTO and EPO patents. 
 
Figure 5.5: Regional Concentrations of Patents and Articles 
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There were a total of 671 alliances between 1997 and 2004 with a regional average 
(mean) of 18, although the median average was only 2. Alliances were even more 
heavily concentrated than other organisational and knowledge indicators. Between 
them three regions – Berkshire, Buckinghamshire and Oxfordshire, East Anglia and 
Inner London – had 70% of all these alliances (see Figure 5.6). Alliances can be split 
between „local‟ (i.e. UK) and „international‟ (i.e. non-UK) ties to differentiate 
between the location of this external knowledge. There were 152 local alliances 
compared with 519 international ones meaning that local alliances only represent 
around a third of international alliances.  
 
Figure 5.6: Regional Concentrations of Company Alliances 
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There was an average (mean) of 4.11 local ties per region, although the median was 
only 1, whereas for international ties the average (mean) was 14.03, although, again, 
the median was only 1. The three main regional concentrations had more international 
alliances (73%) than local alliances (60%) suggesting that these regions were more 
tied into international nodes of biotech knowledge than other regions.  
 
Although there were three regional concentrations of alliances, these concentrations 
may have been disproportionately influenced by the location of the larger publicly-
listed biotech firms like Celltech Group plc (bought by UCB Pharma in 2004) in 
Berkshire et al and Cambridge Antibody Technology plc (bought by AstraZeneca plc 
in 2006) in East Anglia. A map of the alliance structure of these large firms (see 
Figure 5.7 and Figure 5.8) shows that such large firms have an enormous number of 
alliances that can influence the regional averages.    
 
These alliance networks also show the extent to which the number of international ties 
depends on the number of large firms in a region. This point will be explored in a 
little more depth below when mapping economies and externalities of scale. 
Furthermore, it reveals an interesting feature of the different biotech concentrations, 
namely the important role that individual firms (e.g. Celltech or Cambridge Antibody 
Technology) can play in linking regions into wider global markets and sources of 
knowledge.  
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Figure 5.7: Celltech Group plc Alliance Network (2000-2004)  
 
 
 
 
 
 
 
 
 
 
 
Source: Bioworld. 
 
Figure 5.8: Cambridge Antibody Technology plc Alliance Network (1997-2004) 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Bioworld. 
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5.2.2.3Employment levels 
 
Although the knowledge stocks and ties that biotech firms have are important, they 
can only tell one part of the story. Just as important is the expertise embodied in 
company employees and university staff that represent a clearer example of regional 
tacit knowledge stocks (Prevezer 1997, 2003). There were 43,180 biotech firm 
employees and 9310.3 university staff across the UK. However, there was only data 
on two-thirds of the biotech firms (296). The regional average (mean) for biotech 
employees was 1167, whilst for university staff it was 251.6.  
 
Figure 5.9: Regional Concentrations of Biotech Employment and University 
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There were six main concentrations of the former, representing 61% of the British 
total, and four of the latter representing half of all university staff (see Figure 5.9). 
One region alone – Berkshire et al – represented over 20% of all biotech employees 
due to the location of several large firms in that region. In relative terms (see Figure 
5.10), there were higher concentrations of biotech employees in both Greater 
Manchester and Surrey et al, regions with only 14 and 22 biotech firms respectively. 
This suggests that regions have distinct firm compositions, which, in this case, shows 
that Inner London, East Anglia and Eastern Scotland have fewer large firms than 
Berkshire et al, Greater Manchester and Surrey et al. In contrast, the relative number 
of university staff is similar across all these regions apart from Surrey et al where it is 
significantly higher than the other regions. 
 
Figure 5.10: Relative Regional Concentrations of Biotech Employment and 
University Employment 
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Overall there is a significant difference in the concentration of private and public 
employees across the UK. This supports the argument that public science capacity is 
not a sufficient condition for innovation, although it is still a necessary one (Feldman 
2002). Furthermore, it shows that knowledge derived from universities is not 
necessarily a central feature of biotech innovation processes (see Lawton-Smith et al 
2000; Lawton-Smith 2002; Leibovitz 2004; although contrast Cooke 2002c; 
McKelvey 2004). However, it appears as though a specific relative level of university 
employment is important in different ways to different regions.  
 
5.2.2.4Firm types 
 
Whilst employment and other knowledge inputs (e.g. patents, alliances) are all 
important, the identification of the particular characteristics of each biotech 
concentration involves exploring the specific types of firms in these regions. This 
relates to the number of firm-level features such as the main sector of activity (e.g. 
therapeutic, diagnostic, agricultural), firm sizes (e.g. small, large) and firm origins 
(e.g. spin-outs, subsidiaries). Such characteristics can have an important impact on 
knowledge economies in a number of ways. First, sectoral similarities across a region 
can provide firms with both competition and complementary competencies that then 
stimulates innovation (Prevezer 1997; cf Cooke 2002b). Second, size can provide an 
indication of economies and externalities of scale. On the one hand the former 
represents a stock of knowledge in one large organisation that dominates a region 
(e.g. Walcott 2001). On the other hand, the latter represents the diversity of multiple 
stocks of knowledge held in a number of distinct small organisations that through 
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interaction encourage the iterative production of knowledge (von Hippel 1994). 
Finally, a firm‟s origin can provide an indication of the importance of local (i.e. spin-
out) or international (i.e. subsidiary) knowledge resources to innovation.  
 
At a sectoral level, UK biotech firms were categorised according to a fivefold 
typology consisting of Therapeutic, Diagnostic, Services, Agriculture and 
Environment (see Figure 5.11). This showed that 46% of the biotech firms were 
involved in the Therapeutic sector, developing and marketing biomedical products 
like biopharmaceuticals. This places the UK somewhere between the USA and 
Europe in terms of industry composition; in the US Human Healthcare represents 
53% whereas in Europe it is 37% (Critical I 2006).  
 
Figure 5.11: Sectoral Distribution of the UK Biotech Industry 
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The relationship between these sectors is not always clear, in terms of complementary 
competencies, but a correlation analysis showed that, at the NUTS2 scale, the 
therapeutic sector had a reasonably strong association with both the Service and 
Diagnostic sectors (see Table 5.7). In contrast there was no significant relationship 
between the Therapeutic sector and either the Agriculture or Environment sectors, 
suggesting that the Therapeutic sector shares competencies with (or relies upon) 
Diagnostics and Services. There were weaker associations between the Environment 
sector and both Diagnostic and Agriculture sectors, which suggested that certain firms 
benefit from locating near other firms from their own sectors and complementary ones 
(Woiceshyn 1995; Gray and Parker 1998; Cooke 2004a).  
 
Table 5.7: Correlation Analysis of Regional Biotech Sectors 
 Therapeutic Diagnostic Services Agriculture Environment 
Therapeutic - - - - - 
Diagnostic .577** - - - - 
Services .696** .486** - - - 
Agriculture .319 .171 .127 - - 
Environment .188 .362* .106 .434** - 
** Correlation significant at the 0.01 level 
* Correlation significant at the 0.05 level 
Source: Various (see p.97). 
 
The size of a biotech firm can reveal the extent to which a region benefits from 
economies of scale and scope (Parr 2002). The former can be represented by the 
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existence of medium and large-sized enterprises (MLEs) because they engage in 
large-scale internal knowledge production and therefore do not need to acquire 
knowledge externally (or can do so to a lesser extent). In contrast the latter is 
represented by micro and small-sized enterprises (MSEs) that engage in small-scale 
internal knowledge production and therefore need to acquire knowledge externally. 
This encourages and stimulates greater interaction between organisations. From the 
secondary data on employment covering 296 firms, it was possible to map the 
concentration of both MLEs and MSEs to show where regional knowledge production 
was internalised and externalised (Ernst and Kim 2002; Cooke 2004c).  
 
In total there were 199 MSEs and 97 MLEs with respective regional averages (mean) 
of 5.4 and 2.62. There was an obvious concentration of MLEs in a few regions with 
only three having 10 or more and therefore representing 40% of the total. These 
included Berkshire, Buckinghamshire and Oxfordshire (17), East Anglia (15) and 
Inner London (10). MSEs were also concentrated in these three regions as well as 
three other regions (see Figure 5.12 below). Notably, Eastern Scotland had a 
relatively low number of MLEs despite being characterised as a concentration by 
other organisational and knowledge indicators. 
 
The different concentrations of MLEs and MSEs therefore helps to distinguish 
between different types of region by providing some indication of dynamic change as 
successful MSEs develop into MLEs, as well as illustrating the extent to which certain 
regions are characterised by certain types of knowledge production. In this case, the 
three MLE concentrations also had significant concentrations of many other 
organisational and knowledge indicators, which suggested that MLEs played both an 
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important role in promoting knowledge production and were important sites of 
knowledge production. However, these regions also had high concentrations of MSEs 
meaning that externalised knowledge production and interaction were just as 
important as economies of scale. 
 
Figure 5.12: Regional Concentrations of MSEs and MLEs 
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 Source: Various (see p.97). 
  
The final firm-level characteristic – firm origin – is also regionally concentrated. 
Since previous research has argued that both local and international linkages are 
important (Leibovitz 2004; Ryan and Phillips 2004), the source of a firm‟s knowledge 
capabilities is a useful indicator for considering the scalar relationships of biotech 
firms. To examine this, secondary data on the origins of firms as either a spin-out or 
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subsidiary was collected. From the available data, this showed that there were 145 
spin-outs and 73 subsidiaries in the UK with respective averages (mean) of 4.26 and 
2.09 per region. Over 68% of all spin-outs were concentrated in just four regions and 
44% of subsidiaries were concentrated in the same locations (see Table 5.8).  
 
Table 5.8: Regional Concentrations of Spin-outs and Foreign Subsidiaries 
REGIONS SPIN-OUTS SUBSIDIARIES 
Inner London 38 5 
Berks, Bucks & Oxon 29 9 
East Anglia 21 12 
Eastern Scotland 10 6 
 
Source: Various (see p.97). 
 
In the first instance the concentration of spin-outs indicated the importance of public 
science investment as a stimulus of innovation in those particular regions, whilst 
subsidiaries indicated the importance of international knowledge sources. Secondly, 
the concentration of spin-outs indicated the age of a particular biotech concentration 
since on average spin-outs were founded later than other firms. 
 
5.3 THE FOUR CENTRES OF UK BIOTECHNOLOGY  
 
The purpose behind considering the different types of biotech organisation and 
knowledge indicators was twofold. First, the secondary data can be used to reveal 
whether there were any regional concentrations of biotechnology in Britain, which it 
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did and second it helped to outline the particular characteristics of these regional 
concentrations. We cannot assume that each concentration developed along a similar 
trajectory or that such trajectories were consistently path dependent once a region 
„locked-in‟ to biotech. In contrast, it was more useful to consider Ray Hudson‟s 
(2005) concept of „path contingency‟, which seeks to address how both development 
and decline are processes that regional economies go through as they adapt to 
changing circumstances.  
 
Using the data outlined above it was evident that the UK biotech industry was heavily 
concentrated in the East and South-east of England, in what gets characterised as the 
„golden triangle‟ in relation to university research. There was one outlier, Eastern 
Scotland, although this region covered a relatively large land area stretching from 
Perth, Dundee and Stirling down through Edinburgh to the Scottish Borders. From 
these locations it was possible to identify four regions based on NUTS2 categories 
that represent four centres of UK biotechnology. Each region has different 
characteristics in relation to both the organisational composition and content, 
knowledge stocks and production, as well inter-regional and international interaction. 
In previous research (e.g. Acharya 1999; Cooke 2003b; McKelvey et al 2004; Ryan 
and Phillips 2004) the characteristic of biotech concentrations and „clusters‟ has been 
represented in stylised terms. As such they include dedicated biotechnology firms 
(DBFs) – that comprise small and medium-sized enterprises (SMEs) – alongside 
„upstream‟ (e.g. universities) and „downstream‟ (e.g. large pharmaceutical companies) 
organisations which provide complementary competencies. All these organisations 
are then linked with a number of specialised local service providers including 
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business, financial and legal services, as well as public sector bodies like local 
government development agencies.  
 
Instead of using this stylised typology, the four regional concentrations highlighted 
here were split between knowledge bases and drivers representing the two linked 
features of the knowledge economy presented by Cooke (2002c). The knowledge base 
therefore represented new knowledge stocks that can be used to produce new 
knowledge, which then drives the commercial exploitation of new knowledge. As 
such the former consisted of endogenous knowledge capabilities in a region (i.e. 
knowledge production), whilst the latter consisted of both the endogenous and 
exogenous drivers of knowledge exploitation in a region (i.e. market demand). 
Neither of these elements means that there is an optimal or necessarily advantageous 
spatial characteristic (see Boschma 2004), but rather than each region pursues its own 
contingent path (Hudson 2005). This classification of the four regions according to 
their knowledge base and driver is outlined in Table 5.9 and Table 5.10 below.    
 
In terms of regional knowledge base, it was evident that there were numerous 
differences between UK regions, which were not the result of the different ages of 
each concentration. It is useful, rather, to consider that different knowledge bases will 
lead to path contingent processes of adjustment and change as regions adapt to their 
specific assets in relation to the biotech industry. Thus both East Anglia and Berkshire 
et al had a more recent applied public science base (e.g. PROs), although an older 
basic public science (e.g. universities). This suggested that both regions contained 
specific features of the biotech industry that were constituted by this knowledge base, 
such as a focus on biomedical, as opposed to agricultural, innovation. 
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Table 5.9: Knowledge Base of Regional Biotech Centres 
 EAST 
ANGLIA 
INNER 
LONDON 
BERKS, 
BUCKS & 
OXON 
EASTERN 
SCOTLAND 
Applied public science New Old New Old 
Basic public science Old Old, new Old Old 
Star science High High Low Low 
Public science spend 
(absolute/relative) 
High, high High, low Mid, mid Mid, mid 
Public science training 
(absolute/relative) 
High, high High, low Mid, mid Mid, mid 
Codified knowledge 
(local/international) 
Mid, high High, mid High, high Low, low 
Appropriable knowledge High Mid Very high Mid 
Basic science skills High Very high High High 
 
 
However, East Anglia had a significantly stronger public science than Berkshire et al, 
which also implied that firms in the former region depended more on this source of 
knowledge than those in the latter region. Despite the stronger public science base in 
East Anglia, it was actually Berkshire et al that had the highest incidences of both 
non-appropriable (e.g. patents) and appropriable (e.g. articles, skills) knowledge 
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stocks. Evidently these were derived from biotech firms rather than the science base 
in Berkshire et al. 
 
Table 5.10: Knowledge Drivers of Regional Biotech Centres 
 EAST 
ANGLIA 
INNER 
LONDON 
BERKS, 
BUCKS & 
OXON 
EASTERN 
SCOTLAND 
Science 
commercialisation (firms) 
Old, new New New New 
Economies of scale and 
scope 
Small, med Micro, med Micro, med, 
large 
Micro 
Local origins Mid High High Low 
Foreign origins High Low Mid Low 
External relationships Total, local Total, local Total, local, 
international 
Low 
Complementary service 
competencies 
New Old, new New Low 
Commercial science skills High Mid Very high Low 
 
 
Whereas East Anglia dominated the knowledge base, it is less obvious whether any 
region had a stronger position in relation to knowledge drivers. There were clear 
differences between regions though, with East Anglia containing older SMEs 
originating, more often, as foreign subsidiaries. In contrast, Berkshire et al had 
significantly more large companies and locally derived spin-outs as well as stronger 
 186 
international ties. Overall then it was possible to differentiate from the features 
identified in Tables 5.9 and 5.10 between the four centres of biotechnology based on 
their knowledge stocks and drivers: 
 
 East Anglia: Older, SME and university based; SME driven. 
 Inner London: Newer, university based and driven. 
 Berkshire, Buckinghamshire and Oxfordshire: Global, large firm based; firm 
and university driven. 
 Eastern Scotland: Older, university based and driven.  
 
Thus the biotech industry in East Anglia was older and driven more by the concerns 
of SME commercialisation, whilst in Berkshire et al it was globally-oriented and 
driven by both basic science and large firms. The Inner London concentration was 
relatively new and largely based on and driven by university activity, as was the 
Eastern Scotland concentration, although the latter was considerably more reliant on 
its older roots in the public science base than Inner London. The next thing to do was 
therefore to seek to understand why there were such concentrations and whether there 
was a factor that applies to all such concentrations.  
 
5.4 EXPLAINING BIOTECH CONCENTRATIONS I: PROXIMITY 
 
Because each region had a different set of characteristics yet still represented a 
concentration of the biotech industry it was plausible that there were endogenous 
regional characteristics that stimulate knowledge production and commercialisation. 
Both these aspects of the „knowledge economy‟ had a different source and effect in 
 187 
each region, but were still present across all four regions – as well as all other regions. 
Previous academic work has stressed the importance of proximity with organisations 
benefiting from both formal interaction and the capture of informal knowledge 
interaction such as the knowledge spillovers between organisations (for two recent 
reviews see Moulaert and Sekia 2003; Lagendijk 2006). Proximity goes beyond 
simple access to knowledge though, since it provides the means for firms or 
organisational actors to draw upon the resources of each other through competition, 
interaction and imitation (see Dobbin 2004). Thus firms benefit from proximity to 
public sector organisations (and vice versa), although the relationship between such 
organisations is not unambiguous (Audretsch and Stephan 1999; Lawton-Smith 2002; 
Zucker et al 2002). 
  
Although proximity is important, there are many ways to characterise it (see Zeller 
2004; Boschma 2005).  First, secondary data on firm density (km² per firm) was used 
to illustrate the importance of spatial proximity to innovation processes. Second, 
secondary data on firm propensity (population per firm) was used to show the 
importance of social proximity or the extent to which innovation processes depend 
upon a shared cultural and social structure. Finally, secondary data on firm intensity 
(i.e. population density per firm) was used to show how important organisational 
proximity was to innovation processes. For each type of proximity a score was 
calculated for the UK and for each of the four concentrations (at the NUTS2 scale) to 
see if there were any similarities or differences between the concentrations.  
 
The first graph (see Figure 5.13) shows firm density at the national scale and for each 
biotech concentration. This was used as a proxy because it helps to show how close 
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firms are to one another in physical terms (i.e. distance). As can be seen from the data 
there is very little similarity between the four concentrations, although all four have a 
lower score than the national average. This suggests that physical proximity is 
important to a certain extent. However, the lowest score was for Inner London (5), 
which shows that extremes of physical proximity do not necessary explain why 
biotech concentrates since both East Anglia (193) and Berkshire et al (84) have 
significantly stronger knowledge bases and drivers than Inner London. Eastern 
Scotland represents somewhat of an anomaly because of its high score, but this is 
perhaps explained by the geographic scope of the region 
 
Figure 5.13: Spatial Proximity 
 
Source: Various (see p.97); Eurostat (area). 
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Firm propensity (i.e. firms per population) was used as a proxy for social proximity 
because it shows how likely it is that a person shares common social and cultural 
values and norms (i.e. they work in a similar environment) with other people in a 
particular place (see Figure 14). The data shows that there is a greater degree of 
similarity between the four biotech concentrations than with physical proximity, 
especially when compared with the national score. In some ways this supports the 
argument that social proximity plays an important role in explaining the concentration 
of innovation (e.g. Powell et al 2002; Cooke 2003a; Fuchs and Krauss 2003). 
However, there are still differences between locations with lower scores in the two 
„strongest‟ biotech concentrations. 
 
Figure 5.14: Social Proximity 
 
Source: Various (see p.97); Eurostat (population). 
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The final graph concerns organisational proximity (see Figure 5.15) characterised by 
firm intensity (i.e. population density per firm). As a proxy, this is meant to show the 
likelihood or chance of interaction and therefore the associative strength of different 
places. Here the data again shows some similarities between the four concentrations, 
although there is a major distinction between Inner London and the other locations. 
Consequently it would be difficult to argue that organisational proximity is the most 
significant explanatory factor. 
 
Figure 5.15: Organisational Proximity  
 
Source: Various (see p.97); Eurostat (population, area). 
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The overall conclusion from this analysis of proximity was that whereas spatial and 
organisational proximity appear to represent an unlikely explanation for 
concentrations, social proximity was more significant. However, again it is important 
to reiterate the point that each concencentration is geographical specific since they all 
have different knowledge bases and drivers, as well as differing proximity 
explanations. The reason for greater similarity in social proximity than others could 
be that such proximity provides a „community of practice‟ from which all 
organisations in a location can draw including biotech firms, public science institutes 
and even service providers (see Audretsch 2003). This meant that the social and 
cultural values underpinning behaviour is beneficial to economic performance of 
individual organisations (see Saxenian 1994a). Thus temporal, spatial and social 
processes are all important in the mediation of innovation processes, which entails a 
dynamic and systemic approach for explaining the reasons for concentrations (see 
McKelvey et al 2004).  
 
5.5 EXPLAINING BIOTECH CONCENTRATIONS II: DYNAMIC 
SYSTEMS 
 
A dynamic and systemic approach to understanding biotech concentrations draws 
upon work in evolutionary economics (Nelson and Winter 1982) and innovation 
studies (Freeman 1982), and has recently been applied to understanding „regional 
competitiveness‟ (Boschma and Lambooy 1999; Boschma 2004; Cooke 2004d). The 
dynamic aspect relates to the cumulative process that leads to an embedded advantage 
for organisations that operate in a particular location as knowledge accumulates 
through usage, whether or not there has been „successful‟ innovation (Boschma 
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2004). The systemic aspect concerns the importance of diffusion of knowledge across 
multiple organisations through specific co-ordination mechanisms that then reinforce 
particular innovation processes (see Lundvall 1992; Cooke 1998, 2004d). To show 
that biotech concentrations were dynamic necessitates an historical analysis of the 
relationships between complementary organisations. To illustrate that they were 
systemic requires both an historical and proximity analysis of the relationship 
between different organisations.  
 
First, the biotech territorial innovation system was represented by the relationship 
between different organisations at NUTS2 scale in the early 2000s (see Table 5.11). 
This showed that there were very strong associations between (a) biotech firms and 
PROs, (b) service providers and top-rated university departments (i.e. RAE 5*), as 
well as strong associations between (c) firms and other university departments. There 
were weaker, although still strong, relationships between PROs and university 
departments that grew stronger with the department RAE rating.  
 
Table 5.11: Biotech Innovation System (NUTS2) 
NUTS2 FIRMS HEIs HEIs 5* PROs SPs 
FIRMS 1.0000     
HEIs 0.6762 1.0000    
HEIs 5* 0.7562 0.9035 1.0000   
PROs 0.9049 0.6297 0.6970 1.0000  
SPs 0.7902 0.8887 0.9007 0.6881 1.0000 
 
Source: Various (see pp.97-100). 
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This suggested that top-rated university research was undertaken in regions where 
there are PROs, or that PROs were established in regions where top-rated research 
was undertaken, supporting the view that „star scientists‟ are important to biotech 
firms (Zucker et al 1998; Zucker et al 2002). The latter interpretation supports the 
argument that academic links are weaker than sometimes thought, and that applied 
research provides greater input into innovation in the firm (Lawton-Smith 2002; 
Leibovtiz 2004), although the role of the scientists is of crucial importance in 
explaining concentrations (Bagchi-Sen et al 2001). 
 
One important point to consider was whether the scale of the territorial innovation 
system affected the strength of the association between different organisations. 
However, using a smaller scale (i.e. NUTS3) to analyses the same data revealed 
similar strength relationships, although most are slightly weaker (see Table 5.12). 
Certain relationships remained the same or grew stronger, such as between biotech 
firms and service providers.  
 
Table 5.12: Biotech Innovation System (NUTS3) 
NUTS3 FIRMS HEIs HEIs 5* PROs SPs 
FIRMS 1.0000     
HEIs 0.6523 1.0000    
HEIs 5* 0.7145 0.8307 1.0000   
PROs 0.8788 0.6248 0.6976 1.0000  
SPs 0.7912 0.8025 0.7718 0.6877 1.0000 
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Source: Various (see pp.97-100). 
 
One interpretation of this finding was that it indicated how important intermediate 
services were in the biotech innovation system, providing firms with access to 
external knowledge that they have not internalised (e.g. legal, marketing, management 
services) or providing crucial financial resources through local VC or business angels 
(Cooke 2001c; Bagchi-Sen et al 2004; Zook 2004). However, it needs to be stressed 
that the smaller-scale innovation system did not differ markedly from a broader scale 
system. The importance of scale was also unsupported by an analysis of a large-scale 
innovation system (i.e. NUTS1). This shows, once again, an almost identically strong 
set of associations with the smaller NUTS2 and NUTS3 scales (see Table 5.13).  
 
Table 5.13: Biotech Innovation System (NUTS1) 
NUTS1 FIRMS HEIs HEIs 5* PROs SPs 
FIRMS 1.0000     
HEIs 0.5572 1.0000    
HEIs 5* 0.5570 0.8145 1.0000   
PROs 0.8962 0.5314 0.4395 1.0000  
SPs 0.7785 0.8438 0.9121 0.6165 1.0000 
 
Source: Various (see pp.97-100). 
 
All this suggests that the effect of spatial scales on territorial innovation systems was, 
at best, ambiguous, but, at worst, did not play a significant role in explaining the 
concentration of organisations in particular locations. However, the scalar 
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relationships did show that these connections between biotech organisations were part 
of a systemic process that involves a number of different organisations, especially 
applied research and intermediate services.  
 
Second, the dynamic aspect of biotech innovation was represented by the spatial 
relationship between organisations over time. The data covered the relationship 
between organisations founded at the NUTS2 scale during 5-year periods of time, 
where this was possible to ascertain. The time periods were 1999-2003, 1994-1998, 
1989-1993, 1984-1988, and pre-1984. There were some limitations with this 
approach, particularly the lack of data on organisations that have ceased operating, but 
it provided one means to assess the cumulative process of knowledge production and 
transfer emphasised in some theories, particularly ones derived from evolutionary 
concepts (see Cooke 2002c; Boschma 2004). The data showed a clear cumulative 
accumulation of biotech organisation across British regions (see Figure 5.16).  
 
Figure 5.16: Regional Cumulative Accumulation of Biotech Firms 
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Source: Various (see p.97). 
 
There were associations over time with firms, PROs and service providers, whilst the 
data on university departments was more limited because it only covered 1996 and 
2001 (i.e. RAE years). The latter association was very strong for all departments 
anyway (R² value of 0.931) and indicated that there was a fairly strong trajectory to 
university research. The association between „star‟ university departments (i.e. 5* 
RAE) was much weaker with an R² value of 0.588, which suggested that world-class 
research was less path dependent, possible because there is more reliance on „star 
scientists‟ (Zucker et al 2002). This finding did support the contention that biotech 
firms do not necessarily rely upon local experts for their scientific advice; e.g. the 
number of local scientists on their scientific advisory boards (SABs) are low (see 
Casper and Karamanos 2003; Casper and Murray 2004). 
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However, for PROs and service providers there was a strengthening of the association 
with biotech firms over time, although there was less of an association difference over 
time when comparing the organisations to themselves. For biotech firms there was a 
definite cumulative process of association shown in the relationship between adjacent 
time periods as they became stronger (highlighted in Table 5.14). Early foundation 
(i.e. 1983 and before) also has a strong association across all other time periods 
suggesting that these firms play a partial role in encouraging later firms to found in 
similar locations (see Prevezer 1997, 2003). 
 
 
 
 
Table 5.14: Dynamic Biotech Innovation (1983-2003) 
NUTS2 FIRM 2003 FIRM 1998 FIRM 1993 FIRM 1988 FIRM 1983 
FIRM 2003 1.000     
FIRM 1998 0.835 1.000    
FIRM 1993 0.785 0.788 1.000   
FIRM 1988 0.581 0.478 0.388 1.000  
FIRM 1983 0.615 0.676 0.712 0.352 1.000 
 
Source: Various (see p.97). 
 
With service providers there was no cumulative process since there was a similar 
level of association between each time period indicating that there was little relative 
cumulative increase over time; i.e. the R² value remained around 0.8 and 0.9 across all 
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periods. This finding supported the contention that intermediate services were 
important for concentrations, but because of the diverse knowledge they provide 
rather than their specific applicability to the biotech industry (cf Kenney 1998; Cooke 
et al 2003). In contrast to service providers, PROs followed a cumulative process 
similar to firms although early foundations did not seem to be as important for PROs. 
This suggested that applied research was also subject to a cumulative process of 
knowledge production and transfer, like firms but unlike service providers, and that as 
a consequence public investment in applied research played a crucial role in 
embedding knowledge capacity in regions and thereby encouraging concentrations. 
 
5.6 ANALYSING THE SCALAR RELATIONS OF BIOTECH 
CONCENTRATIONS 
 
Although the data on organisations shows that there were both systemic and dynamic 
relationships between them, it provided only a limited explanation of the scalar 
relationship between organisations because it excluded knowledge and the impact this 
has on concentrations (Frenken and van Oort 2003, 2004). For example, intermediate 
services may be more important to firms at a small, localised scale because this spatial 
proximity provides these services providers with greater local knowledge of the needs 
of different organisations. Alternatively, intangible knowledge inputs, like patents 
(Deeds and Hill 1996), may be more important at a wider scale because organisational 
proximity is more important than spatial proximity (Rallet and Torre 1999; Boschma 
2005). To analyse such scale relationships it was necessary to consider the 
relationship between regional knowledge bases and drivers and the concentration of 
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biotech firms. All such aspects of the innovation system were analysed using NUTS1, 
NUTS2, and NUTS3 scales in order to provide comparability with each other.  
 
The main focus of the analysis was whether there was any difference across the three 
NUTS scales between the knowledge base, knowledge driver and the concentration of 
biotech firms. This could then provide an explanation as to what scale the knowledge 
bases and drivers have an impact on the concentration of firms, rather than simply 
assuming that mere concentration in one location was advantageous. The relationships 
covering knowledge bases is shown in Figure 5.17 and for knowledge drivers in 
Figure 5.18 below.  
 
For the former (knowledge stocks), scale appeared relatively unimportant in relation 
to applied public science (i.e. number of PROs), funded PhD studentships, and EPO 
patents. The smallest scale appeared the most important in no circumstance, whereas 
the largest scale (NUTS1) was most important only in relation to tacit knowledge 
stocks (i.e. articles). This means that the mid-scale (NUTS2) was crucial for most of 
the knowledge base, although it often shared this position with one of the other scales 
usually the wider, NUTS1 scale. The local knowledge base therefore appeared to be 
of little importance in explaining the concentration of biotech firms, although basic 
research was more important at the two smallest scales. In contrast, the widest scale 
(NUTS1) showed a significant relationship between firms and tacit knowledge (i.e. 
articles), which implied that localised tacit knowledge was not as important for 
explaining concentrations of the biotech industry as might be thought (see Gertler 
2003; Asheim and Gertler 2005).  
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Figure 5.17: Scalar Relationships between Knowledge Bases and Biotech Firms 
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Source: Various (see pp.97-100). 
 
However, this does support research on the biotech industry that argues that local 
knowledge is less important than might initially be thought (see Breschi et al 2001; 
Leibovitz 2004). With regards to knowledge drivers, there were even fewer 
differences between the scales, suggesting that knowledge drivers operate across all 
three scales. However, there were weaker associations at the smallest scale (NUTS3) 
with foreign origins, biotech employment and company alliances. This suggested that 
external interaction, in the form of foreign subsidiaries and inter-organisational 
linkages, could not be explained by small scale concentration. Instead they were 
reliant upon wider scales that enabled both wider external search patterns for 
organisations at that scale and greater visibility of organisations at that scale for 
international actors seeking partners or investment opportunities in the UK. It was 
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particularly interesting that biotech employment has a progressively stronger 
relationship with biotech firms as scale increases. 
 
Figure 5.18: Scalar Relationships between Knowledge Drivers and Biotech Firms 
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Source: Various (see pp.97-100). 
 
This analysis implied that concentrations were not constituted through local labour 
markets, which, again, suggests that a localised conception of tacit knowledge – this 
time embodied in skills – needs to be reconsidered. Again, previous research on the 
biotech industry has already made similar points, although not explicitly about tacit 
knowledge. For example, Casper and Karamanos (2003) and Casper and Murray 
(2004) have both argued that the science advisory boards of UK biotech firms do not 
rely on local scientists. This finding might be specific to the UK considering the size 
of the country and relative ease with which scientists can move between biotech 
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concentrations in the South-east and East of England, if not the rest of the country as 
well. Overall then, this analysis supported the notion that the knowledge dynamic, 
whether as stocks or drivers, was constituted by scale (Coenen et al 2004).  
 
5.7 CONCLUSION 
 
In summary, the secondary data analysed above illustrates a number of important 
points that need exploring further. Before addressing these it is important to note that 
the extent of the biotech industry in the UK was limited, especially in relation to the 
claims made by the government (e.g. DTI 1999a; BIGT 2003). The findings here are 
supported by other research showing that the number of biotech firms in the UK is 
between 430 and 450 and has not been rising for a number of years (see Critical I 
2005, 2006). This aside, the first analytical point to note is that although there are 
concentrations of biotech organisations and knowledge capabilities across the UK this 
does not mean that the innovation process is constituted by homogenous factors. In 
fact the four main regional concentrations exhibited a number of major differences 
between each other. Although it could be suggested that these differences represent 
the effect of the age of the respective concentrations, there are differences that cannot 
be explained simply by age. Thus whilst East Anglia was characterised by an older, 
SME knowledge base and drive, it had far fewer biotech employees than Berkshire et 
al because the latter region was dominated by larger firms that were more globally 
focused. In contrast to both these regions, Inner London was dominated by new firms, 
universities and service providers suggesting that it was better to consider London as 
a centre for intermediate services and investment and thereby contradicting the 
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concept of local services in the biotech industry as some proximity theories have 
contended (e.g. Stuart and Sorenson 2003). 
 
After the identification of biotech concentrations, the next consideration in this 
chapter was what form of proximity (see Boschma 2005) could usefully explain these 
concentrations. Of the three types considered here – social, spatial and organisational 
– social proximity seemed to be the most consistent factor across all four 
concentrations. Social proximity can be conceived as the similarity between values 
and norms shared by organisations, strategies and employees, all of which engender 
an easy transition for knowledge and labour between such organisations. This meant 
that the innovation process in these concentrations could be considered as both 
systemic and dynamic, in that it entails a number of inter-organisational relationships, 
interactions and movements that occur over a number of years.  
 
The final part of this chapter explores the importance of different spatial scales on the 
relationship between knowledge and concentrations, to consider not only where these 
inter-organisational interactions occur, but also what impact different scales have on 
these relationships and their input into the innovation process. This data revealed that 
there was largely a limited impact of the different scales on knowledge drivers (i.e. 
biotech commercialisation), implying that localised explanations are insufficient for 
understanding the impact of knowledge on successful biotech innovation. It also 
implied that broader issues around market demand are crucial for understanding the 
biotech industry and mean that any explanation cannot be confined to the local scale. 
With regards to the knowledge base, there were a number of clearer relationships. 
There was little evidence to support the argument that local knowledge specifically is 
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crucial to the innovation process (e.g. McKelvey 2004) or even the argument that 
local knowledge connected with global biotech nodes is important (e.g. Coenen et al 
2004). Instead there was support for the argument that local knowledge is not as 
important as may be first thought (Breschi et al 2001; Leibovitz 2004).  
 
However, despite these findings there are a number of issues that could not be 
explained or even explored using the secondary data available here. These concern the 
importance of different types of knowledge used by innovators, such as explicit and 
tacit knowledge, and where such knowledge originates. However, there was limited 
secondary data available on such knowledge, making it problematic to claim specific 
arguments. There is also a need to explore the different knowledge uses of actors in 
different concentrations because the four main regional concentrations had distinct 
characteristics; in particular, it is important to understand how the different use of 
knowledge will will impact on innovation processes in those particular locations. 
Finally then, there are a number of issues around the relationship between knowledge, 
the scale at which it operates and how this impacts on the innovation process. 
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CHAPTER 6 
EXPLAINING THE BIOECONOMY II:  
THE KNOWLEDGE-SPACE DYANMIC IN THE UK 
BIOTECHNOLOGY INDUSTRY 
 
6.1 INTRODUCTION 
 
The analysis of secondary data in Chapter 5 showed that there were concentrations of 
biotechnology in the UK in terms of both the knowledge base and knowledge driver. 
Although these concentrations mapped onto regions identified in earlier policy reports 
(e.g. DTI 1999a) and previous academic research (e.g. Lawton-Smith et al 2000; 
Cooke 2003b; Leibovitz 2004), the size of the identified biotech concentrations was 
lower than a number of these earlier studies. There were fewer that 450 biotech firms 
in the UK and no regional concentration had more than 70 of these firms. 
Furthermore, there was little sense in which knowledge drivers were dependent upon 
scale and therefore locality. Thus the concentration of biotech can be seen as an effect 
of innovation processes embedded in specific locations, which entails a territorial 
understanding of the knowledge-space dynamic in and across different places.  
 
Much of the recent theoretical literature on these issues focuses on distinguishing 
between different spatial innovation processes, defined as territorial innovation 
models (TIMs) by Moulaert and Sekia (2003), that cover the material, relational and 
associational characteristics of space (see also Lagendijk 2006). Across this literature 
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there is a particular focus on the importance of tacit knowledge because it is seen as 
„sticky‟ (von Hippel 1994; Markusen 1996), dependent on constant interaction and 
learning (Howells 1996; Gertler and Levitte 2005), and transferred through face-to-
face contact (Gertler 2003). However, this focus largely assumes that space is 
important because tacit knowledge is important and restricted to local interaction, 
which essentially reverses causality (Malmberg and Maskell 2002; MacKinnon et al 
2002). In this chapter, the thesis addresses this concern by focusing on what types and 
forms of knowledge are embedded in particular spaces and at different scales in 
response to hypothesis two: 
 
H2: Successful innovation in the knowledge economy depends on place-specific 
dynamic and systemic processes because different types of knowledge 
originate in different places and at different scales necessitating interaction 
both within and beyond concentrations. 
 
In order to consider whether tacit knowledge is actually limited to a local space (and 
explicit to a wider scale), a number of respondents who had been associated with 
successful innovation (i.e. a commercialised product) were surveyed about where they 
acquired knowledge during the innovation process. Knowledge was split between 
different types (e.g. customer, university sources), forms (e.g. explicit, tacit, 
commercial) and locations (e.g. local, national, international). In each case 
respondents were asked to rank them according to a Likert 1 to 5 scale. Aside from 
the central objective to consider the location of tacit knowledge, the objectives of this 
chapter are to consider whether different concentrations, as outlined in Chapter 5, 
have different spatially-bounded innovation processes, drawing on different types and 
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forms of knowledge from different scales. These can be split further into a concern 
with whether the knowledge bases and knowledge drivers of innovation are 
particularly spatially embedded and if so at what scale. Throughout there is an 
assumption that the innovation process is a dynamic system, operating across different 
scales, which is supported by the overall findings that the various knowledge types, 
forms and locations all inter-twine in the innovation process although they do so at a 
distinctly non-local scale.  
 
6.2 KNOWLEDGE DYNAMICS 
 
There are two major issues that need to be addressed in any research on knowledge in 
the innovation process. First is whether there is a distinction between explicit and tacit 
forms of knowledge and their respective impact on innovation. Second is the breadth 
of different types of knowledge necessary during the innovation process from basic 
science through to marketing. Both issues are crucial aspects of the knowledge 
dynamic in the biotech industry.  
 
First then, the literature on the role of knowledge in the economy distinguishes 
between the concepts of explicit (i.e. codified) and tacit knowledge originally 
formulated by Michael Polanyi (1967, 1973). The difference between the two depends 
on the degree of „articulation‟ and „formalisation‟ (Howells 2002; Gertler 2003; 
Asheim and Gertler 2005). In Jeremy Howells (1996, 2000, 2002) work he 
distinguishes between the two forms of knowledge in terms of codification and 
embodiment, in that explicit knowledge consists of tangible assets (e.g. products) and 
„formal‟ intangible assets (e.g. patents).  In contrast, tacit knowledge consists of 
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„knowing‟ that arises from the requirement for “speed and simultaneity”, the inability 
to articulate and, even where it can be articulated, the loss entailed in language 
(Howells 1996: 94). As such tacit knowledge is constituted by learning and is 
therefore not directly separate from explicit knowledge since use of the latter 
necessitates the former (Senker and Faulkner 1996; Howells 2000). In the thesis, 
explicit knowledge was characterised as written material that respondents have access 
to, whilst tacit knowledge was characterised by direct, verbal communication with 
people to reflect the need for learning through imitation in close proximity (Gertler 
2003).  
 
Second, the innovation and knowledge economy literature focuses on knowledge 
predominantly drawn from only one aspect of development, namely research and 
development. This ignores the importance of different types of knowledge used 
during the innovation process that contribute both a „push‟ and a „pull‟ effect on 
knowledge development and commercialisation (Howells 2000). The former consists 
of knowledge that contributes to the knowledge base (i.e. creation) such as basic 
science, applied science and manufacturing processes, whilst the latter consists of 
knowledge that contributes to the knowledge driver (i.e. exploitation) such as market, 
financial and regulatory processes (Gibbons et al 1994; Cooke 2002c). All such 
knowledge types, whether base or driver, consist, in turn, of explicit and tacit forms, 
although again with a necessary connection between the two forms. During the thesis 
the types of knowledge were differentiated in terms of the origin of the knowledge 
defined as the organisation from which respondents derived it.  
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Further to the distinctions between different forms and types of knowledge above, a 
distinct category for commercial or financial knowledge was considered separately 
from both other knowledge types and forms. Therefore during the primary data 
collection three different forms of knowledge were identified as crucial to innovation, 
although they were still conceptualised as co-dependent. Knowledge was split 
between explicit and tacit forms, which were themselves both split between different 
knowledge types consisting of organisational sources that were split between 
knowledge base and driver as shown in Table 6.2 below.  
 
Table 6.1: Knowledge Source: Base or Driver 
KNOWLEDGE SOURCE KNOWLEDGE BASE OR DRIVER 
Manufacturer Base 
Supplier Base 
University Base 
PRO Base 
Competitor Driver 
Customer Driver 
Business Consultant Driver 
Regulator Driver 
Trade Association (explicit only) N/A 
Informal Network (tacit only) N/A 
 
The split of the knowledge sources between base and driver mirrors, to some extent, 
the importance of supply-side and demand-side dynamics in the innovation process, 
with the latter of particular importance in terms of knowledge of markets, diffusion 
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and commercial exploitation (Fagerberg 2005). The first knowledge type considered 
here is explicit knowledge, followed by tacit and then commercial. 
 
5.2.1 Explicit Knowledge Sources 
 
The primary data on explicit knowledge was split between nine different sources 
which were all considered to be aspects of the overall biotech innovation process and 
included manufacturers, competitors, suppliers, customers and so on (see CRIC 2000; 
also see Chapter 2 and 3). Respondents included both „innovators‟ and „service 
providers‟ to cover a range of actors involved in the innovation process, who were all 
asked to rate how frequently they „read material‟ (i.e. explicit knowledge) from nine 
knowledge sources covering universities through to regulators. All responses were 
aggregated to provide a total score that represents the overall innovation process, 
although their separate scores have been disaggregated as well. The different 
responses are contained in Figure 6.1 below, which distinguishes between total, 
innovator and service provider responses.  
 
The numeric value represents the mean score on the 1 to 5 scale referring to the 
frequency of access that a respondent had to a particular knowledge source. The most 
frequent sources of explicit knowledge for all respondents were competitors (3.45), 
customers (3.39), and universities (3.32). There were no major differences between 
innovators and services respondents, although service providers access customers 
(3.57) more frequently than do innovators (3.23). One point to make is that whilst 
competitors and customers have a modal value of 4, universities only have a modal 
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value of 3 suggesting that respondents had less frequent contact with knowledge bases 
than knowledge drivers (see Table 6.2). 
 
Figure 6.1: Explicit Knowledge Sources  
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Source: Survey.  
 
Table 6.2: Modal Averages for Consumer, Competitor and University Explicit 
Sources 
 TOTAL SERVICE 
PROVIDER 
INNOVATOR 
Competitors 4 4 4 
Customers 4 4 3 
Universities 3 4 3 
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All the other explicit knowledge sources were less frequently accessed by respondents 
with a mean value around 2.5 for manufacturers (2.56), suppliers (2.68), business 
consultants (2.55), PROs (2.84), regulators (2.57), and trade associations (2.50). Most 
had a modal average of 3, except for regulators and trade associations with 2 and 1 
respectively. As before, there were few differences between innovators and service 
providers although innovators „read‟ more material from manufacturers, suppliers and 
regulators, whilst service providers „read‟ more from business consultants, PROs and 
trade associations. This suggested that innovators tended to draw on the knowledge 
base more, whereas service providers have no obvious preference. However, it was 
noticeable that in both cases the respondents accessed knowledge drivers more 
frequently (e.g. customers and competitors) than knowledge bases, aside from 
university sources. This finding was important because it illustrated the role of 
demand-side knowledge, something that is often missing in territorial innovation 
models (TIMs) in regional studies and economic geography because they concentrate 
on the endogenous aspects of locations (see Moulaert and Sekia 2003 for a 
discussion).  
 
It is evident that access to explicit forms of knowledge drivers (i.e. demand-led) was 
an important aspect of the innovation process, even though the knowledge base was 
still important in relation to universities. There were also very few differences 
between innovators and service providers, except in relation to trade associations. 
Such results contrast with the emphasis on the idea that there is a scientific and 
technical „logic‟ that drives biotechnology developments as suggested by McKelvey 
et al (2004). Furthermore it contradicts the argument by McKelvey (2004) that the 
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introduction of a product affects the market, rather than that the market encourages 
the introduction of a particular product type. However, there may be differences in the 
importance of knowledge base and driver between different global sites of innovation. 
For example, Ryan and Phillips (2004) have argued that Europe is more supply-side 
led (i.e. knowledge base) because it has a less mature biotech industry, whilst the US 
is more demand-side led (i.e. knowledge driver) because the industry is more mature. 
The results here suggested that, in the UK at least, the market has reached a stage of 
maturity where demand-side sources were more important than supply-side ones, 
although only in reference to explicit knowledge sources. Finally, these results 
confirmed that university research was crucial to the biotech innovation process, 
whether or not there were established links between industry and academia (cf. 
Lawton-Smith 2002; Leibovitz 2004). Finally, the relationship between the demand-
side (i.e. market) and supply-side (i.e. basic science) could not be clearly delineated, 
suggesting that the innovation process incorporated both aspects in the development 
and diffusion of specific products and technologies. There was no correlation 
relationship at all between the frequency of competitor (0.042) and customer (-0.075) 
contact and university contact, showing how distinct these two different sources of 
knowledge were. 
 
5.2.2 Tacit Knowledge Sources 
 
The primary data on tacit knowledge again concerned a similar set of sources, with 
one difference; trade associations were exchanged for informal networks. Tacit 
knowledge was represented by direct „spoken‟, and therefore personal, contact by a 
respondent with someone from a knowledge source. Again, frequency was measured 
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on a 1 to 5 scale and the results split between total, innovators and service providers. 
The most frequent sources of tacit knowledge were customers (3.60), universities 
(3.45), and informal networks (3.81). There were significant differences between 
innovators and service providers regarding these sources, with service providers rating 
the frequency of contact with both customers (3.98 versus 3.27) and universities (3.75 
versus 3.19) more highly. Other knowledge base tacit sources were less frequently 
accessed by respondents, with the average for manufacturers (2.46), suppliers (2.65), 
and PROs (2.68) disguising low modal values of 1, 2 and 2 respectively. In relation to 
knowledge driver sources, there were also low mean and modal averages covering 
competitors (2.49), business consultants (2.55), and regulators (2.27); modal values of 
1, 3 and 1 respectively. The final source, informal networks, was the most frequent 
source with a mean of 3.81 (see Figure 6.2).  
 
Figure 6.2: Tacit Knowledge Sources 
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Source: Survey. 
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There were few dramatic differences between innovator and service provider 
respondents, although service providers had frequent contact with more sources of 
knowledge than did innovators, excluding manufacturers and suppliers (and less 
significantly, regulators). The two most significant results were the difference in 
frequency of access to tacit knowledge from competitor sources than with explicit 
knowledge, as well as the frequency of contact with informal networks. Evidently 
respondents used knowledge driver sources less frequently when it was tacit implying 
that the knowledge base – especially if informal networks were considered as a 
knowledge base – was more frequently tacit. This contrasted with the results above 
regarding the importance of access to explicit, demand-side knowledge, although 
service providers more frequently accessed a number of demand-side tacit knowledge 
sources than innovators, suggesting that the use of different knowledge forms 
depended on an actor‟s position in the innovation process.  
 
These results do suggest that there was more of a scientific and technical „logic‟ to 
developments in biotechnology (e.g. McKelvey et al 2004), although there was still a 
strong demand-side drive (e.g. customers). There was also support for the argument 
that industry-academic contact was crucial for innovation and therefore supported 
theories highlighting the role of scientists to biotechnology innovation (e.g. Bagchi-
Sen et al 2001; Zucker et al 2002). However, in contrast to the secondary data, basic 
science was a more frequent source than applied science. Finally, the frequency of 
access to informal network sources was pronounced. One respondent emphasised this 
by claiming that: 
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“Local informal/social networks are very important as sources of advice and 
support. This is why clusters develop” (SP 33362). 
 
Another respondent claimed that the decision to locate in a specific place was: 
 
“Driven by access to clinical expertise.” 
 
Although the same respondent continued by implying that trust was also a particularly 
important element as well, since:  
 
“We happened to be in Oxford; therefore lead partners in that area. [You] Go 
after opinion leaders irrespective of location. You‟re after the person and their 
networks … Success of any project is dependent on relationships with 
collaborators - developing trust and peer respect in quality of research and 
delivering results - after this they‟d be more willing to give access to their 
networks” (I 208). 
 
In some ways then, this suggested that the development of informal networks and 
trust occur simultaneously, because access to networks depended on trust (strength of 
connection) which, in turn, depended on the development of networks (structure of 
connection). This also depended upon the type of organisations and people involved, 
with one respondent noting that the academic environment enabled more 
opportunities to experiment because it was a more „trusting‟ environment: 
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“The local environment provides access and opportunity to try out ideas and 
to test ideas with a close and trusting community as we are based on a 
University Campus.  Previously I have worked on Science Parks but have not 
found the same easy access and interchange with other science park based 
companies” (I 133). 
  
These findings confirmed a number of previous theories that emphasise the 
importance of social and informal relationships to the biotech innovation process (e.g. 
Lawton-Smith et al l 2000; Breschi et al 2001; Fuchs and Krauss 2003; Cooke 2003a). 
Although there is a vast literature on the role of trust and „social capital‟ in economic 
(and other) behaviour (e.g. Woolcock 1998), it is often a contentious and opaque 
debate. Suffice to say here, social capital affects the innovation process by reducing 
the amount of uncertainty faced by actors within it and therefore encouraging 
investment in new science and technology (Powell et al 2002; Niosi and Bas 2004). 
The frequency of contact with these informal network sources also had a reasonably 
strong correlation relationship with the frequency of university tacit sources of 
knowledge; the correlation relationship between the two was 0.512**. There were 
weaker correlations with other tacit sources, such as business consultants and 
competitors, suggesting that informal networks were more important as avenues of 
knowledge transfer in the knowledge base, rather than for knowledge drivers. As one 
respondent put it:  
 
“I can‟t speak more highly of the importance of informal / social networks to 
innovation. The importance of „social entrepreneurship‟ where a culture of 
innovation is created has been seen in Oxford, Cambridge and I‟m working on 
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it here in [Canadian city]. Create the culture, nationally, locally and socially 
and the innovation will follow” (SP 33348).  
 
5.2.3 Commercial Knowledge Sources 
 
In academic research on the biotech industry finance and investment are highlighted 
as central stimulating drivers of innovation, not only in terms of the investment of 
funds, but also in terms of the provision of managerial resources and advice (e.g. 
Gompers and Lerner 1998, 2001; Kenney 1998; Cooke 2000; Powell et al 2002). 
Furthermore, according to some authors, intellectual property (IP) structures have 
been changed in several countries to suit this specific type of financial investment 
focused on speculative venture funding (Cooke 2004d; Niosi and Bas 2004; Birch 
2007). Instead of asking about the frequency of contact with such commercial 
knowledge sources, respondents were asked how important different types of finance 
were to development. Respondents rated importance on a 1 to 5 again, where 1 means 
unimportant and 5 very important. It is important to note here that despite the stylised 
characterisation of the biotech industry as dependent upon venture capital (VC), very 
few firms actually ever receive any VC investment let alone list on a stock exchange 
(Critical I 2006: 13). Instead, as one respondent joked, firms rely upon the 3F‟s of 
funding: “…family, friends and fools”. 
 
Despite this comment, the overall mean for personal finance (2.36) was actually 
relatively low, although still more significant than bank loans (2.02). This did not 
necessarily reflect the lack of personal financial investment, but rather an assessment 
of its importance to the innovation process. However, it did cast doubt on the claim 
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that personal finance is a frequent source of funding for biotech firms in the UK 
(Salter 2002). This was especially pertinent considering that respondents thought that 
the most significant commercial knowledge sources were venture capital (VC) (3.63), 
government awards/schemes (3.35), and public equity investment (i.e. IPO) (3.24). 
All these represented a number of well known sources of finance that characterise 
different stages in the innovation process; i.e. government funding until VC which 
then led to IPO. Interestingly, other early financing such as business angels (2.76) had 
a modal average of 1, indicating that to many respondents it was a relatively 
insignificant commercial knowledge source. This was the same modal value as 
personal finance and bank loans. Finally, contract work had a mean value of 2.90 
suggesting that it was seen as partially important (see Figure 6.3 below).  
 
Figure 6.3: Importance of Commercial Knowledge Sources 
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Source: Survey. 
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As the two comments by respondents show, the UK government played an important 
role in the innovation process, at least in initial stages:  
 
“We obtained a SMART award to set up the company, which is a spinout 
company from the University of [Scottish University].  This award enabled us 
to set up the company” (I 134). 
 
“The state has an important role at the beginning of a company life eg SMART 
awards etc and then when a company is big enough to sell products. It does 
not play much of a role in between” (I 25). 
 
However, the second respondent also pointed out that the role of government finance 
after initial stages was limited until firms had a product to sell.  
 
Perhaps unsurprisingly, service providers‟ valued all forms of commercial knowledge 
more highly than did innovators. In some cases there were significant differences 
between their assessments, such as with business angels (3.56 versus 2.05), contract 
work (3.59 versus 2.35), and public equity investment (3.95 versus 2.66). This 
illustrated a difference between the knowledge base (innovators) and knowledge 
driver (service providers) focus of the two respondent groups. For service providers 
the aim of innovation was the commercial exploitation of knowledge through a 
successful IPO (i.e. exit – see Loeppky 2005). However, for innovators the aim was 
the creation of new scientific knowledge through the development of successful 
technological products. Either way, the lack of early private investment (i.e. business 
angels) did not appear to be an impediment to respondents, which may either illustrate 
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the argument that there was a lack of seed capital in the UK (Martin and Thomas 
1998) or that such early and often local investment did not play as important a role as 
has been suggested (e.g. Cooke et al 2003). However, the probability was that the 
importance of different commercial knowledge types depended on the location of the 
respondent, rather than that each type played a similar role in each UK location (see 
Rickne 2004). This is discussed later in the chapter. 
 
5.2.4 The Tacit-Explicit Knowledge Relationship 
 
In discussions of the difference between tacit and explicit knowledge, these two forms 
are sometimes conceived as separate and dichotomous variables that impact in 
different ways upon the innovation process (e.g. Lever 2002: 861). However, other 
authors have emphasised the importance that Michael Polanyi placed on the 
relationship between explicit and tacit knowledge (e.g. Senker and Faulkner 1995; 
Howells 2002; Gertler 2003; Simmie 2003). One cannot exist without the other in 
terms of knowledge production and transfer. The importance of considering this 
relationship is illustrated in the correlation relationships between the frequency of 
contact respondents had with explicit and tacit knowledge sources (see Table 6.3). As 
the highlighted cells in Table 6.3 show, the strongest relationships between explicit 
and tacit knowledge sources were with the equivalent source. No other relationship 
was stronger than the weakest relationship between explicit and tacit competitor 
sources (0.407**), although some came close. It was also notably that the relationship 
between competitor knowledge forms was significantly weaker than for other 
knowledge sources.  
 222 
Table 6.3: Correlation Relationships between Explicit and Tacit Knowledge Sources 
T
A
C
IT
 S
O
U
R
C
E
S
 
 
EXPLICIT SOURCES 
 Manufacturer Competitor Supplier Customer Consultant University PRO Regulator 
Manufacturer 0.654** 0.186 0.340** 0.013 0.116 -0.043 0.050 0.282** 
Competitor -0.171 0.407** 0.062 0.274** 0.382** 0.209* 0.277** 0.106 
Supplier 0.317** 0.192 0.717** 0.259** 0.198* 0.02 -0.005 0.202* 
Customer -0.054 0.191 0.118 0.697** 0.313** -0.004 -0.054 0.005 
Consultant 0.044 0.251* -0.095 0.212* 0.764** 0.208* 0.153 0.234* 
University -0.025 0.220* -0.142 0.125 0.286** 0.565** 0.299** 0.108 
PRO -0.136 -0.038 -0.182 -0.026 0.132 0.394** 0.767** 0.040 
Regulator 0.133 0.333** 0.043 -0.128 0.195* 0.109 0.152 0.655** 
Informal Network 0.028 0.189 -0.065 0.164 0.293** 0.161 0.120 0.146 
** Correlation is significant at the 0.01 level (2-tailed) 
* Correlation is significant at the 0.05 level (2-tailed) 
Source: Survey. 
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The strongest relationships were with supplier, business consultant and PRO sources 
(all were above 0.7) followed by manufacturer, customer and regulator sources (all 
between 0.6 and 0.7). From this data it was reasonable to surmise that both knowledge 
base and knowledge driver sources rely upon the interaction between explicit and tacit 
knowledge forms, since there was no clear difference between them. However, the 
clearly weaker relationship of competitor knowledge sources suggested that such 
knowledge was less reliant on the relationship between different forms of knowledge, 
which could mean that some knowledge was more reliant upon this relationship than 
others.  
 
The slightly weaker relationship between university explicit and tacit knowledge 
forms could indicate that such explicit knowledge was easier to access and therefore 
required less tacit learning (Cox et al 2000) or that most breakthroughs were tacit and 
therefore did not necessitate a close relationship between explicit and tacit academic 
knowledge (Zucker et al 2002). However, one important reason for the weaker 
relationship between university and also competitor sources, could be that in both 
cases these sources were globally oriented, rather than locally or even nationally 
based. The spatial basis of all these knowledge sources has been remarked upon as a 
crucial aspect of this whole debate, since proximity, in many forms, can have an 
important impact upon the production, diffusion and absorption of knowledge (see 
Howells 2002; Boschma 2005). It is to this issue of space that the chapter turns next. 
 
6.3 SPACE DYNAMICS 
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The literature on territorial innovation models (TIMs) has changed considerably over 
the past two decades, although theories still largely concentrate on the endogenous 
features of specific locations. In their critical survey, Moulaert and Sekia (2003) 
provide a useful outline of a number of these different theories, covering the early 
work on agglomeration economies through to the latest research in clusters, learning 
regions and regional innovation systems (e.g. Porter 2000; Morgan 1997; Cooke 
2004d). In his own critical survey, Arnoud Lagendijk (2006) splits these theories 
between „structuralist-organisational‟, „social-institutional‟ and „cognitive‟ 
conceptualisations. Recent research in economic geography has also explored possible 
connections between evolutionary economics and geography, creating the idea of 
evolutionary economic spaces that consist of the accumulation of behaviour and 
structures at both organisational and environmental levels (Boschma 2004; see also 
Boschma and Lambooy 1999). However, as mentioned, one issue with this literature 
is the emphasis placed on the endogenous characteristics of space, particularly the 
inter-linkages between organisations. Such a focus sidelines the consideration of 
exogenous influences on economic activity such as national or supranational 
regulation, global market demands, or simply regional interdependence.  
 
The academic focus on local knowledge embedded in firms and its importance in the 
innovation process (see Maskell and Malmberg 1999; Malecki 2000) is derived from 
a concern with the concentration of innovation in particular places and the importance 
of proximity as a consequence. In contrast, it is important to consider how innovation 
is also subject to dispersal across different places as a consequence of innovation 
processes that depend on inter-spatial and inter-scalar learning and knowledge  
(MacKinnon et al 2002). Thus recent research suggests that there are local sites of 
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knowledge and innovation that are tied into wider global networks, ensuring that these 
localised nodes do not get „locked-in‟ to a particular trajectory (e.g. Bathelt et al 
2004). In relation to the biotech industry this has been variously described through the 
existence of „megacentres‟ or „nodes of excellence‟ (see Coenen et al 2004; Cooke 
2004a, 2004c). The importance of such global connections was evident in the primary 
data with respondents‟ assessment of the location of final demand (see Figure 6.4) 
showing that most respondents rated international markets (4.52) as more important 
than national ones (3.39), which were rated, in turn, more important that local markets 
(2.03).  
 
Figure 6.4: Location of Final Demand 
1 2 3 4 5
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Importance (1=not important; 5=very important)
Service Provider
Innovator
TOTAL
 
Source: Survey.  
 
As one of the respondents argued:  
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“Innovation is helped by having local centres of excellence in a particular 
field (which usually means more experienced investors) and a highly qualified 
workforce, but most commercially important projects are aimed at 
international markets which may be totally different from the UK. Therefore, 
you cannot really rely on these factors to ensure success, but it all helps!” (I 
141). 
 
This emphasis on international markets resulted from the dominance of the USA in 
the biotech industry with, for example, 60% of global biopharmaceutical sales (Bibby 
et al 2003). Respondents‟ therefore saw this market as the main one for their products, 
rather than the rest of the world. Either way though, the pronounced emphasis on 
international markets supports the argument that innovative firms and regions 
orientate themselves to external markets rather than internal ones (Malmberg 2003; 
Simmie 2004). 
 
Although some elements of the innovation process, in this case demand, were clearly 
oriented towards the international scale, it was crucial to understand the particular 
scalar relations involved in supposedly endogenous spatial features such as 
knowledge bases and drivers of innovation. As the last chapter showed, such drivers 
were less dependent upon scale than were bases, although this did not answer the 
question of exactly at what scale such processes operate. To address such issues, this 
section considers the primary data collected on the location of explicit, tacit and 
commercial knowledge sources. Three different scales were used to identify the 
importance of space – local, national and international – which respondents used to 
 227 
rate where knowledge sources were most frequently located, again using a scale from 
1 (none) to 5 (most).  
 
6.3.1 Location of Explicit Knowledge 
 
Although some research focuses on the importance of spatial proximity to innovation 
(e.g. Cooke 2002b; Johnson and Mareva 2002), other research on the spatial 
concentration of biotechnology emphasise the importance of non-local linkages 
(Leibovitz 2004), although often in relation to concentrated „nodes of excellence‟ (e.g. 
Coenen et al 2004). Such issues were partially addressed in the findings from the 
primary data on the location of explicit knowledge, although there were significant 
divergences from this literature in that most of the knowledge accessed was least 
likely to be from local sources (see Figure 6.5). The mean value for local explicit 
knowledge was only 2.28, compared with 3.60 and 3.76 for national and international 
sources respectively. This may indicate that global markets were more important than 
local markets, since the most frequent explicit knowledge accessed by respondents 
was from customer and competitor sources (see previous section).  
 
However, it was also possible that local sources of knowledge were simply 
unimportant, or at least appeared to be unimportant for respondents. As one of the 
innovator respondents put it:  
 
“[Location is] Not at all necessary. Electronic contacts and business travel 
allow the establishment and maintenance of international contacts…” 
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Although they then pointed out that: 
 
“…being near to a strong research resource (in my case the University of 
[South-east England]) has always been of fundamental importance. Mostly 
through intelligence-gathering, hearing about competitors or promising new 
research” (I 99). 
 
Figure 6.5: Location of Explicit Knowledge 
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Source: Survey. 
 
This aside, the different rating of locations of explicit knowledge was even clearer 
when the data was split between innovator and service provider respondents. The 
marked difference between the former whose mean rating of local sources was only 
1.79 was significantly lower than the rating of the latter (mean of 2.84), illustrating 
the relative lack of concern with local knowledge within innovating firms and 
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universities. In contrast the high mean rating of 4.21 innovators gave international 
sources compared with the much lower 3.27 rating from service providers, showed the 
importance of globally-based knowledge for some actors. Thinking systemically it 
would appear as though certain organisations (e.g. lawyers, management consultants, 
accountants) – probably locally-based themselves – tied other organisations (e.g. 
biotech firms, universities) into local knowledge. However, such inter-linkages were 
not necessarily that strong since even for the service providers local knowledge 
sources were less important than national or even international ones.  
 
Overall, these findings did not support the contention in a number of TIMs that it is 
the endogenous characteristics of different spaces that constitute successful innovation 
or even, in more recent argument (e.g. Bathelt et al 2004; Coenen et al 2004), that 
local-global linkages play a central role. In several ways the findings contradicted 
both explanations. The dominance of both national and international locations of 
explicit knowledge implied that localised knowledge was significantly less important, 
whether in terms of providing endogenous capabilities or tying global knowledge into 
localised knowledge, than may be thought. However, this finding did support the 
argument that explicit or codified knowledge has, to some extent at least, become 
„ubiquitous‟ and available to everyone world-wide (Maskell and Malmberg 1999; 
Malecki 2000). 
 
6.3.2 Location of Tacit Knowledge 
 
The finding that explicit knowledge was not localised did not contradict the argument 
put forward in most TIMs, especially the most recent theory that local-global linkages 
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are vital to innovation, as long as tacit knowledge was found to be localised or 
“sticky” (von Hippel 1994). Academic research treats tacit knowledge as spatially 
embedded because it is seen as reliant upon face-to-face communication and is 
therefore more difficult to transfer over spatial distance (Howells 2002; Gertler 2003; 
Asheim and Gertler 2005). One of the respondents summed this up when they stated 
that: 
 
“Location can affect the innovation derived from the informal and social 
network when communication is in person.” 
 
However, they then argued that: 
 
“However, this might be not a problem since we have the advanced 
communication technology for obtaining information internationally” (I 123). 
 
The importance of such informal networks and the subsequent personal interaction 
implied that tacit knowledge may be a more localised form of knowledge. However, 
the findings from the primary data did not necessarily support this conclusion (see 
Figure 6.6). Although the findings were not as clearcut as for explicit knowledge, it 
was still evident that tacit knowledge was most often drawn from national and 
international locations since respondents rated these as 3.57 and 3.36 respectively. In 
contrast, the mean value for local was 2.88, which, although higher than for explicit 
knowledge, was still lower than the other two locations. 
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Figure 6.6: Location of Tacit Knowledge 
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Source: Survey. 
 
Furthermore, these results showed that the difference between innovator and service 
provider respondents was even more pronounced with tacit knowledge, at least in 
relation to local sources. Innovators rated local sources much lower than did service 
providers (2.33 versus 3.51), whilst almost the opposite finding was evident in 
relation to rating international sources (3.73 versus 2.94). This corroborates the earlier 
evidence that service providers relied more upon localised knowledge, whilst 
innovators relied more upon global, and in this case national, knowledge. One of the 
respondents, whilst extolling several advantages of Oxfordshire as a region, such as:  
 
“Oxford has access to clinical and academic experts…” 
 
Went on to warn that: 
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“…people can be too Oxford-centric though. You need to think globally and 
not let local boundaries restrict you. Good collaboration will lead to good 
results … [although] academic-industry ties are treated apprehensively by 
academics” (I 208). 
 
Previous research on tacit knowledge emphasises that tacit knowledge is produced 
through the interaction between organisations, in that they learn new ways of doing in 
the process of interaction (Lundvall 1996). As such, learning is an iterative process 
and tacit knowledge is iteratively produced (Nonaka and Takeuchi 1995) 
simultaneously during the learning process and as other forms of knowledge (i.e. 
codified) are produced (Asheim and Gertler 2005). In this sense, one of the central 
features of the biotech industry then is the systemic nature of the innovation process, 
in that a variety of organisations are involved, which necessitates the interaction 
across a number of different locations during product development. An example of 
this is the product Mylotarg, which was marketed by Wyeth Corporation (previously 
named American Home Products) and approved by the US FDA in May 2000 (Rader 
2003).  The development of this product was dependent on a series of global linkages 
between several organisations, all contributing different knowledge inputs. The UK 
firm Celltech plc (now owned by the Belgium firm UCB Pharma) played a crucial 
role in this development process, but so did several other firms. These contributions 
can be briefly and rather crudely mapped out as shown in Figure 6.7 below.  
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Figure 6.7: Product Development History: Mylotarg  
 
 
Source: Rader (2003); Celltech website; PhRMA website; Wyeth website; survey 
response.  
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From the Mylotarg example and the data on tacit knowledge location it was evident 
that the innovation process was dependent upon a range of different spaces that were 
constituted through the simultaneous production and transfer of tacit knowledge that 
occurred across multiple scales. Thus the argument that tacit knowledge is necessarily 
localised was not supported by the results here; at best such knowledge was 
constituted at a national scale, although there were still significant international 
features. This may be a particular feature of the biotech industry or the UK national 
innovation system, in that the UK is significantly smaller geographically than the 
USA, although the Mylotarg example also illustrated that even in the USA innovation 
cuts across different national locations. One of the respondents drew upon this point 
in their argument that: 
 
“However, the UK is a small area (compared to the US) so the cluster 
argument for areas of the UK is less persuasive. Why is Pfizer located at 
Sandwich and AstraZeneca in Cheshire, while all other pharma companies 
cluster round London? It would appear that low cost investment and historical 
ties were more important in these decisions than anything else” (SP 333122). 
 
6.3.3 Location of Commercial Knowledge 
 
As another crucial aspect of the innovation system, the location of commercial 
knowledge was also important to consider. The association of „enterprise‟ (as in 
enterprising) with innovation necessitates the commercial exploitation of knowledge, 
not just its production, which in turn necessitates the commercial creation and 
exploitation of markets (DTI 1999c). Regarding biotechnology, some academics 
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argue that the market itself has been constructed (Green 1991, 2002) or that specific 
national economies produce specific market orientations (Kettler and Casper 2000; 
Loeppky 2005). In their work on „constructed advantage‟, Cooke and Leydesdorff 
(2006: 10) also suggest that knowledge-based growth is dependent upon changing 
structural frameworks covering the economy, governance, knowledge infrastructure, 
and community and culture. Consequently, the commercial framework of the 
innovation process has a direct impact upon the type, intensity and global-orientation 
of innovating firms; for example, elsewhere Cooke (2004d) suggests that localised 
innovation can be split between „institutional‟ (IRIS) and „entrepreneurial‟ (ERIS) 
regional innovation systems. The former is public sector based and driven, whilst the 
latter is private sector based and driven, and therefore they will produce different 
knowledge and thus products from each other. 
 
However, the results from the primary data did not conclusively support the idea that 
there are regional innovation systems with specifically regional financial or 
investment characteristics in the UK. As one respondent pointed out: 
 
“The availability of funding is a national structure, but most providers are 
south centric, therefore it is easier to raise VC in the South.  However, there 
are recognised centres, which do attract attention. The major restriction is 
availability of management teams and high networth individuals which are 
much more prevalent in London and the home counties.  In some areas of the 
UK it is difficult to attract the recognised board members who are required to 
attract capital investment. „Money follows people‟” (SP 33332). 
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This claim was supported by the data on the location of commercial knowledge, 
which showed that the national scale was the main location for it with a mean rating 
of 4.01 against 2.67 for local and 3.03 for international locations. The local scale was 
the least significant since it also had a modal rating of 1 against 2 for the international 
scale. Again there was a difference between innovator and service provider 
respondents with the former (2.34) rating the local less highly than the latter (3.06; 
more significantly the modal rating is 4). However, both rated national and 
international locations similarly. Thus service providers again emphasised the local 
scale higher than innovators (see Figure 6.8).  
 
Figure 6.8: Location of Commercial Knowledge 
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Source: Survey. 
 
This difference could have been a consequence of the different positions that each 
respondent group had within the innovation process. For example, innovators were 
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more likely to draw upon both basic science funding in the forms of research grants 
and early stage financing in the form of government awards or schemes. In contrast, 
service providers because their role came after the initial research and development 
when firms were seeking to commercialise technologies or knowledge were more 
likely to emphasise funding particular to commercial exploitation (e.g. VC or IPO 
sources). 
 
One innovator supported this argument in their statement that: 
 
“Financing basic R&D is state driven and an important role to play [by 
government in promoting innovation]. Investment is heavily bolstered by 
Wellcome, so the government could do better” (I 18). 
 
However, two service providers commented that: 
 
“The government role‟s in innovation is almost non-existent” (SP 33362).  
 
“The government needs to really support innovation, because for the most 
part, it pays lip service” (SP 33320).  
 
The difference between these responses illustrated that service providers and 
innovators view finance very differently because of their position within the 
innovation process. Thus innovators saw government funding as crucial, whilst 
service providers focus more on later investment. However, not all service providers 
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(or innovators) fell into such simply characterisations. For example, one of the service 
providers stated that:  
 
“The Government has two vital roles in innovation in the bio area: ensuring 
investment in science at Universities is ongoing and helping the spin out 
process. The latter is being addressed by Challenge Funds but more is 
required. The recognition of the importance of business input to the spin out 
process needs a greater awareness at the top level. More financial input would 
help as long as it is channelled correctly. The key issue is deciding whether an 
innovation is sufficient to be a stand-alone business or whether consolidation 
with other technology is required. If the latter, should it be licensed into an 
existing business or consolidated with other emerging technologies” (SP 
333122). 
 
Consequently, the location of commercial knowledge, whilst largely nationally based, 
was not easy to determine overall. The different types of finance needed for a firm 
meant that at different periods of its life-cycle – or the product life-cycle – they 
needed different types of finance, a point reiterated by many of the respondents, both 
innovators and service providers. Thus there was less support for the idea that VC 
investment was concentrated in the UK (see Powell et al 2002) or that it was a 
necessary characteristic of the biotech innovation process as has been argued in 
relation to the USA (e.g. Acharya et al 1998; Cooke 2000). Instead, the UK appeared 
to be dominated by a financial infrastructure concentrated on London that then fed 
into concentrations located within easy reach of the capital; i.e. Cambridge and 
Oxford. One respondent suggested that: 
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“London is a great pull during the early stages of a SME Technology 
operation, with a wide and capable supply of resources and finance.” 
 
However, the same respondent also suggested that this focus on London was part of a 
firm‟s life-cycle, which meant that during early stages it was important to locate close 
to London, but later on this was less important: 
 
“As the organisation grows however, the limitations of the city become a 
major issue in regard to recruitment and finding suitable premises as scale up 
and market internationally” (I 133). 
 
Overall then, the low importance attributed to local knowledge – whether explicit, 
tacit or commercial – meant that there had to be other locational characteristics that 
influenced the concentration of firms, which then prove advantageous to the 
production, exploitation and diffusion of knowledge, both within a particular space 
and with other places. These can be considered as the locational assets of such spaces. 
 
6.3.4 Locational Assets 
 
The wealth of literature on TIMs seeks to explain why innovation occurs in certain 
places and not others (see Moulaert and Sekia 2003; Lagendijk 2006). The importance 
of proximate organisations with localised linkages to innovation, as argued in Porter‟s 
(1990, 2000) „cluster‟ theory, regional innovation systems (RIS) (e.g. Cooke 1998) 
and learning regions (e.g. Morgan 1997), are not supported by the findings on the 
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location of knowledge above. Furthermore, there was limited empirical support for the 
argument that local firms – or more precisely, successful local firms – were 
predominantly locally oriented; rather, research has shown that non-local linkages are 
more important (Malmberg 2003; Malmberg and Power 2005). Perhaps more 
important are the local inter-linkages that encourage trust and co-operation between 
firms in specific places (Gordon and McCann 2005). This earlier research, however, 
also highlights the importance of certain features of particular spaces that benefit 
innovating firms, such as the access to transport links, or the supply of business 
services; i.e. assets particular to a specific location (Storper 1995; Simmie 2003). 
These material characteristics may help to explain the concentration of the biotech 
industry.  
 
To answer these questions, primary data was collected on the „quality‟ of locational 
assets. Quality was derived from respondents‟ assessment of a series of spatially-
embedded characteristics ranging from local labour costs to the availability of 
premises. Again respondents rated these on a scale between 1 (awful) to 5 (excellent). 
The range of locational assets was drawn from the literature on biotech TIMs. 
However, because it only concerned the assessment of respondents, it reflected their 
judgement of locations rather than any evaluation of the effect of different assets on 
the innovation process per se (see Figure 6.9). Respondents rated housing costs 
poorly in their regions, suggesting that they were high (mean of 2.26). They also 
thought that traffic levels were high (2.56). It has been argued that these two factors 
impact detrimentally on staff recruitment (Walcott 2001; Lawton-Smith 2002), 
although labour costs were not considered to be as poor (3.02) meaning that housing 
and traffic may not impact on attracting external labour (see Bagchi-Sen et al 2004). 
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 Figure 6.9: Locational Assets  
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Quality (1=awful; 5=excellent)
 
Source: Survey. 
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Another anomaly was that the quality of transport infrastructure, congestion aside, 
was rated highly in the assessment of access to an international airport (3.64), national 
road network (3.80), and rail network (3.65). Such transport access was important 
because it provided the means for respondents to contact a variety of different 
organisational and spatially situated knowledge sources, which can be particularly 
important for innovating organisations (Simmie 2003). As one respondent said: 
 
“Location is important in one respect. One must be located in a good 
infrastructure, near a good airport, railways, so that international visitors can 
visit easily. Also, some good hotels and restaurants are important” (I 25). 
 
The set of locational assets concerned with networking and advisory services were 
rated very highly by respondents with business advice services (3.45), social forum 
(3.44), corporate forum (3.31), and professional associations (3.20) all above an 
average of three. This showed that the regional social network and attendant sources 
of advice were seen as above average reinforcing the idea that such social ties are 
important in innovation (Breschi et al 2001; Cooke 2003a; Fuchs and Krauss 2003). 
However, it was unclear exactly what these contribute to the innovation process, 
although we could speculate that it provided a means for respondents to reassure 
themselves about their activities by exploring and then adhering to certain social 
expectations (see DiMaggio and Powell 2004). The set of locational assets also 
concerned the cost (2.81) and availability (3.28) of premises, which showed that 
whilst costs were seen as high the availability of such premises was not seen as a 
problem. Overall then, the range of these locational assets provided some insight into 
how different places provided more than just access to different types of knowledge 
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used in the innovation process. Different spaces also provided a number of other 
factors that can prove as important, if not as directly influential on the process. Thus 
expensive housing costs and high congestion can make certain places unattractive for 
employees and deter them from locating in certain places. Alternatively, lack of 
access to transport infrastructure may preclude firms from siting in other locations 
because it could cut them off from access to internationally distributed knowledge. 
There were a number of different dynamic relationships between both knowledge and 
space that needed to be addressed to explain the spatial concentration and dispersal of 
the innovation process.  
 
6.4 KNOWLEDGE-SPACE DYNAMICS 
 
Considerations of knowledge and space as distinct aspects of any innovation system 
produce a distorted picture of their effect upon innovative activity because they 
reduce both concepts to individual and disconnected factors. Knowledge is reduced to 
an input that can be derived from internal or external processes, whereas space is 
conceived in terms of locally-bounded processes involving localised linkages (Phelps 
2004), which are expected to feed into the local process. Space is thereby reduced to 
an external influence on firms through the spatial positioning of productive inputs. 
Bringing these concepts together produces an explanatory approach, defined as the 
knowledge-space dynamic, that incorporates characteristics of both perspectives 
representing more than the assumption, in earlier territorial innovation models 
(TIMs), that a „successful‟ region must, of necessity, imply successful knowledge 
production and diffusion resulting in innovation  (see Grabher and Stark 1997). Here 
knowledge-space is the relationship between knowledge production in space and its 
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simultaneous diffusion across space, where knowledge cannot be represented by a 
single factor at a single scale. 
 
This does not imply that all knowledge production and diffusion occurs in the same 
manner, in fact it implies the opposite; all knowledge is produced and diffused in 
different ways depending upon the context of its production and context of it 
diffusion. The interplay between explicit and tacit knowledge forms, of different 
knowledge types and their sources, operates within and across a number of 
geographical spaces. Consequently innovation occurs in particular places because of 
the embedding of different knowledge forms, types and sources produced and 
diffused across a number of scales. In the knowledge economy, the innovation process 
is thus constituted by the knowledge relationships within and between locations that 
necessitate social, cultural and organisational proximity as well as functional, relation 
and associational characteristics.  
 
In order to illustrate the significance of this knowledge-space dynamic, primary data 
was collected on both the source and location of knowledge, as already analysed 
above. This was then split between respondents based in concentrations of the British 
biotech industry and non-concentrated respondents, as well as split between the 
specific concentrations identified in the last chapter; i.e. East Anglia, Berkshire et al, 
Inner London and Eastern Scotland. Alongside this data, respondents were surveyed 
on their perceptions of government intervention as well as labour markets to ascertain 
the importance respondents assign to such macro-scale influences as state action and 
labour mobility. To start with though we consider the territories from which 
respondents draw different forms and types of knowledge. 
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6.4.1 Territories of Knowledge-Space 
 
Understanding knowledge-space entails an approach that is both territorial and 
comparative through the consideration of different sources and origins of knowledge 
used by actors within different spatial configurations. The territorial framework is 
represented by the relationship between different sources of explicit and tacit 
knowledge and its origin in different spaces and at different scales. The comparative 
framework is provided through a comparison of „clustered‟ and „non-clustered‟ 
respondents, as well as comparisons between different types of „clustered‟ 
respondents.  
 
The relationships between the different origins of the two knowledge forms (i.e. 
explicit, tacit) showed that overall there was a reasonably strong association between 
similar spatial configurations in that local explicit knowledge was correlated with 
local tacit (0.557) knowledge. There was a slightly weaker relationship at the national 
scale (0.522) and a stronger explicit-tacit relationship (0.685) at the international 
scale. There was a stronger relationship between local knowledge forms amongst non-
clustered respondents (0.684) than clustered ones (0.489), and stronger relationships 
between both national knowledge forms (0.559 versus 0.455) and international 
knowledge forms (0.722 versus .652) for clustered respondents. These results showed 
that concentrations of actors did not necessarily lead to the localised production and 
diffusion of explicit and tacit knowledge within a particular territorial system; rather 
they somewhat contradicted this perspective in that clustered respondents had stronger 
relationships between national and international knowledge forms. This confirmed the 
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work of people like Breschi et al (2001) and Leibovitz (2004) who have argued that 
local knowledge and linkages are not as crucial to biotechnology than for other 
industries. However, it also contradicted research that stresses the link between local 
knowledge and global knowledge in specific „nodes of excellence‟ (e.g. Coenen et al 
2004) because there were negative associations between both local and international 
explicit and tacit knowledge forms; the former was –0.506 and latter –0.311.   
 
The relationship between specific sources and their origins concerned explicit, tacit 
and commercial knowledge. The first of these showed that there were few instances 
where a particular knowledge source (e.g. manufacturer, competitor, customer) was 
associated with a particular spatial scale. There were weak or no correlation 
relationships between local, national and international locations and explicit sources 
for manufacturers, customers, PROs, and regulators. For the other knowledge sources 
the strength of the associations was weak or very weak. There were no relationships 
between local and national location and either competitors or suppliers, but they had a 
weak association with international location; 0.353 and 0.358 respectively. Explicit 
knowledge from universities and trade associations had similarly weak relationships 
with national location, but not with either the local or international scale. This 
partially corroborated the view of one of the respondents that: 
 
“You can‟t make a company innovative by putting it in a certain location. 
Innovative people will perform anywhere in whatever field they work in” (I 
160). 
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For tacit knowledge, there were weak or no relationships between location and 
manufacturer, supplier, customer, consultant, university, PRO, regulator or informal 
network sources. The strongest association was between competitor sources and the 
local scale (0.307). Again for commercial knowledge there were very weak or no 
relationships between location and venture capital, bank loans, contract work or 
public equity investment. However, there were weak associations between local origin 
and personal finance, business angels and government awards/schemes; there was also 
a weak negative association between international origin and the former two types of 
finance.  
 
These data results contradicted a number of assumptions about the spatial location of 
knowledge production and diffusion. In particular the argument that tacit knowledge 
is, by necessity, contextually specific and therefore difficult to transfer or acquire, 
whilst explicit knowledge is „ubiquitous‟ and therefore easier to transfer or acquire  
(see Markusen 1996; Malmberg and Maskell 1999; Malecki 20000; Gertler 2003). 
Although the data did not necessarily support a strong claim otherwise (i.e. that tacit 
knowledge could originate anywhere), it did provide some support for claims that 
social and organisational proximity, as opposed to spatial proximity (see Boschma 
2005), were more important in biotechnology as Breschi et al (2001) have argued.  
 
After outlining some of the knowledge-space relationships, the next thing to consider 
is whether there are any differences in these relationships between clustered and non-
clustered respondents, which might help explain the argument that localised tacit 
knowledge is crucial to the innovation process. To illustrate this, the relationships 
discussed above were split between respondents in the four concentrations outlined in 
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Chapter 5 and those outside of these four main concentrations; the former were 
termed „clustered‟ respondents, whilst the latter „non-clustered‟. The only major 
difference for explicit knowledge between these two groups was that non-clustered 
respondents did not draw upon international origin knowledge from competitors or 
national origin knowledge from trade associations, although clustered respondents 
did. There were more differences with tacit knowledge. Non-clustered respondents 
drew upon more knowledge from the following than clustered respondents: 
 
 Local competitor knowledge 
 International supplier knowledge 
 Local consultant knowledge 
 Local and negative international university knowledge 
 Local PRO knowledge 
 and local informal networks. 
 
In contrast clustered respondents drew on less local competitor knowledge and more 
national informal network knowledge than non-clustered respondents did. Finally, for 
commercial knowledge non-clustered respondents valued national venture capital 
more highly, whilst clustered respondents did not have a negative association between 
international location and either personal finance or business angels, as revealed 
above across all respondents. Clustered respondents also did not stress the local origin 
of government awards/schemes. Again, these findings did not support the view that 
clustered actors benefit from localised knowledge upon which they can draw more 
easily because of spatial proximity (e.g. Porter 2000). Instead they appeared to 
support the general research finding, summarised by Malmberg (2003), that clusters 
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or concentrations do not rely upon local linkages and knowledge, but rather upon a 
range of spatial scales for knowledge inputs into the innovation process. As one of the 
respondents argued: 
 
“The issue of innovation and location are not necessarily linked as implied by 
your questionnaire. In my mind, innovation is 'people' driven and depends on 
the interaction of a group who are looking to change/improve something” (SP 
333122). 
 
Since these interactions can take place across a number of different scales and 
contexts, and in a variety of organisational or institutional environments, they 
precluded a simple territorial explanation of innovation processes and the inherent 
knowledge characteristics of particular territories or places.   
 
6.4.2 Comparisons of Knowledge-Space 
 
As the previous section shows, it is important to consider the knowledge 
particularities of different spaces. This involved the comparative analysis of the 
different relationships between knowledge forms, sources and origins against the four 
main biotech concentrations identified in Chapter 5. These concentrations included 
East Anglia, Inner London, Berkshire et al, and Eastern Scotland. Respondents were 
differentiated between these four concentrations and those who came from outside of 
these locations (i.e. non-clustered). The initial data under consideration was the source 
of explicit and tacit knowledge. The main difference in mean ratings between the five 
different spatial sites – four clusters and one non-clustered – were that the non-
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clustered respondents access explicit competitor sources more often than respondents 
in all the concentrations, apart from Eastern Scotland (see Figure 6.10). Otherwise, 
compared with non-clustered respondents, East Anglia and Inner London respondents 
accessed explicit regulator knowledge less often, whilst Berkshire et al respondents 
accessed explicit customer knowledge less and Eastern Scotland accessed explicit 
customer knowledge more often and PRO and trade association sources less often.  
 
Figure 6.10: Comparative Data on Explicit Competitor Sources  
1 2 3 4 5
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Berkshire et al
Eastern Scotland
Frequency (1=never; 5=all the time)
 
Source: Survey.  
 
These results implied that explicit competitor sources were not a vital source for 
certain concentrations since some concentrations, perhaps because of their location 
around London and its transport links, did not rely upon such explicit sources because 
they were closely tied into international markets. As one respondent commented:  
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“I would never put my business away from the Oxford/Cambridge/London 
triangle, for example the innovation centre in Sittingbourne (which I have 
visited) is way too far out of things to be of any use to my two businesses” (I 
153). 
 
More isolated respondents may therefore have had to rely upon explicit knowledge of 
markets. This possibility was supported by the finding that East Anglia and Berkshire 
et al respondents did not access explicit customer sources as often as other 
respondents. 
 
There were more differences with tacit knowledge sources when compaaring 
respondents. The main ones were the lower frequency of contact between non-
clustered respondents and the four clustered groups regarding manufacturer, supplier 
and customer (excluding Inner London) knowledge sources. Inner London 
respondents also had more frequent contact with tacit competitor and PRO sources, 
whilst more interestingly East Anglia respondents had less contact with tacit 
university sources. Finally, for commercial knowledge sources there were a number of 
significant differences between non-clustered and clustered respondents. All clustered 
respondents, no matter which concentration they belonged to, rated venture capital 
more highly than non-clustered respondents did. They also rated public equity 
investment more highly, except for Eastern Scotland respondents who rated it 
significantly lower than all other respondents. Both Inner London and Eastern 
Scotland rated contract work highly, whilst Berkshire et al rated business angels 
higher than others.  
 
012345Location W r i t t e n  C o m p e t i t o r  S o u r c e s  ( m e a n  s c o r e )UKNon-clusteredEast AngliaInner LondonBerkshire et alEastern Scotland
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The origin of the knowledge sources for the non-clustered and four clustered 
respondents was shown in the difference between the location of explicit, tacit and 
commercial knowledge (see Figure 6.11, Figure 6.12 and Figure 6.13 respectively). 
This was expressed in terms of the mean rating given by respondents to the source of 
such knowledge between the local, national and international scales.  
 
Figure 6.11: Comparative Spaces of Explicit Knowledge  
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Source: Survey. 
 
East Anglia respondents emphasised local explicit and local tacit sources over non-
clustered respondents. More importantly, they also had less frequent contact with 
international tacit sources. The same trend was evident with Berkshire et al 
respondents who also had more contact with local tacit sources, as well as local 
commercial knowledge. In contrast, Inner London and Eastern Scotland respondents 
were much more internationally focused with higher ratings for contact with 
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international explicit, tacit and commercial knowledge sources than non-clustered 
respondents (and the other concentrations). 
 
Figure 6.12: Comparative Spaces of Tacit Knowledge 
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Source: Survey. 
 
It was perhaps unsurprising that each concentration – in some ways at least – was 
oriented towards different spatial scales since, as one respondent noted: 
 
“Location is important from the perspective of bringing together the resources 
for the innovation process to happen. It is clear that a particular area will 
favour innovative organisations of the same sort because many of the 
ingredients are present, especially when new organisations are formed” (SP 
333122). 
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Figure 6.13: Comparative Spaces of Commercial Knowledge 
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Source: Survey. 
 
Not all locations contained a diverse mix of organisations for respondents to draw 
upon and therefore it was necessary for them to search outside of their particular 
location for the necessary knowledge. One interesting finding was that Berkshire et al 
respondents stressed local finance implying that there was more early stage financing 
capability in this region than elsewhere, which contrasted with the global and large 
firm basis of knowledge in this concentration (see Chapter 5). 
 
Overall then it was possible to use these results to support the earlier finding (see 
Chapter 5) that there were four distinct concentrations of biotechnology in the UK. 
There was also some support for the idea that concentrations develop over time (e.g. 
Cooke 2001), although in this case the importance of local knowledge appeared to 
strengthen over time rather than weaken as the concentration matured. This 
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contradicted the argument that mature „clusters‟ were more closely tied into global 
networks rather than local ones (see Wolter 2003), unless the data showed that certain 
UK concentrations (i.e. East Anglia and Berkshire et al) were overly insular in their 
focus. Such a finding would suggest that they will in the near future „lock-in‟ to a 
particular innovation process that leads to „path contingent‟ development (see Hudson 
2005). Another conclusion could be that none of the British concentrations were 
mature, but instead a number of the more emergent concentrations (i.e. Inner London 
and Eastern Scotland) were reliant upon international connections because they 
focused more on market drivers, since they were major finance centres, and not the 
technology base.  
 
6.4.3 External Influences on Knowledge-Space  
 
Although each concentration may have had different characteristics that affected the 
innovation process in different ways dependent upon the relationship between 
knowledge and space, there was still a national scale impact from government policy, 
especially in relation to intellectual (IP) property protection. This was evident in the 
national institutional framework in which biotech concentrations operated, except it 
was also important to remember that biotech firms, organisations and even locations 
can themselves influence the institutional environment.  
 
It was interesting to begin this examination of the role of the state by considering what 
respondents thought about the importance of internal knowledge to innovation. Across 
the board, whether respondents were innovators or service providers, cluster or non-
clustered, they rated a range of internal knowledge sources highly (see Figure 6.14). 
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For example, the mean rating they gave scientific and technical staff was 4.54 – they 
also rated the importance of international patents at similar levels (4.46). Of the other 
internal knowledge none was below a rating of 3.50 suggesting that such internal 
sources, however represented, were considered as crucial by both clustered and non-
clustered respondents. The already mentioned emphasis on the „logic‟ of the science 
and technology of biotechnology (see McKelvey et al 2004) played an important part 
in the self-understanding of the innovation process, if not also to innovation itself. 
This perhaps supported the research by Hall and Bagchi-Sen (2001) showing that 
biotech managers consider success as internally derived and failure as the result of 
external interference. 
 
Figure 6.14: Importance of Internal Knowledge to Innovation 
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Source: Survey. 
 
 257 
Respondents emphasised this when they claimed that it was:  
 
“Senior staff and academics at university [who] were the most important 
internal knowledge source” (I 35). 
 
Or that: 
 
“[The] Academic stars in groups [are] where the knowledge comes from” (I 
36). 
 
However, it was interesting to note that clustered respondents rated the importance of 
managerial internal knowledge, whether managerial staff or management practices, 
less highly than non-clustered respondents did. This was evident across all the four 
UK concentrations, particularly in Inner London, suggesting that certain types of 
knowledge were less relevant for these respondents, perhaps because they benefitted 
from external sources of management knowledge derived from the concentration of 
intermediate services (Powell et al 2002; Cooke 2004c). This contrasted with one 
respondent‟s claim that: 
 
“I believe that leadership is an important part of the innovation process and if 
it is present throughout an organisation and gives a clear message to the 
innovators about their role and direction, then that organisation will produce 
high quality innovations” (SP 333122). 
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It was therefore possible that clustered respondents were more technology based, 
whilst non-clustered respondents were more market driven and therefore the latter 
viewed managerial knowledge as more important. Clustered respondents, in turn, 
were situated in places of highly concentrated scientific and technical knowledge (e.g. 
university towns like Cambridge and Oxford), which meant that they were more likely 
to be embedded in this culture rather than a market-driven one. 
 
6.4.3.1 Government Intervention 
 
Whilst there was a strong emphasis on the impact of internal knowledge on the 
innovation process, there was less recognition that some external influences like the 
government played an important role; however, IP protection was highlighted. Such 
former external influence covered the importance of government intervention on 
innovation (see Figure 6.15). The highest rating that respondents gave was to 
intervention concerning IP, which was seen by both clustered and non-clustered 
respondents as important (mean of 3.74). The other highly rated interventions 
included basic science investment (3.59) and R&D policy (3.50), although clustered 
respondents‟ placed more emphasis on the importance of these two interventions. This 
supported the claim that public investment is crucial to the development of 
biotechnology and biotech concentrations, both in terms of external contracting (see 
Feldman and Francis 2002) as well as the large infrastructure investment needed in 
science and research (Cooke 2003a, 2004a, 2004b). The influence of historical 
decisions and the public sector therefore had an important impact on the development 
of the concentrations (see Feldman and Francis 2002; Leibovitz 2004).  
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Figure 6.15: Government Intervention 
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Source: Survey. 
 
However, the role of government intervention in other areas of innovation was 
sometimes deemed irrelevant at best and negative at worst by the respondents. For 
example, one claimed that: 
 
“[Government plays] A very minor role, early stage grants are useful and tax 
incentives for business angels and VC helps with later stage financing” (I 
141). 
 
Whilst another claimed that government policy was: 
 
“Not always handled in most efficient way, such as Finance Act 2003 and tax 
issue. Massively negative affect” (I 36). 
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These issues, alongside the low rating of government procurement (mean of 2.30) and 
the importance of international markets, perhaps explained why respondents often 
stress the need for government to be more involved in promoting innovation through 
funding and regulatory changes. One respondent bemoaned the role of government as: 
 
“Currently, sadly, an ever diminishing one. The demise of Smart Awards is a 
big mistake by the governments and even the old Smart scheme could have 
been more business friendly” (I 153). 
 
Another emphasised the fairly limited role played by government when they claimed 
that: 
 
“The State can only play a part in making available grants, loans, tax credits 
and releasing companies from red tape. The red tape applies to all aspects of 
running a small business. It can‟t make people innovative however it can help 
create a culture where people are encouraged to set up a business in the UK. 
At the present time there are not many positive points to being a UK company. 
Anybody who is serious about biotech would set up in the USA” (I 160). 
 
All these views of government intervention illustrated that respondents did not view 
the government as a particularly important influence when it came to being a 
customer or regulator, although they did emphasise the important influence 
government had in relation to public investment in science and promotion of R&D 
policy. This finding supported earlier research that stressed the impact of such 
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investment in basic and applied research (e.g. Cooke 2002b, 2003a, 2004b) as well as 
the importance of national economic structures and systems especially in terms of IP 
protection (see Tait et al 2006). However, a number of other findings somewhat 
contradicted this view of the minimal importance of national state involvement such 
as the emphasis on international markets, which suggested that, for the UK at least, 
other governments had more of an influence than the UK government. This was also 
the case with IP protection since international patents were viewed as more important 
than national ones (see Figure 6.16). Consequently, global institutional structures, 
especially relating to IP, may appear more influential to respondents than their 
national government.  
 
Figure 6.16: Importance of Intellectual Property Protection 
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Source: Survey. 
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Interestingly, clustered respondents‟ rated almost all government intervention as more 
important than non-clustered respondents, but most especially health policy, public 
science investment and IPR regulation. Thus non-clustered respondents rated 
government procurement and health and safety regulations more highly, suggesting 
that such government actions had more impact on those in a dispersed innovation 
system. The higher rating given by non-clustered respondents to national markets 
supported this finding; however, the higher rating they also gave to international 
markets did not support this conclusion. In relation to the importance of IP, there were 
a number of differences between clustered and non-clustered respondents. Non-
clustered respondents rated both commercial secrecy and employee skills and 
experience as more important than IP protection, in contrast to clustered respondents. 
However, there were distinctions between the four different concentrations on other 
types of IP protection. For example, East Anglia and Inner London respondents both 
rated national and international patents more highly than either non-clustered or 
Berkshire et al and Eastern Scotland respondents. These results suggested that for 
certain respondents innovation consisted of the pursuit of IP protected knowledge (i.e. 
clustered respondents), whilst for others such IP was less important (i.e. non-
clustered). The latter may be a consequence of the concentration and dispersal of the 
innovation process in that the latter were subject to less scrutiny by their peers and 
therefore less in need of protecting their knowledge.  
 
6.4.3.2 Labour Markets 
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The final national institutional framework was the labour market. This represented 
one of the main features of the innovation process because both the knowledge base 
and driver can be appropriated from multiple scales as required. This was particularly 
relevant in relation to the discussion of explicit and tacit knowledge forms, since the 
latter was largely a product of interaction as it was „experiential‟ rather than codified 
and therefore more difficult to transfer between organisations (see Gertler 2003). This 
is the main reason that spatial proximity has been highlighted as a crucial factor in the 
innovation system (e.g. Fagerberg 2005). One means through which knowledge does 
transfer, however, is through the movement of labour. As one of the respondents put 
it:  
 
“Constantly changing groups of people available within the Biotech Cluster 
mean we always see new people and new ideas. It‟s easy to see something in 
action, we can just drive over to see it without wasting a day” (I 84). 
 
As mentioned earlier, respondents also stressed the importance of certain internal 
knowledge sources, particularly those of the technical and scientific staff (mean 4.54), 
and employee skills and experience as a form of IP protection (mean 4.39). Thus the 
location of labour markets was a particularly pertinent indicator for knowledge-space 
in that a large element in the production and diffusion of knowledge across space was 
dependent upon the movement of people.  
 
For purposes here, labour markets were split between “technical and scientific staff” 
and “managerial staff” to respectively represent the knowledge base and knowledge 
driver in the innovation process; the former provided access to science knowledge 
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whilst the latter provided access to market knowledge. These two labour sources were 
themselves split between local, national and international scale labour markets. Out of 
the six different labour markets, the most important one according to respondents was 
the national-managerial (mean of 3.84) followed by national-technical (3.70). These 
were closely followed by local-technical (3.51) and then local-managerial (3.08), 
whilst the international labour markets for both technical and managerial labour were 
rated lower at 2.69 and 2.80 respectively. However, the local labour markets were 
considered to be less important by innovators than service providers, in both cases, 
although for local-technical they were still important. It is possible to argue that this 
was because the local labour market provided an important means to access both 
knowledgeable workers and diffuse knowledge across local organisations and 
institutions. As one of the respondents said: 
 
“[A] Biotech and High Tech centre of excellence with a mobile pool of 
workers attracts innovators; we know we can attract, pay and retain good staff 
because they know there are plenty of jobs for partners also in the tech 
industry” (I 84). 
 
The differences between clustered and non-clustered respondents showed that non-
clustered respondents saw local-technical and international-technical as less important 
than the national average of respondents from the four concentrations. East Anglian 
respondents rated local-technical and international-technical far more highly than 
other respondents and national-managerial and international-managerial lower than 
most respondents, except for Eastern Scotland respondents who rated the latter two 
the lowest (see Figure 6.17 below). All the concentrations were distinct from each 
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other, which again emphasised the importance of considering each in terms that did 
not preclude a specific analysis.  
 
Overall, this data partially confirmed previous research on the crucial role played by 
local staff turnover (e.g. Henry and Pinch 2000) and the importance of local staff 
generally because of their immobility (Zucker et al 2002; Fuchs and Krauss 2003; 
Wolter 2003). This was especially relevant to clustered respondents in comparison 
with non-clustered ones.  
 
Figure 6.17: Labour Markets  
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Source: Survey. 
  
One respondent pointed out that: 
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“There is a critical mass of biotech in the area that enables companies to keep 
going and recruit good people. People know that here is more security 
because as one firm dies another rises up so there are jobs and people don‟t 
have to move when they change jobs” (I 84). 
 
These findings also partially contradicted the claims by Casper and Karamanos (2003) 
that there was a high inward migration of scientists into concentrations of 
biotechnology. Instead it would be more accurate to suggest that the inward migration 
of nationally-based scientists was important, although the internationally migration 
was actually emphasised more by most clustered respondents (except East Anglians) 
than for the overall sample and non-clustered respondents. Local-technical labour 
markets remained important for these clustered respondents as well, implying that 
there was a mingling of international and local technical labour supporting the theory 
that the local-global connection is crucial to innovation (e.g. Bathelt et al 2004). 
 
6.5 CONCLUSION 
 
It was notably in each case that respondents acquired and accessed knowledge from a 
range of sources located in different places. Certain knowledge forms and types may 
be accessed more than others, but the lowest average rating given to any knowledge 
form and type was 2.50 for explicit knowledge (trade associations), 2.27 for tacit 
knowledge (regulators), and 2.02 for commercial knowledge (bank loans). In turn the 
lowest rating for the spatial origin of these knowledge forms and types was 2.28 for 
explicit forms (local), 2.88 for tacit forms (local) and 2.67 for commercial forms 
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(local). In each case the lowest rating was given to locally-based knowledge, no 
matter what form of knowledge, which suggested that the spatial basis of knowledge 
had little to do with its form at least in relation to the current conceptualisation of the 
local-boundedness of tacit knowledge.   
 
A number of other interesting findings were evident in these results. First, the most 
highly explicit knowledge types (i.e. competitors, customers, universities) were 
predominantly market-making types of knowledge (i.e. drivers rather than bases). 
This suggested that knowledge commercialisation was concerned with markets over 
technology – perhaps obvious – but there was an indication here that this was largely 
nationally and, more importantly, internationally focused. In relation to biotechnology 
this is hardly surprising considering the dominance of the North American market. 
Second, the most highly rated tacit knowledge (i.e. consumers, universities, informal 
networks) was both technology-making and market-making, although we have to 
assume that informal nertworks concerned both the demand and supply sides of 
innovation. Third, the association between the explicit and tacit forms of knowledge 
was clear, although it was not always of the same strength. Therefore, both forms 
were vital to understanding the innovation process and both forms tended to originate 
at the national and international scales, rather than local. In fact, the local scale did not 
feature as a prime location for any of the three forms of knowledge (explicit, tacit, 
commercial). Fourth, the rating given to commercial knowledge emphasised the 
importance of commercial exit (i.e. VC, IPO), although respondents stressed the need 
for different funding at different stages of development.  
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Overall though, respondents derived knowledge from all the different knowledge 
forms, sources and locations; there were no cases in which any instance of the 
knowledge-space dynamic was missing from the innovation process. In each case 
there may be a different emphasis on knowledge-space, but across the sample it was 
not missing. However, there were differences between the respondents based on their 
positioning within „clusters‟ or not. Thus non-clustered respondents rated local 
explicit and tacit knowledge more highly, whilst clustered respondents rated 
international explicit and tacit knowledge higher, along with national for both. Non-
clustered respondents were more localised than their clustered counterparts, although 
with certain UK concentrations (i.e. East Anglia and Berkshire et al) this was not the 
case. There was a striking negative relationship between local and international 
knowledge across both explicit and tacit forms, which suggested that the linking of 
global knowledge into local knowledge was not as relevant to the biotech industry 
(e.g. Bathelt et al 2004). Instead such linkages occured and played out across a 
number of different scales, all of which proved important to the innovation process in 
one way or another.  
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PART II  
 
SUMMARY 
 
In this section the thesis has addressed the three hypotheses outlined earlier in Chapter 
1, 2 and 3. The historical background and context of the British biotech industry 
outlined in Chapter 4 showed how national and global institutional changes have had 
significant impacts on the commercialisation of biotechnology. As such it illustrated 
the importance of these different scales. Chapter 5 built on this general overview by 
exploring the specific concentration of biotechnology across the UK, which showed 
that there were four main concentrations, although none of these had more than 70 
biotech firms. In seeking to explain the reason for such concentrations, the chapter 
showed how social proximity was important, especially in terms of different dynamic 
systems of innovation embedded in different places. This then led to the analysis of 
the primary data in Chapter 6, which focused on the knowledge and innovation 
processes in different locations. This analysis draw upon the theoretical and 
methodological framework developed in Part I called the knowledge-space dynamic 
and illustrated how innovation was dependent upon interaction both within and across 
different concentrations. Consequently it was possible to argue that the positioning 
and embedding of different knowledge processes in different locations entails an 
external (i.e. extra-local) outlook on the part of firms and actors involved in 
successful innovation. 
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PART III 
Conclusions and Policy Implications 
 
This section provides the overall conclusions for the thesis in Chapter 7 that are 
derived from the data analysis in the last section before exploring a number of policy 
implications from these findings in Chapter 8. As such this section summarises the 
overall conclusions from this examination of the relationship between knowledge, 
space and technology by running through the three hypotheses outlined in Chapter 1 
before taking a critical look at the biotech industry. The latter task is important 
because of the claim that biotechnology represents a revolutionary technological 
paradigm that totally alters our understanding of individual health and also national 
economic development (BIGT 2003; see also Rifkin 1999; Oliver 2000). The 
discussion of policy implications therefore considers how this emphasis on the 
potential of biotechnology and the wider knowledge economy leads to a focus on 
certain concerns that encourages specific policy agendas. The pursuit of such agendas 
precludes the adoption of alternatives that can lock-in innovation, economic 
performance and technological development to one paradigm, a paradigm that may 
not actually achieve its claimed potential.   
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CHAPTER 7 
MAIN CONCLUSIONS:  
KNOWLEDGE, SPACE AND TECHNOLOGY? 
 
7.1 INTRODUCTION 
 
This thesis has explored the relationship between knowledge, space and technology 
by focusing on a particular „knowledge-based‟ industry in the broader knowledge 
economy, where this has been defined as the production and commercial exploitation 
of new knowledge through new knowledge (see Cooke 2002c). As such the definition 
of biotechnology has also been broadly applied consisting of the application of 
biological processes in production and / or the production of biological commodities 
(see DTI 1999a, 1999b); i.e. an enabling technology as much as new series of 
products (House of Lords 1993). The central contention of the thesis has been that 
biotechnology, as a case study of the „knowledge economy‟, has concentrated in 
particular places because place-specific processes lead to successful innovation. Thus 
the central hypothesis is: 
 
Despite being an internationally distributed sector, biotechnology innovation 
is concentrated in regional nodes because these locations provide advantage 
through a knowledge-space dynamic that encompasses functional, relational 
and associational processes. 
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This hypothesis was developed after reviewing the existing literature on the 
knowledge economy and the relationship between knowledge and space in the 
innovation process, which led to the concept of the knowledge-space dynamic 
(Chapter 2). As part of this dynamic, three further hypotheses were developed that 
considered the relationship between knowledge, space and technology in more depth. 
These were: 
 
H1: There are „knowledge economy‟ concentrations because successful innovation 
depends on dynamic (i.e. across time) and systemic (i.e. across organisations) 
processes embedded in and across specific places. 
 
H2: Successful innovation in the knowledge economy depends on place-specific 
dynamic and systemic processes because different types of knowledge 
(including supply and demand) originate in different places and at different 
scales necessitating interaction both within and beyond concentrations. 
 
H3: The knowledge economy depends on different locations and scales of 
knowledge because different places have different locational assets that 
contribute to successful innovation in different ways and therefore necessitate 
linkages within and between locations. 
 
This conceptual perspective was then used to develop a methodological framework in 
which innovation could be conceived in both dynamic and systemic terms as well as 
address a number of concerns with existing research approaches (Chapter 3). 
Following on from this, there were three chapters that covered the background and 
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context (Chapter 4) of the UK biotech industry, the analysis of secondary data on the 
biotech industry (Chapter 5), and the analysis of the primary data derived from a 
mixed methods survey (Chapter 6). These chapters explored the three hypotheses 
outlined above. The first was addressed in Chapter 5 in an examination of the 
secondary data on the UK biotech industry, whilst the second was addressed in 
Chapter 6 using primary data. The third hypothesis was investigated in all three 
chapters.  
 
The reason that the thesis focused on the knowledge economy and, in particular, the 
biotech industry is because of the strong policy interest and action in developing a 
„knowledge-based‟ economy and society in the UK and Europe (e.g. DTI 1998; 
Lisbon Agenda 2000), as well as the pursuit of biotechnology as a central feature in 
this vision. For example, the European Commission (EC) and Organisation for 
Economic Co-operation and Development (OECD) have recently defined the 
biotechnology industry as a „knowledge-based bio-economy‟ (EC 2004, 2005) or 
more simply „the bioeconomy‟ (OECD 2005; also see OECD 1999). They 
characterise the biosciences as a “new wave of innovations” (ibid.: 1) and “significant 
drivers of productivity and competitiveness” (EC 2004: 1) that offer vital 
opportunities for the promotion of social, economic and environmental goals, building 
upon the drive towards a „knowledge economy‟ in developed economies. 
Consequently the biotech industry is meant to provide the possibility for developed 
economies to over-come some of the problems with changing industrial structure (i.e. 
de-industrialisation) and the attendant economic, social and political ramifications of 
these changes. In particular there is a concern with national competitiveness, 
investments in learning and knowledge as well as skills upgrading, uneven regional 
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development and changing healthcare. The thesis conclusions and findings (7.2) 
outlined here will relate to a number of these issues by detailing how the knowledge-
space dynamic can be usefully applied to the knowledge economy and what the 
findings mean for different policy-makers, which will be explore in more depth in 
Chapter 8.  
 
7.2 MAIN CONCLUSIONS 
 
7.2.1 Knowledge-Space Dynamics in the Knowledge Economy 
 
To briefly summarise the concept of the knowledge-space dynamic it is important to 
remember that it is derived from a number of different theories crossing several 
subjects (e.g. economics, economic geography, economic sociology etc.). However, 
the central proposition is that regional development in the knowledge economy is 
based on innovation and that each location has a different and place-specific set of 
characteristics that factor into the innovation process. Furthermore, each location is 
tied into a wider series of scales (e.g. national, global) that contribute to regional 
development as much as the local, place-specific characteristics do. The knowledge-
space concept is therefore concerned with incorporating both supply and demand 
features in the innovation process although not by considering these as spatially 
dependent, but rather as existing across all spatial scales. Thus supply and demand 
features of innovation can both be local or international, or both; all of which depends 
upon the specificities of place. 
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The knowledge-space dynamic seeks to avoid a number of theoretical and empirical 
problems with existing research, in particular issues around the conceptualisation of 
space / scale and causation (see Chapters 2 and 3). These include the focus on 
„successful‟ regions (e.g. Silicon Valley), the assigning of agency to a region and the 
reversal of causality (Maskell and Malmberg 2002). Instead the aim was to consider 
what knowledge contributed to innovation processes occurred – at what scale and in 
what locations – and then relate these to specific concentrations of the biotech 
industry in order to enable a comparative perspective as well. A fundamental feature 
of this approach has been the emphasis on the idea of place-specificity in that all 
concentrations of the biotech industry in the UK are distinct from one another, even 
though they may share similar characteristics. Consequently it is important to 
acknowledge that the knowledge economy – at least in relation to biotechnology – 
cannot be limited to individual countries or even firms, but is constituted by the 
relationships between such entities. Therefore the knowledge economy is essentially 
an expansion of linkages between these entities, rather than an inherent characteristic 
of each entity per se. Thus the pursuit of regional or national based knowledge 
economy policies will not produce the desired effects unless they focus on expanding 
the number of extra-locational connections and inter-linkages. 
 
Regarding the specific hypotheses, they were addressed in different analytical 
chapters of the thesis. The first hypothesis was examined in Chapter 5, which covered 
the analysis of secondary data on the biotech industry.   
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H1: There are „knowledge economy‟ concentrations because successful innovation 
depends on dynamic (i.e. across time) and systemic (i.e. across organisations) 
processes embedded in and across space. 
 
This chapter showed that there were four specific concentrations of biotechnology in 
the UK designated as East Anglia; Berkshire, Buckinghamshire and Oxfordshire; 
Inner London; and Eastern Scotland using the NUTS2 scale. They all had a higher 
than average number of biotech organisations (i.e. firms, university departments, 
PROs and service providers) and a number of other notable knowledge features. The 
four locations could be crudely split between the more „regional‟ concentrations of 
East Anglia and Berkshire et al and the more „urban‟ concentrations of Inner London 
and Eastern Scotland, although each was still distinct from the others. In seeking to 
explain these concentrations it was evident that social proximity (see Boschma 2005) 
was the most crucial factor, which then led to an explanation based on the theory of 
dynamic systems. Perhaps most interesting was the differences between knowledge 
features at different spatial scales, indicating that these factors were not necessarily 
positioned or embedded at the most local or smallest scale (NUTS3 in this case). 
Overall though this data showed that there was little support for the argument that 
local knowledge specificity is crucial (see McKelvey 2004) or that local knowledge 
was linked into global biotech nodes (see Coenen et al 2004). Rather it supported the 
view that local knowledge was relatively unimportant by itself and that innovation 
processes depended upon inter-spatial linkages (see Breschi et al 2001; Leibovitz 
2004).  
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The second hypothesis was explored in Chapter 6 dealing with the analysis of the 
primary data collected using a mixed methods survey.   
 
H2: Successful innovation in the knowledge economy depends on place-specific 
dynamic and systemic processes because different types of knowledge 
(including supply and demand) originate in different places and at different 
scales necessitating interaction both within and beyond concentrations. 
 
In particular this chapter concerned the relationship between the dynamics of 
knowledge and space in the innovation system. Although there were place-specific 
innovation processes, these were not necessarily limited to the local or regional scale, 
but cut across these scales to enable innovative actors access to a wide variety and 
diversity of knowledge. Such knowledge originated in different places and had to be 
acquired by innovators working in specific places and scales, and this entailed 
working within and beyond these places and scales. It was especially evident in the 
primary data that actors acquired their knowledge from non-local sources, whether 
such knowledge consisted of tacit, explicit or commercial forms. The international 
scale was actually the most frequently accessed by such actors in relation to explicit 
knowledge and more frequent than local or tacit knowledge. Furthermore, the 
relationship between explicit and tacit knowledge at these different scales was 
negative implying that it did not involve the acquisition of international tacit 
knowledge and then the diffusion at the local scale (see Bathelt et al 2004). 
Consequently the argument that regional concentrations are successful because of 
tacit knowledge (see Gertler 2003; Fagerberg 2005) was not strongly supported in 
relation to the biotech industry. The knowledge processes outlined here showed that 
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tacit knowledge was acquired from national and international sources more frequently 
and that the local and international sources did not mix. 
 
The final hypothesis cuts across all three empirical chapters (Chapters 4, 5 and 6) 
because it explores the specific locational characteristics that contribute to innovation 
processes across different scales.  
 
H3: The knowledge economy depends on different locations and scales of 
knowledge because different places have different locational assets that 
contribute to successful innovation in different ways and therefore necessitate 
linkages within and between locations. 
 
Chapter 4 outlined the historical background and global context of the UK biotech 
industry, illustrating how it had developed and been constituted in relation to the US 
biotech industry. It also showed how dominant the US biotech industry is and 
therefore the importance of considering the inter-linkages with US firms that were 
highlighted in the earlier research on European biotechnology (Senker et al 1996; 
Sharp 1996; Acharya et al 1998; Saviotti et al 1998). This was reinforced in Chapter 5 
with the examples of the alliance networks of both Celltech Group plc and Cambridge 
Antibody Technology plc. However, Chapter 4 also showed how important 
institutional changes had been in encouraging the biotech industry in the UK (4.3.3), 
especially international intellectual property rights (IPR), which was supported by the 
evidence in Chapter 6 on the importance of specific types of IP and government 
intervention. The emphasis on intellectual property laws and in particular 
international patents was pronounced (6.4.3.1). Overall this supported the argument 
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that the linkages between different places and scales was crucial for successful 
innovation, not least because of the simple fact that the US market dominates global 
biotechnology (Bibby et al 2003) and therefore the UK biotech industry had to orient 
itself in relation to it.   
 
The theoretical research on the biotech industry has moved through a number of 
different conceptual approaches starting with the focus on strategic management in 
the performance of alliances and collaborations (e.g. Hamilton et al 1990; 
Chakarabarti and Weisenfeld 1991; Dodgson 1991; Woiceshyn 1995; Deeds and Hill 
1996; Powell et al 1996; Powell et al 2004). Building on this literature to some extent, 
especially in relation to the links between academia and industry (Owen-Smith et al 
2002; Chiesa and Toletti 2004; Owen-Smith and Powell 2003), the literature on 
biotechnology has revolved around innovation studies on academic-industry 
relationships and technology transfer as well as the importance of different markets 
and national innovation systems (e.g. Green 1991, 2002; Walsh et al 1995; Sharp 
1996; Senker et al 1996; Bartholomew 1997; Martin and Thomas 1998; Saviotti 1998; 
Saviotti et al 1998; Senker et al 2000). During this period there was also an interest in 
the importance of „star scientists‟ and knowledge spillovers derived from work in the 
„new economic geography‟ (or „geographical economics‟) of Krugman and others 
(e.g. Audretsch and Feldman 1996; Audretsch and Stephan 1996; Prevezer 1997, 
2003; Zucker et al 1998, 2002; Audretsch 2002). However, more recently there has 
been a growing interest in biotechnology in regional studies and economic geography 
(as opposed to „geographical economics‟) that stresses the importance of local and 
global linkages (e.g. Breschi et al 2001; Coenen et al 2004; Cooke 2004b; Leibovitz 
2004; Ryan and Phillips 2004; Zeller 2004). Finally, there are a number of scholars 
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who utilise political economy perspectives like the „varieties of capitalism‟ concept 
(Hall and Soskice 2001) and covering the national and international differences 
between innovation processes (e.g. Kettler and Casper 2000; Casper and Kettler 2001; 
Coriat et al 2003; Quere 2003; Loeppky 2004, 2005; Lofgren and Benner 2005).  
 
The knowledge-space dynamic builds upon all this research by positioning the 
innovation process in specific places at the same time that it is embedded across a 
number of scales from the local through to the global. Thus some places may be more 
closely tied into other locations and therefore benefit from certain advantages (e.g. 
external knowledge), whilst others may be more isolated and therefore benefit from a 
different set of advantages (e.g. knowledge excludability). However, in each case the 
innovation process incorporates a range and diversity of knowledge that cannot be 
acquired from the local or even regional scale. Therefore it was vital for innovators to 
connect across scales to access different sites of knowledge and institutional strength; 
e.g. it was important for biotech firms to access knowledge on regulations that exist at 
the national scale and are instituted at this scale. It was the linkages between sites of 
biotech innovation – e.g. organisations and their inhabitants – which constituted the 
dynamic and systemic elements in the innovation process. Such relationships were, in 
turn, constituted by a number of functional (i.e. material), relational (i.e. social) and 
associational (i.e. interactional) processes that determine their impact on innovation. It 
was these linkages and connections, at the local, national and global scale, that 
represent phenomena to be explained, rather than the characteristics of different 
locations alone.  
 
7.2.2 The Biotech Industry: Fact and Fantasy? 
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The empirical data collected in this thesis raises a vital question, one that cannot be 
ignored without leaving some central theoretical and policy concerns unanswered. 
That is, why is there so much „noise‟ about the biotech sector? Perhaps the most 
significant finding in this thesis is that the biotech industry, whether construed in 
terms of biopharmaceuticals or the wider application of the biosciences, is relatively 
small in the UK and across the world. For example, Ernst and Young (2003a: 5) have 
pointed out that the biotech industry “as a whole has never been profitable”. The EC 
(2004: 1) does estimate that the „bioeconomy‟ is worth €1.5 trillion, although the 
2005 global biotech report by Ernst and Young (2005) suggests that this is highly 
optimistic. Instead Ernst and Young report global revenues of $46.5 billion for public 
companies, which deflates the EC figure somewhat. More importantly perhaps, a 
significant proportion of this identified revenue comes from a limited number of 
biopharmaceutical products, whilst a large proportion of other biotech industry 
pharmaceutical outputs actually consist of chemical products, rather than biologicals.  
 
Several commentators from academia (Nightingale and Martin 2004; Martin et al 
2006), government (BIGT 2003; FDA 2004) and industry (Bibby et al 2003; 
McKinnon et al 2004) have also noted a „productivity crisis‟ in the pharmaceutical 
industry (see Figure 7.1).
xxiii
 This can be seen as both a cause and consequence of the 
„rise‟ of the biotech industry (see Martin et al 2006). As R&D expenditure increased 
to $50 billion in 2003 the number of pharmaceutical products has also fallen after a 
brief rise in the mid-1990s following regulatory changes in the USA that made 
approvals (especially for orphan products) easier (Nightingale and Martin 2004). 
During this period biologicals represented a growing proportion – around a third – of 
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FDA approvals (FDA 2004; McKinnon et al 2004), although there were still less than 
10 „biotech‟ approvals per year between the first product (recombinant human insulin) 
in 1982 and 2003 (Ashton 2001; Tufts CSDD 2004). It has been claimed that the 
increasing cost of pharmaceutical product development was the major reason for this 
„crisis‟ (Tufts CSDD 2002, 2004); the current figure claimed is between $800 million 
and $1.7 billion per product (FDA 2004). However, these figures have been disputed 
in the past, primarily because they include „opportunity costs‟ (see Public Citizen 
2001), so do not necessary explain the dearth of „innovation‟ (see also NIHCM 2002).  
 
Figure 7.1: Pharmaceutical „Productivity Crisis‟ 
 
 
 
 
 
 
 
 
 
 
Source: BIGT 2003. 
 
Alongside the „productivity crisis‟ there are concerns about the efficacy and safety of 
new biological products (Horrobin 2003; Arundel and Mintzes 2004; Joppi et al 
2005). Although several organisations (e.g. BIO) and reports (e.g. BIGT 2003) have 
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claimed that there are a large number of biotech products on the market (over 250 and 
over 110 respectively), these claims are subject to some criticism (see Pratley 2003). 
For example, Arundel and Mintzes (2004) argue that there were actually only about 
60 biopharmaceuticals approved between 1986 and 2004 for the US and European 
markets and of these 56% were orphan products for small disease groups (Ashton 
2001). In their analysis Arundel and Mintzes (2004: 9) go on to argue that only 
around a third of the approvals offered „some advance‟, an „important advance‟ or 
„major advance‟ over existing products. This was better than the 10% for all other 
drugs, but still meant that two-thirds of biopharmaceuticals were no better than 
existing treatments (ibid.: 10). In another evaluation, Joppi et al (2005: 895) argued 
that only 15 out of 61 biotech “products represented therapeutic innovation” with 
another 22 offering only limited “non-therapeutic advantages”. The rest were “me-
too” products. However, one distinguishing feature of all these new biotech products 
is their increased cost for patients and healthcare systems (Rasnick 2003; Joppi et al 
2005). 
 
The focus on the biopharmaceutical sector perhaps disguises the broader impact of the 
biotech industry. However, the focus on this sector is understandable considering the 
level of profit that such products accrue. For example, Amgen‟s Epogen product had 
sales of $8,880 billion in 2002/03 (Nightingale and Martin 2004). Furthermore, the 
global revenues of the biotech industry – covering public companies only though – 
stood at $46.55 billion in 2003 (Ernst and Young 2004a) of which around 43 % was 
derived from only 10 products (WorldPharma 2005). The continuing dominance of 
this „blockbuster‟ model has been questioned (Thayer 2004; Mittra 2005; Martin et al 
2006), although the high costs of R&D and marketing excludes smaller companies 
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from operating throughout the biotech value chain at present. Thus despite declining 
product pipelines, large pharmaceutical companies still play a central role in the 
biotech industry and the promise of new biotechnological processes like genomics or 
pharmacogenetics has not as yet displaced the blockbuster model and may in some 
ways preclude quick adoption (see Glassman and Sun 2004).  
 
Of particular interest for regional development is the employment opportunities 
presented by biotechnology, especially in skilled occupations. Again these appear 
limited. According to Ernst and Young (2005), in 2003 there were around 195,000 
global jobs with fewer than 35,000 in Europe. This contrasts with claims of 19,000 in 
the UK alone by the DTI (1999a) in the late 1990s and 25,885 in 2003 (BIGT 2003). 
The secondary data analysis in the thesis showed that there were around 43,000 
employees in the UK biotech industry in 2003, although this covered total 
employment and not skilled employment. A consultancy report by Critical I (2005) 
for EuropaBio – the European trade body – claimed that R&D employment in UK 
biotech was around 9,500 in 2003. Thus the extent to which the biotech industry 
contributes to the expansion of skilled employment appears limited and does not 
justify the notion that it contributes significantly to the promotion of the „knowledge 
economy‟.  
 
Although skilled employment appears low, the biotech industry may still contribute to 
regional development through positive externalities and knowledge spillovers and 
therefore its promotion may still be justified. However, the number of biotech firms 
has remained fairly static in the UK throughout the 2000s at between 400 and 450 
firms (see DTI 2005, 2006). The UK has a relative strength in biotechnology but its 
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regional spread is highly uneven. The main UK concentrations (over half of all firms) 
were in just four regions (NUTS2): Berkshire, Buckinghamshire and Oxfordshire; 
East Anglia; Inner London; and Eastern Scotland. This means that the benefits of the 
biotech industry accrue to these four regions over and above any other region, which 
could compound existing disparities between regions in relation to employment 
opportunities and investment.  
 
7.2.3 The Biotech Industry: Concentrated and Diffused? 
 
Despite the uneven spread of UK biotech firms, the claim that they are embedded in 
clusters – in the Porterian sense – also requires scepticism especially by national and 
regional policy-makers. The secondary data showed that there were only four biotech 
concentrations in the UK. However, even these four locations exhibited very different 
trends in terms of organisational composition, knowledge bases and knowledge 
drivers. As the oldest, East Anglia was both small firm and university based, which 
was similar to Berkshire et al although the latter was also based on large firm as well. 
In contrast, Inner London was relatively new with a strong service provider sector and 
university base. This was similar to Eastern Scotland, although the latter had fewer 
service providers. All four had different strengths and weaknesses that necessitate a 
more nuanced approach to regional development than the application of one set of 
policy prescriptions. 
 
It is also important to note that the scale at which these concentrations function was 
not clear-cut either. Although there were strong correlations between organisations at 
the smallest scale (NUTS3), further research (see Birch forthcoming.) has shown that 
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the strength of association did not decline as the scale was enlarged and in some cases 
it actually increased. These correlations also existed with reference to a number of the 
knowledge indicators such as number of patents, alliances and journal articles. This 
would suggest that a focus on the largest scale (NUTS1, equivalent to a GOR) would 
be as relevant as one that focuses on smaller scales (i.e. NUTS2 and NUTS3).   
 
The differences between locations were also evident in the primary data where 
respondents in the four concentrations drew upon knowledge from different locations 
to different extents (see Figures 6.11, 6.12 and 6.13, pp.252-254). Most respondents 
in concentrations (and non-concentrated respondents) drew upon national sources to a 
similar extent, except for Eastern Scotland respondents who drew upon international 
sources more often than all other respondents did. This perhaps suggested that Eastern 
Scotland respondents were more reliant on international knowledge sources than 
others either because they were located further away from the centres of UK 
knowledge or because they were more tied into international knowledge networks or 
markets. The former seems less likely because Inner London respondents also drew 
more upon international sources than East Anglia and Berkshire et al respondents. 
However, East Anglia and Berkshire et al respondents drew upon local explicit and 
tacit sources more than other respondents, which suggested that they were located in 
concentrations that more closely fit the classic cluster model presented by Porter 
(1990, 2000; Porter and Solvell 1998) and others. 
 
The lower rating given to international sources by respondents from East Anglia and 
Berkshire et al also supported this suggestion. The secondary data provided evidence 
that both regions had a significant number of formal international alliances – 97 and 
 287 
189 respectively – suggesting that the local sources were less formal. This supported 
the argument by Bathelt et al (2004) that certain locations represent centres of „local 
buzz‟ that are tied into „global pipelines‟. However, Inner London also had a large 
number of formal international alliances (95), perhaps as a result of its position as a 
global city tied into other global cities (Simmie 2004), although Eastern Scotland 
(another possible global city) only had 30 formal international alliances.  
 
Overall though the primary data did not show that knowledge was spatially embedded 
in concentrations of biotechnology firms. Neither explicit nor tacit knowledge was 
localised (nor was commercial knowledge). Explicit knowledge, particularly for 
„innovator‟ respondents, was internationally focused, whilst tacit knowledge was 
nationally focused with international sources still more common than local ones. This 
confirmed neither the literature on the importance of localised linkages in cluster 
theories (e.g. Porter 2000) nor the importance of the binary embedding of local and 
global knowledge (e.g. Coenen et al 2004; Cooke 2004a). Furthermore it contradicted 
the broader literature on the importance of localised tacit and explicit knowledge to 
innovation (Asheim and Gertler 2005; Fagerberg 2005). The data did show that tacit 
knowledge was more localised (than international) for „service provider‟ respondents, 
although national sources were still more common, suggesting that some actors relied 
upon it more than others do. Overall this meant that knowledge used in innovation 
was embedded across a number of spatial scales, necessitating a number of extra-local 
connections for successful product development. One example of this is the 
development of the biotech product Mylotarg over a 20-year period from initial 
research through to marketing (see Figure 6.7, p.233). 
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Despite the low rating respondents given to localised sources of knowledge, they 
rated the quality of network forums (i.e. social, business) and organisations (i.e. trade 
bodies) highly in their regions. There might be a simple reason for this. It may be that 
such activities did not represent sources of knowledge per se, but rather an 
environment in which respondents could affirm their activities and reinforce their 
social position (e.g. as members of a „biotech industry‟). Such activities could 
therefore represent the sites of institutional isomorphic processes (see DiMaggio and 
Powell 2004) through which respondents develop a shared sense that they belong to a 
„community of practice‟ (see Henry and Pinch 2000). However, this is mainly 
speculation based on personal experiences at bioscience networking events. As for 
other regional assets, transport links were rated highly, which supported the argument 
that innovators were tied into extra-local networks and therefore need easy access to 
those other locations (Simmie 2003). 
 
Finally then, a particularly interesting finding was that the relationship between 
explicit and tacit knowledge location was strongest at the local scale for „non-
clustered‟ respondents; i.e. those outside of the four main concentrations. In contrast 
for „clustered‟ respondents the strongest explicit-tacit relationship was at the 
international scale, although it was also strong at the national scale. Because explicit 
and tacit knowledge are not binary distinctions, but are rather co-constituted (see 
Senker and Faulkner 1996), this suggested that the argument that locations act as 
repositories of „local buzz‟ (i.e. tacit knowledge) tied into „global pipelines‟ (i.e. 
explicit knowledge) (Bathelt et al 2004) may be too simplistic. Instead the findings 
here implied that „clustered‟ actors drew upon international and national explicit and 
tacit knowledge more than „non-clustered‟ actors did. This finding was reinforced by 
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the negative relationship between locally-based and internationally-based explicit and 
tacit knowledge. This may be because „clustered‟ actors work in sectors (e.g. 
therapeutics) that were highly complex and reliant upon specific, analytical 
knowledge and capabilities that cannot be sourced from only one location. Instead 
they need to be tied into wider, national and international, knowledge networks and 
spaces. This means that localised, face-to-face contact may not be as essential to 
innovation as has been suggested (e.g. Fagerberg 2005), at least for the biotechnology 
industry.  
 
7.3 CONCLUSION 
 
Numerous perspectives on the biotechnology industry are possible. Two opposing 
ends of the spectrum can be summarised as follows. On the one hand it has huge 
potential to both create wealth and ameliorate a number of problems (social, health or 
otherwise) and therefore we need to adopt an optimistic view, as one survey 
respondent argued. On the other hand it is an industry surrounded by an inordinate 
amount of hype and unfulfilled potential that detracts resources and attention away 
from other possible solutions to our problems (social, health or otherwise). In some 
ways the former leads into the latter because the technological potential highlighted 
by proponents functions to attract resources and investment on the basis of future 
expectations. In their Triple Helix model, Etzkowitz and Leydesdorff (2000: 117) 
have argued that: 
 
“The classic legitimation for scientific research as a contribution to culture 
still holds and military and health objectives also remain a strong stimulus to 
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research funding. Nevertheless, the future legitimation for scientific research, 
which will keep funding at a high level, is that it is increasingly the source of 
new lines of economic development.” 
 
Furthermore, Michael and Brown (2003) have argued that these expectations play a 
part in the subsequent „failure‟ of biotechnology to fulfil its vaunted potential, 
although it may still produce a good return on investment despite this failure. 
However, the hype surrounding biotechnology (see Caulfield 2000; Helen 2004) may 
also obscure the wider impact it has on fields outside of the high profile sectors like 
therapeutics such as biopharmaceuticals.  
 
In theoretical terms, biotechnology is an interesting object of research because it is an 
industrial sector that is not yet established and may yet never reach its lauded 
potential, depending on your point of view. As an example of the knowledge 
economy it usefully illustrates a number of difficulties with the concept that have 
persisted from its emergence in the 1960s through to the current policy agenda 
pursued in the UK and European Union. Does knowledge or profit drive the pursuit of 
innovation? If so, does knowledge depend on wealth? If it does depend on wealth, as 
Sokol (2003, 2004) argues, then this has major implications for economic 
development both in developed and developing economies. It would suggest that the 
possibilities of upgrading less-favoured regions, for example, are going to be limited 
since they already suffer from regional uneven development and wealth disparities. 
How useful is the concept of knowledge economy then? Perhaps it represents the 
culmination of the neoliberal project (see Peck 2001) since it originated in the work of 
scholars dedicated to „liberal‟ tenets such as Hayek, von Mises and Machlup as well 
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as Michael Polanyi and Daniel Bell (Hodgson 1999; Hull 2000). Perhaps it heralds a 
new era of enlightened capitalism in which a significant proportion, although not all, 
benefit from being „knowledge workers‟ who do “make our money from thin air” 
(Leadbeater 1999: viii; also Brint 2001). However, either way it would appear that the 
benefits of the knowledge economy will be limited to a small proportion of the 
population – a third at most according to Webster (2001) – whilst the majority work 
within other forms of industrial or service employment (see Thompson et al 2001). 
Such concerns are central to policy-making. 
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CHAPTER 8 
POLICY IMPLICATIONS:  
WHITHER THE KNOWLEDGE ECONOMY? 
 
8.1 INTRODUCTION 
 
If the notion that the world economy has both globalised and regionalised over the 
past few decades (see Storper and Scott 1995; Scott 2000; Scott and Storper 2003) is 
to be understood properly, we need to refer to the vertical (i.e. intra-organisational) 
and horizontal (i.e. inter-organisational) integration of production across distributed 
locations (Gereffi 1999; Henderson et al 2002). It is therefore important to consider 
how regional economic development is bound up in a set of processes embedded not 
only within the local and even national scale, but also the international scale. In 
particular regional development appears to depend upon extra-local linkages as well 
as the connections that combine local, national or global production and distribution 
processes, embedding organisations in local, national and global institutions (see 
Dicken et al 2001; Coe et al 2004).  
 
The „local‟ and the „global‟ processes in the knowledge economy and especially the 
biotechnology industry are perhaps more pronounced than in other sectors. For 
example, despite arguments that the biotechnology industry is largely concentrated in 
intra-linked, embedded „clusters‟, the empirical evidence for these claims is more 
limited (Coenen et al 2004; Leibovitz 2004; see also Malmberg 2003; Malmberg and 
Power 2005). The thesis supports this more limited and hopefully nuanced 
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perspective. Thus although locational characteristics contribute to the innovation 
system, the collective and social processes of knowledge production within and across 
organisations, institutions and actors produces a spatially-constituted „virtuous‟ 
feedback mechanism and infrastructure (see Asheim and Gertler 2005; Fagerberg 
2005; cf Malmberg and Power 2005). In interpreting the implications of such spatial 
relations it is necessary to consider the links between local, national and global actors 
in meaningful ways that explain regional development as a consequence of locational 
attributes, relational linkages and interactional processes. This contrasts with a 
previous emphasis on the endogenous basis of knowledge, learning and innovation 
derived from the work of Schumpeter, Penrose, evolutionary economists and others 
(Best 2001; Cooke 2002c; Boschma 2004; Fagerberg 2005; Cooke and Leydesdorff 
2006). Instead it is necessary to consider the effect of the interface between local, 
national and global places, systems and processes that constitute regional 
development (e.g. Bathelt et al 2004).   
 
Consequently, the theoretical and empirical basis of this thesis raises a number of 
concerns around the pursuit of „knowledge economy‟ policies such as those built into 
the 2000 Lisbon Agenda or the particular regional and national policies on the biotech 
industry in the UK. As outlined in the thesis conclusion (Chapter 7), the state of the 
biotech industry is not robust with some questioning the „revolutionary‟ claims 
around biotechnology (Nightingale and Martin 2004) and its potential contribution to 
healthcare (Rasnick 2003; Arundel and Mintzes 2004; Joppie et al 2005) and in 
particular economic development. The latter is of most concern here in this discussion 
of the policy implications raised by the thesis conclusions and research findings. It is 
especially notable that the research and human investment in biotechnology has, so 
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far at least, not produced a viable (i.e. profitable) industrial sector based on 
biotechnology (see Ernst and Young 2003a; Lawrence 2006). Nor has this produced a 
noticeable impact on regional development in the most pertinent regions of the UK or 
Europe; i.e. less-favoured regions or old-industrial regions. Considering the expense 
and continuing uneven development of such regional economies, it is surprising that 
biotechnology and the knowledge economy more generally are offered as potential 
opportunities (Swyngedouw 2000; Sokol 2003). This chapter will therefore outline a 
number of ways that the thesis can critically contribute to the ongoing debate around 
regional development and the policies encouraged and engaged in around the 
knowledge economy and biotechnology.  
 
8.2 POLICY-MAKING IN THE KNOWLEDGE ECONOMY  
 
8.2.1 Cluster Policy Implications  
 
One initial concern is that the current UK government has seized upon the notion that 
national competitiveness – itself a contentious term (Budd and Hirmis 2004; Turok 
2004; Bristow 2005) – and therefore economic growth in Britain are dependent upon 
the expansion of a „knowledge economy‟ (see DTI 1998, 1999c; Brown 2005). In the 
1998 Competitiveness White Paper, Our Competitive Future, the government outlined 
how geographical and social organisation – e.g. clusters and networks – promote both 
regional productivity and regional development (see also HM Treasury 2001). In 
subsequent policy initiatives the government has therefore sought to encourage such 
organisational forms and capacity. For example, in 2000 they introduced an 
Innovative Clusters Fund to finance incubation and cluster infrastructure by regional 
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development agencies (RDA), which they complemented a year later with a Regional 
Innovation Fund (DTI 2003: 102-3). Across these cluster policies the position and 
importance of biotechnology has been pronounced with two Department of Trade and 
Industry reports concerning biotechnology clusters produced in 1999 called Biotech 
Clusters (DTI 1999a) and Genome Valley (DTI 1999b). Alongside the DTI, other 
government departments have produced policy documents that seek to promote 
cluster developments in Britain, such as the DETR (now ODPM) Planning for 
Clusters report (DETR 2000), the ODPM Our Towns and Cities report (ODPM 
2000[2004]), and the Treasury‟s Lambert Review (HM Treasury 2003).  
 
Consequently the promotion of clusters can be seen as a crucial aspect of regional 
development policies across multiple government departments as well as regional 
agencies like the RDAs in England and Scottish Enterprise in Scotland; in particular 
as a means for promoting the knowledge economy (HM Treasury 2001; DTI 2003). 
Specific cluster-oriented policies include legislation for Business Planning Zones to 
ensure “flexible planning regimes” for high-technology clusters in disadvantaged 
areas alongside a regional policy framework that encourage flexibility at the local 
policy level (HM Treasury et al 2003: 34). Part of this flexibility comes from the 
establishment of the English RDAs in 1999, which had a budget of £1.7 billion in 
2003/04, and the subsequent reforms to their financial structures (HM Treasury 2001: 
46-7). Most RDAs have identified biotechnology, in one form or another (e.g. 
biosciences, life sciences, healthcare), as a key sector in their regional economic 
strategies, no matter what the size of the sector in their region. For example, the South 
West Regional Development Agency (SWRDA) has identified biotechnology as an 
„emerging‟ sector even though the secondary data in the thesis showed that there were 
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only 11 biotechnology firms in that region. Another instance is the North West 
Development Agency (NWDA) which identified healthcare (and biotechnology) as a 
key sector even though the data shows only 31 biotechnology firms. More than in the 
South West, but significantly lower than would be expected for such a regional policy 
emphasis (see Figure 8.1). 
 
Figure 8.1: „Regional‟ Distribution of Biotechnology Firms 
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Source:  Various (see p.97). 
 
RDA policy in relation to the biotechnology industry appears over-enthusiastic with 
the focus on localised industrial clusters not only problematic because of the small 
number of biotechnology firms, but also in light of further findings from the 
secondary and primary data considered here. First, and in contrast to the cluster 
perspective, it is possible to illustrate the importance of national and global inter-
linkages over local ones in the development of biotechnology products, especially 
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biopharmaceuticals. Although the number developed by British firms is limited, one 
case study suffices to illustrate this point, that of Mylotarg® co-developed by Celltech 
Group plc (now part of UCB Pharma). Mapping the relationships involved in its 
development reveal that it arose from a diverse and diffused number of organisations 
and actors (see Figure 6.7, p.233).  
 
Secondly, the primary data shows that there were stronger localised associations 
between explicit and tacit knowledge for „non-clustered‟ respondents and stronger 
national and especially international associations for „clustered‟ respondents. This 
implied that clustered respondents drew upon national and international based 
knowledge more often, although there were differences between different 
concentrations. In some ways this contradicts the argument that clusters facilitate 
inter-linkages between local and global knowledge (e.g. Bathelt et al 2004) because 
there were also strong negative associations between locally and internationally based 
explicit and tacit knowledge. Overall, it was possible to argue that non-clustered 
respondents were the ones tied into localised knowledge and that such close spatial 
proximity was relatively unimportant for most actors. Consequently the focus on 
cluster policies may prove problematic for many regions because it could lock them 
into a particular set of relationships and expectations that prove hard to break. 
 
8.2. Regional Policy Implications 
 
Regional policy in the UK has its origins in the late 1920s with the establishment of 
the Industrial Transference Board designed to encourage the movement of workers 
between regions. Subsequent overcapacity and unemployment problems led to the 
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Special Areas Acts of 1934 and 1937 and the 1945 Distribution of Industry Act, 
which sought to aid industry and emphasise the positioning of industry in areas where 
workers already lived (Tondl 2001; Adams et al 2003; Armstrong and Taylor 2004). 
Since then the latter policy dimension has been dominant, although the position of 
regional policy in government agendas has often fluctuated. During the late 1940s and 
1950s there was little interest in it, although this changed in the 1960s when regional 
policy sought to address (a) the perceived decline of UK economic performance, and 
(b) concerns about the excessive growth of Greater London. During the 1980s this 
regional policy drive was dismantled as it became embedded in industrial policy 
focused on competitiveness, rather than social issues, especially in relation to science 
and technology: e.g. the 1993 Realising Our Potential White Paper (Potts 2002; 
Armstrong and Taylor 2004). 
 
Current regional policy (post-1997) continues to emphasise the importance of science 
and technology, especially in terms of improving productivity, which is highlighted 
by the government as the main factor affecting regional GDP difference (HM 
Treasury 2001; HM Treasury et al 2003). A series of Spending Reviews (1998, 2000, 
2002) have been directed at improving the performance of UK regions and reducing 
regional „growth rate‟ disparities, although not absolute disparities (see Adams et al 
2003: 5). The government has argued that productivity accounts for around 60% of 
these regional economic disparities (HM Treasury 2001), which in turn is 
characterised as the effect of five drivers including skills, investment, innovation, 
enterprise and competition (HM Treasury et al 2003). However, this emphasis on 
productivity has been criticised for a number of reasons. First, it relies upon a narrow 
evidence base derived from mainstream economic sources embodying both an 
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ahistorical and asocial understanding of regional development and performance 
(Forthergill 2005). Second, the lack of concern with differences in industrial structure 
and divisions of labour – both continuing issues in regional development – mean that 
the policy focus on productivity ignores the “elementary observation that different 
industries and services have different levels of value added per head” (Fothergill 
2005: 663; see also Bristow 2005).  
 
Since regional policy has focused on the endogenous features of different locations, it 
has promoted economic performance (i.e. competitiveness) above other aspects of 
regional development (i.e. sustainability, in the strong as opposed to weak sense – see 
Chatterton 2002). First, as the secondary data presented and discussed in Chapter 5 
illustrates, specific concentrations of biotechnology exhibited different characteristics. 
For example, some regions were university-based, whilst others are firm-based, whilst 
the relationship between knowledge factors (e.g. patents, alliances) and organisations 
was relatively similar across three different scales (NUTS1, NUTS2 and NUTS3) (see 
also Birch forthcoming). Consequently the representation of all regions as atomistic 
and bounded territories ignores the variety of regional composition and importance of 
multiple scales (see Phelps 2004). Second, the primary data showed that most 
knowledge, whether explicit, tacit, or commercial, was not localised. In particular, 
explicit knowledge was international, whilst tacit and commercial knowledge were 
national, although still more international than local. It is therefore important to 
emphasise that innovation processes operate across multiple spaces and scales that 
necessitate linkages between such dimensions above a focus on endogenous qualities. 
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8.2.3 National Policy Implications 
 
One possible reason why regional policy is so focused on competitiveness and 
productivity may be that it has been closely tied to national policy. For example, 
competitiveness has been the dominant policy concern for over two decades, at least 
since the founding of the US Council of Competitiveness in the early 1980s by the 
Reagan administration (see Tyson 1992; also http://www.compete.org/). It has been 
an increasing concern, despite being a contentious concept (Krugman 1996; Kitson et 
al 2004; Bristow 2005), across a number of different regional, national and 
supranational scales and across many different countries. In academic and policy 
discourse it is defined as the ability to produce goods/services for international 
markets and the ability to maintain and/or increase living standards (Tyson 1992; 
Krugman 1996; Rosamond 2002; Budd and Hirmis 2004; Kitson et al 2004; Turok 
2004; Bristow 2005; Cantwell 2005). National UK policy seems to have focused on 
competitiveness because of the assumption that globalisation has endangered the 
economic performance of countries because they have become more „open‟ to 
external trade, therefore driving the expansion and illustrating the importance of 
export-based production and services (Porter 2003). Thus the economic development 
of regions and nations has been constructed and constituted as a consequence of the 
performance of these locations in a global competitive market, characterised by the 
expansion of global inter-linkages and inter-dependencies across these regional and 
national economies (see Brown 2005; also The Sapir Group 2005).  
 
Part of the conceptualisation of economic performance as a consequence of locational 
(e.g. region, nation, trade bloc) competitiveness, means that these locations are 
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assumed to be competing for a share of global markets (Gardiner et al 2004). The 
characterisation of poor competitiveness of the European Union, in comparison to the 
USA, appears to be a self-confirming explanation for the lower levels of economic 
growth in the EU because the major global market is the US market. Consequently, 
any competitiveness policy designed to secure a greater share of global markets 
would, by definition, be aimed at securing a greater share of the US market and 
therefore sustaining the dominance of the US economy. In particular this means 
sustaining the technological solution, product development and organisational change 
that secure a greater share of this market (see Harvey 2003, 2005). For example, the 
global pharmaceutical and now biopharmaceutical markets are dominated by the 
North American market which represents 50 % (Thayer 2004) and 60 % (Bibby et al 
2003) of world sales respectively. Consequently countries are forced to adopt the 
institutional features of US capitalism such as the emphasis on particular types of 
innovation processes (see Cooke 2004d) or specific intellectual property rights 
(Drahos and Braithewaite 2002). This process is not simply one-way, however, with 
the USA increasingly adopting regulatory changes pursued by the EU to ensure 
competitiveness in pharmaceutical production (see Abraham and Reed 2002, 2003). 
 
A critical look at the concept of competitiveness reveals it to be a contentious concept 
because it is largely derived from the idea that locations (e.g. regions, nations) 
compete against one another, as would firms, for global market share. Despite being a 
problematic notion, the „competitiveness agenda‟ has come to dominate government 
policy in developed economies (see Slaughter and Rhoades 1996). In this agenda, the 
market is presumed to exist as an external environment in which firms, economic 
actors and even locations operate and compete; according to Schoenberger 
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“competitiveness simply describes the result of responding correctly to market 
signals” (quoted in Bristow 2005: 286). Instead, markets can be conceptualised as 
instituted processes – as Polanyi (1957) and others have suggested – in that the 
specific decisions and subsequent behaviour of actors constitute markets; i.e. they are 
internally produced.  
 
Since the biotech industry in the UK was unevenly spread, its systemic and dynamic 
development compounds the unequal concentration of firms and other organisations 
around the country (see Figure 5.16, p.195). The changing processes of interaction 
over time mean that the competitiveness of the national biotech industry is constituted 
by the operation of a small number of organisations in a limited number of places, 
primarily in the South-east and East of England, and, to a lesser extent Central 
Scotland. Consequently these regions come to represent the basis for national 
competition in the global biotechnology market, embedding the uneven spatial 
relationships further and the uneven access to and distribution of knowledge-based 
production factors like skilled labour, R&D investment and intermediate services (e.g. 
knowledge-intensive business services). These „growth regions‟ thereby dominate 
national industrial and competitiveness policy precluding other regions from 
„competing‟ in the same value-added sectors because such sectors necessitate an 
enormous historical investment in specific infrastructure. For example, these 
geographically uneven processes benefiting some regions at the expense of others 
have led, according to Jamie Peck (2001), to interest-rate policies that seek to control 
inflation in the South-east of England and London, but have led to manufacturing job 
losses in the North of England (Harvey 1999).  
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8.2.4 Supranational Policy Implications  
 
Simultaneous with the national agenda, policy at the European supranational level 
mirrors the changes in emphasis on the importance of competitiveness and the 
knowledge economy both with the 2000 Lisbon Agenda and the follow-up Sapir 
Group formed in 2002. In their report the Sapir Group outlined their aims as driving 
Europe to “become the most competitive and dynamic-knowledge-based economy 
with sustainable economic growth and greater social cohesion” (The Sapir Group 
2005: 962). These are exemplified in the present EU interest in the promotion and 
expansion of the „bio-economy‟ as a crucial part of this development of the 
knowledge economy. Thus the EU Science and Research Commissioner, Janez 
Potočnik, claims that the “life sciences and biotechnology are significant drivers of 
growth and competitiveness” (EC 2005: 1), whilst more broadly the OECD (2005: 1) 
has started an 18-month project to “design a bioeconomy policy agenda for 
governments”. The push to adopt a specific set of policies oriented towards promoting 
the knowledge economy, particularly in relation to biotechnology, entails a number of 
problematic issues concerned with the possibility of regional, national and 
supranational path dependency and lock-in to this agenda. 
 
First of all, although there has been an ongoing theoretical and research concern with 
the concepts of path dependency and lock-in in economics (e.g. Dosi 1988; Arthur 
1989, 1999) and regional studies (Boschma 2004; Hassink 2005; Hudson 2005), this 
has tended to focus specifically on innovation, technology and knowledge, rather than 
the overall economic system. Regional path dependency and lock-in are constituted 
through the operation of particular industrial sectors and the associated organisational 
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and institutional actors that embed processes of production, consumption and 
exchange embodying the features of the particular sector. Since regional performance 
has previously benefited from these embedded processes there is little motivation to 
change them; instead they are strengthened and deepened producing lock-in. This sits 
uneasily with the focus on regional drivers of growth and innovation because such a 
view privileges the status quo – e.g. current technologies and organisations (see 
Chapman et al 2004) – meaning that regions lose the capacity to adjust or adapt to 
changing circumstances (Hassink 2005). When they do change they become subject, 
once again, to another set of embedded processes of production, consumption and 
exchange.  
 
Secondly and alongside the concern with micro-scale path dependency and lock-in, 
there are broader questions about the problem of a wider, macro-scale lock-in to 
specific economic strategies, ideologies and processes encompassed by neoliberal 
discourse and policy (Peck 2004) or the „American economic model‟ (Kitson 2005). 
The work of Jamie Peck and Adam Tickell, jointly and individually, stresses the need 
to understand neoliberalism not as a “naturalized, external force” producing 
globalising effects, but instead as a “self-actualizing” discourse through which 
specific policies and structures are institutionalised as prescriptions for economic 
development; e.g. deregulation, privatisation, „free‟ markets (Peck and Tickell 2002: 
382). Such development is unevenly spread as neoliberal processes form their own 
localised identity through local policies, decisions and discourses (see Harvey 2005). 
Overall there is a threat that the pursuit of deregulation, privatisation and other 
neoliberal policies “produces a neoliberal “lock-in” to public-sector austerity and 
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growth-chasing economic development” (Peck and Tickell 2002: 394), where the 
consequences for certain regions are placed above those of other regions. 
 
Thus there are a number of criticisms that can be levelled at the „knowledge economy‟ 
focus in supranational policy. The main one is that the extent of knowledge-based 
employment is significantly lower than such policy prescriptions emphasise. This has 
been shown in the thesis in relation to the level of skilled employment in the biotech 
industry, which, at around 10,000 in the UK, may not warrant the public and private 
investment in the sector. Furthermore 46% of all British jobs are in sectors where 
under 15% of the workforce are graduates, mainly in the service sector (Hepworth and 
Spencer 2003: 7), whilst some of the highest growth occupations in the UK during the 
1990s – i.e. the height of the „knowledge economy‟ – were in hairdressing, 
educational assistants, welfare workers, telephone sales, nursery nurses, domestic 
staff and shelf-filling (see Figure 8.2).  
 
These changes during the height of the „dot.com‟ era illustrate the dominance of 
employment growth in sectors that cannot be characterised as hi-tech (e.g. 
hairdressing), high skilled (e.g. shelf-fillers) or dependent upon high levels of R&D 
investment (e.g. educational assistants), although they are all no less central to 
economic performance. In contrast it is possible to argue, as Thompson et al (2001) 
have done, that the high growth sectors of employment in developed economies have 
been in sectors dependent upon personal and communicative skills rather than 
knowledge skills. 
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Figure 8.2: Highest Growing Jobs in the UK 1992-1999 
0
50
100
150
200
250
300
350
H
a
ir
d
re
ss
in
g
M
a
n
a
g
e
rs
S
o
ft
w
a
re
E
n
g
in
e
e
rs
E
d
u
c
a
it
o
n
a
l
A
ss
is
ta
n
ts
W
e
lf
a
re
W
o
rk
e
rs
E
le
c
tr
ic
a
l
T
e
c
h
n
ic
ia
n
s
T
e
le
p
h
o
n
e
S
a
le
sp
e
o
p
le
B
u
si
n
e
ss
C
o
n
su
lt
a
n
ts
N
u
rs
e
ry
N
u
rs
e
s
D
o
m
e
st
ic
S
ta
ff
IT
 E
n
g
in
e
e
rs
S
h
e
lf
-F
il
le
r
%
 C
h
a
n
g
e
 1
9
9
2
-1
9
9
9
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A major question is whether the employment potential of the UK biotech industry 
warrants the material investment, especially in light of the finding that there were only 
around 43,000 direct jobs and 10,000 „knowledge economy‟ jobs (i.e. in R&D 
employment). Employment was also limited to an average of around 1200 total jobs 
per region with the South-east and East of England containing over half of all biotech 
employment (23,000).
xxiv
 Furthermore a significant proportion of the total university 
employment in „biotechnology‟ departments was also concentrated in the South-east 
and East of England although this time including London. In these circumstances, any 
focus on promoting the knowledge economy as the source of future growth and 
performance at a supranational level reinforces the advantages of such regions, 
especially when policies are pursued alongside those that promote the clustering and 
concentration of such „knowledge‟ sectors. The focus of policy on these „growth 
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regions‟ leads to the possibility that policies promoted as part of the knowledge 
economy are directed at a small number of already dominant and high performing 
regions at the expense of less favoured regions (see Swyngedouw 2000). 
 
From the primary data analysis it would be difficult to contend that there is one 
overall „knowledge economy‟ at the supranational scale that is effective for promoting 
regional economic performance and development across all regions. For example, 
survey respondents drew upon explicit sources of knowledge from more demand-side 
sources (i.e. customers, competitors) implying that they drew upon this „market-
making‟ knowledge, in innovation terms (see Fagerberg 2005), as opposed to tacit 
sources. In turn, respondents drew upon tacit knowledge from more supply-side 
sources (i.e. universities) and informal networks, implying that such knowledge was 
important for „technology-making‟. In particular, respondents highlighted the more 
„trusting‟ environment provided by the academic environment, which suggested that 
such tacit sources require an element of trustworthiness to reduce uncertainty (see 
Gertler 2003). However, the relationship between explicit and tacit sources cut across 
both demand-side and supply-side sources suggesting that in both cases there was a 
need for both explicit and tacit knowledge, rather than an approach that adopts a false 
dichotomy between both forms of knowledge (see Senker and Faulkner 1996).  
 
8.3 CONCLUSION 
 
The policy implications discussed above raise a number of issues for social scientists 
about their role in society. The relative dearth of technical, as opposed to market, 
innovations in relation to biopharmaceuticals – the predominant focus of much 
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biotechnological endeavour – may threaten the future funding of science and 
technology, not only in the biosciences but also in other new technologies: e.g. 
nanotechnology. However, it may also distract, more importantly for social scientists, 
resources and attention from other forms of problem solving such as economic, social 
and political change (see Duster 2003). What role then do social scientists play in the 
promotion and maintenance of a particular approach to understanding the social world 
and offering solutions to social problems? Thus by writing about the biotech industry 
and focusing on its potential and possible impacts, social scientists can unreflexively 
extol the benefits of such technologies to the world, society and regional 
development, despite the contentious nature of such claims. This thesis shows that the 
biotech industry has not – as yet at least – warranted such investment of time and 
money. This is not to say that it will not in the future, just that by focusing on it now 
we may inadvertently produce a self-fulfilling prophecy in which we help to embed a 
specific technological paradigm or technological trajectory that entails a number of 
problematic characteristics (see Ferraro et al 2005; Ghoshal 2005; Birch 2007).   
 
The challenge then comes from recognising where biotechnology both as an industry 
and a technological paradigm may have an important impact on our lives. In part, this 
may arise accidentally during the everyday processes of the dynamics between 
knowledge, space and technology. Or, more likely perhaps, it may arise as a 
consequence of deliberate policy initiatives pursued for particular agendas. In the 
latter case it is important to consider the specific intention and motivation behind 
these agendas in order to address the broader concern with economic development 
that benefits all equally, rather than producing and embedding further inequality and 
uneven development. In part then, this is a political issue and social scientists need to 
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acknowledge this in order to avoid adherence to certain policies and politics. The 
„knowledge economy‟ may not exist as it has been constituted and characterised by 
policy-makers, academics and others, but it can still offer an inspiring vision of 
society. It is question of how we separate this vision (or visions) from its actuality (or 
actualities) that we must ultimately address.  
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PART III 
 
SUMMARY 
 
Part III provides the final touches to the thesis by outlining the major theoretical 
conclusions and analytical findings from the research process. As a whole the process 
has been driven by a theoretical and methodological framework that sort to 
concentrate on the „basics‟ of the innovation process, namely the types, forms and 
sources of knowledge that successful innovators access along a particular 
biotechnology value chain. As such it has shown that the knowledge economy is built 
upon a dynamic that combines knowledge and spatial processes, which means that a 
focus on the internal operations of any innovation system will occlude the important 
external inputs. However, to conceive of them as „external‟ misses the point. They are 
as much part of the innovation process as the „internal‟ features because they directly 
impact on the success or failure of innovation. Consequently we can conceive of 
innovation as the effect of a knowledge-space dynamic which operates across 
different scales and is embedded in different places, all of which contribute in some 
way to the specificities of innovation. 
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APPENDICES
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APPENDIX 3.1 MIXED METHODS SURVEY CODING FRAME 
 
QUESTION      ANSWER  CODE  
 
SECTION A: Relationships 
 
1. Please rate how often you read information from the following sources. 
  
Manufacturers      No information  0 
READMAN      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Competitors      No information  0 
READCOM      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Suppliers      No information  0 
READSUP      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Customers      No information  0 
READCUST      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Business Consultants     No information  0 
READCONS      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Universities      No information  0 
READUNI      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
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Public Research Organisations   No information  0 
READPRO      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Regulators      No information  0 
READREG      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Trade Associations     No information  0 
READTA      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
2. Please indicate where these sources of information are produced. 
 
Local       No information  0 
LOCLREAD      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
National      No information  0 
NATREAD      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
International      No information  0 
INTREAD      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
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3. Please rate how often you talk to people from the following sources. 
  
Manufacturers      No information  0 
PPLMAN      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Competitors      No information  0 
PPLCOMP      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Suppliers      No information  0 
PPLSUP      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Customers      No information  0 
PPLCUST      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Business Consultants     No information  0 
PPLCONS      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Universities      No information  0 
PPLUNI      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Public Research Organisations   No information  0 
PPLPRO      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
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       All the time   5 
 
Regulators      No information  0 
PPLREG      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
Informal Networks     No information  0 
PPLINFOR      None    1 
       1-2 times a year  2 
       Intermittently   3 
       Regularly   4 
       All the time   5 
 
4. Please indicate where these people are located. 
 
Local       No information  0 
LOCLPPL      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
National      No information  0 
NATPPL      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
International      No information  0 
INTPPL      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
5. Please rate the importance of the following sources of finance to innovation. 
   
Personal Finance     No information  0 
FINPF       Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
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Business Angels     No information  0 
FINANGEL      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Venture Capital     No information  0 
FINVC      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Government Awards/Schemes   No information  0 
FINGOV      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Bank Loans      No information  0 
FINBANK      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Contract Work     No information  0 
FINCONTR      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Equity Investments     No information  0 
FINEQUIT      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
6. Please indicate where the finance sources are based. 
 
Local       No information  0 
LOCALFIN      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 317 
 
National      No information  0 
NATFIN      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
International      No information  0 
INTFIN      No sources   1 
       A few sources   2 
       Some sources   3 
       A lot of sources  4 
       Most sources   5 
 
SECTION B: Location 
 
7. Please rate the quality of the following in your region. 
 
Labour Costs      No information  0 
COSTLAB      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Housing Costs      No information  0 
HOUSCOS      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Traffic Levels      No information  0 
TRAFFIC      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Access to International Airport   No information  0 
AIRPORT      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
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Access to National Road Network    No information  0 
ROAD       Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Access to Rail Network    No information  0 
RAIL       Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Business Advice Services    No information  0 
BUSADVIC      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Social Forum      No information  0 
SOCIALF      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Corporate Forum     No information  0 
CORPF      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Professional Associations    No information  0 
PROFASS      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
Cost of Premises     No information  0 
COSTPREM      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
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Availability of Premises    No information  0 
AVAPREM      Awful    1 
       Bad    2 
       Ok    3 
       Good    4 
       Excellent   5 
 
8. Please indicate the importance of the following geographic labour markets in the 
recruitment of innovative staff. 
 
8a. Technical & Scientific Staff 
 
Local       No information  0 
LABTECLO      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
National      No information  0 
LABTECUK      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
International      No information  0 
LABTECIN      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
8b. Managerial Staff 
 
Local       No information  0 
LABTECLO      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
National      No information  0 
LABTECUK      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
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International      No information  0 
LABTECIN      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
9. Please rate the importance of the following in attracting technical and managerial 
staff to your region. 
 
Wages       No information  0 
WAGES      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Working Conditions     No information  0 
WORKCON      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Regional Reputation     No information  0 
REGREP      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Social Network     No information  0 
SOCIONET      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
10. Please rate the importance of the following internal sources of knowledge to 
innovation. 
 
Technical & Scientific Staff    No information  0 
TECSTAFF      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
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Managerial Staff     No information  0 
MANSTAFF      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Scientific Methodology    No information  0 
SCIMETH      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Management Practices    No information  0 
MANPRAC      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
  
Experience with Equipment    No information  0 
EQUIP      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Facilities      No information  0 
FACILITY      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Collaborations      No information  0 
COLLAB      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
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SECTION C: External Influences 
 
11. Please rate the importance of the following to innovation. 
 
National Patent     No information  0 
NATPATEN      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
International Patent     No information  0 
INTPATEN      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Other Intellectual Property Rights   No information  0 
OTHERIPR      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Commercial Secrecy     No information  0 
COMSECRE      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
Employee Skills & Experience   No information  0 
SKILL       Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
12. Please rate the importance of the following markets for innovations.   
 
Local       No information  0 
DEMLOC      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
 323 
National      No information  0 
DEMNAT      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
International      No information  0 
DEMINT      Not important   1 
       Not very important  2 
       Slightly important  3 
       Important   4 
       Very important  5 
 
13. Please rate the effect of the following UK government interventions on 
innovation. 
 
Procurement      No information  0 
PROCURE      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
 
Tax Policy      No information  0 
TAXPOL      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
 
Health Policy      No information  0 
HEALTH      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
 
R&D Policy      No information  0 
RDPOL      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
 
Public Science Investment    No information  0 
PUBSCI      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
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       Vital effect   5 
 
Intellectual Property Laws    No information  0 
IPRREG      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
 
Health & Safety Regulations    No information  0 
HEALTHRE      No effect   1 
       Little effect   2 
       Some effect   3 
       Effect    4 
       Vital effect   5 
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APPENDIX 3.2: BIOTECHNOLOGY PRODUCT SAMPLE 
 
Product Type Sector Launch / 
Approval 
Date 
MAIN Research Location Second Third Fourth 
Vaccine Therapeutic 2001 East Anglia USA Austria x 
Test Diagnostic 2003 East Anglia x x x 
Test Diagnostic 2005 Gloucestershire, Wiltshire & 
N. Somerset 
x x x 
Food test Diagnostic 1998> South Western Scotland x x x 
Treatment Therapeutic 1993> Cheshire x x x 
Animal resistance Agriculture 1988> East Anglia x x x 
Test Diagnostic  East Anglia East Anglia x x 
Animal resistance Agriculture 1984> East Wales East Wales East Anglia x 
Animal resistance Agriculture 1984> East Wales East Wales Kent x 
Animal resistance Agriculture 1984> East Wales East Wales USA x 
Vaccine Therapeutic 1994 Surrey, East and West Sussex x x x 
Test Diagnostic 2000 Berkshire, Buckinghamshire 
and Oxfordshire 
Ireland x x 
Biomaterial  Therapeutic 2001> Inner London Inner London East Anglia x 
Marine test Agriculture 2001> Eastern Scotland x x x 
Platform 
technology 
Services 1999> East Anglia East Anglia  x 
Software Services 1999> East Anglia East Anglia  x 
Animal test Agriculture 1995> Eastern Scotland x x x 
Drug delivery Therapeutic 1999 Surrey, East and West Sussex Inner London x x 
Biomaterial Services 2001 West Midlands West Midlands x x 
Platform Services 2002 Kent x x x 
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technology 
Platform 
technology 
Services 1997> Kent Outer London x x 
Treatment Therapeutic 200 Inner London Eastern Scotland x x 
Test Diagnostic 2000 East Anglia South Africa x x 
Platform 
technology 
Services 1998 North East Scotland x x x 
Platform 
technology 
Services 1990> East Anglia x x x 
Platform 
technology 
Services 1990> East Anglia East Anglia USA USA 
Platform 
technology 
Services 1990> East Anglia x x x 
Drug Therapeutic 2002 East Anglia USA x x 
Test Diagnostic 1981> East Anglia x x x 
Drug Therapeutic 2001 Berkshire, Buckinghamshire 
and Oxfordshire 
Merseyside x x 
Drug Therapeutic 2000 Berkshire, Buckinghamshire 
and Oxfordshire 
USA USA x 
Drug Therapeutic 1999 Berkshire, Buckinghamshire 
and Oxfordshire 
East Anglia USA x 
Vaccine Therapeutic 2000 Berkshire, Buckinghamshire 
and Oxfordshire 
Merseyside x x 
Test Diagnostic 1992> East Anglia x x x 
Test Diagnostic 1992> East Anglia x x x 
Drug (delivery) Therapeutic 2000 East Anglia South Western 
Scotland 
x x 
Bioremediation Environment 2003 Surrey, East and West Sussex x x x 
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Test Diagnostic 2000> Northumberland and Tyne & 
Wear 
x x x 
Software Services 2001> Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, Buckinghamshire and 
Oxfordshire 
x 
Drug (delivery) Therapeutic 1995 South Western Scotland x x x 
Test Diagnostic 1999 Berkshire, Buckinghamshire 
and Oxfordshire 
x x x 
Platform 
technology 
Services 2002> Eastern Scotland Eastern Scotland x x 
Delivery system Therapeutic 1996> Eastern Scotland x x x 
Platform 
technology 
Services 1996> Eastern Scotland France x x 
Software Services 1996> Eastern Scotland Eastern Scotland x x 
Platform 
technology 
Services 1996> Eastern Scotland West Yorkshire West Yorkshire x 
Platform 
technology 
Services  East Anglia x x x 
Platform 
technology 
Services 2005 Inner London Inner London x x 
Platform 
technology 
Services 2002 Kent x x x 
Animal feed Agriculture  Gloucestershire, Wiltshire & 
N. Somerset 
Denmark x x 
Animal feed Agriculture  Gloucestershire, Wiltshire & 
N. Somerset 
Denmark x x 
Treatment Therapeutic  Northern Ireland x x x 
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Treatment 
(delivery) 
Therapeutic  Northern Ireland Ireland x x 
Treatment Therapeutic 2001 East Anglia China x x 
Test Diagnostic 1999> Greater Manchester Greater Manchester x x 
Drug Therapeutic 1986 Outer London Kent x x 
Drug Therapeutic 1986 Outer London Kent x x 
Test Diagnostic  Northumberland and Tyne & 
Wear 
x x x 
Platform 
technology 
Services 1999> Inner London East Anglia Inner London x 
Treatment Therapeutic 1984 Berkshire, Buckinghamshire 
and Oxfordshire 
East Wales x x 
Drug Therapeutic  Berkshire, Buckinghamshire 
and Oxfordshire 
Gloucestershire, 
Wiltshire & N. 
Somerset 
x x 
Test Diagnostic 1998 Surrey, East and West Sussex x x x 
Intermediate 
manufacture 
Services 1992 Berkshire, Buckinghamshire 
and Oxfordshire 
x x x 
Drug delivery Therapeutic 2000 Shropshire & Staffordshire USA x x 
Treatment Therapeutic 2002 Shropshire & Staffordshire USA x x 
Treatment Therapeutic 2000 Shropshire & Staffordshire South Yorkshire Inner London x 
Platform 
technology 
 2002> Greater Manchester Greater Manchester x x 
Test Diagnostic 1997> Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, 
Buckinghamshire 
and Oxfordshire 
x x 
Test Diagnostic 2000> Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, 
Buckinghamshire 
and Oxfordshire 
x x 
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Software Services  Berkshire, Buckinghamshire 
and Oxfordshire 
USA x x 
Drug Therapeutic 2002 Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, 
Buckinghamshire 
and Oxfordshire 
Switzerland x 
Test Diagnostic  Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, 
Buckinghamshire 
and Oxfordshire 
x x 
Animal treatment Agriculture 2000 Kent x x x 
Platform 
technology 
Services 1996> Bedfordshire & Hertfordshire x x x 
Platform 
technology 
Services 1996> Bedfordshire & Hertfordshire x x x 
Animal treatment Agriculture 2004 East Anglia x x x 
Vaccine Therapeutic 1988 Berkshire, Buckinghamshire 
and Oxfordshire 
Merseyside x x 
Vaccine Therapeutic 1993> Berkshire, Buckinghamshire 
and Oxfordshire 
Sweden x x 
Drug delivery Therapeutic  Berkshire, Buckinghamshire 
and Oxfordshire 
Berkshire, 
Buckinghamshire 
and Oxfordshire 
x x 
Drug delivery Therapeutic 1993> Berkshire, Buckinghamshire 
and Oxfordshire 
x x x 
Vaccine Therapeutic  Berkshire, Buckinghamshire 
and Oxfordshire 
Merseyside x x 
Platform 
technology 
Services 1999> East Anglia Canada x x 
Platform 
technology 
Services 1999> East Anglia East Anglia x x 
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Test Diagnostic  Inner London Cheshire Ireland USA 
Drug Therapeutic 2000 Inner London Cheshire West Wales & the 
Valleys 
USA 
Test Diagnostic 1997 East Wales x x x 
Test Diagnostic 2000 East Wales Isle of Man Canada x 
Test Diagnostic 1999 East Wales Denmark x x 
Platform 
technology 
Diagnostic 2003 Northern Ireland x x x 
Bioremediation Environment 1994> South Yorkshire x x x 
Bioremediation Environment 1994> South Yorkshire x x x 
Test Diagnostic 2000> Hampshire and Isle of Wight x x x 
Drug Therapeutic  Eastern Scotland Northern Ireland x x 
Treatment Therapeutic 1999 USA East Anglia x x 
Drug Therapeutic 2001 Hampshire and Isle of Wight x x x 
Drug Therapeutic  Hampshire and Isle of Wight Canada Berkshire, 
Buckinghamshire 
and Oxfordshire 
x 
Platform 
technology 
Diagnostic 2000> East Anglia East Anglia x x 
Test Diagnostic 2005 Berkshire, Buckinghamshire 
and Oxfordshire 
x x x 
Treatment Therapeutic 2001 East Riding USA x x 
Platform 
technology 
Services 2005 East Anglia x x x 
Test Diagnostic 1992> East Wales Greater Manchester x x 
Treatment Therapeutic 2001 North Yorkshire x x x 
Test Diagnostic 1998 East Anglia Kent x x 
Test Diagnostic 1995> Bedfordshire & Hertfordshire x x x 
 331 
Treatment Therapeutic 2002> Eastern Scotland USA x x 
Drug delivery Therapeutic 2002 East Anglia USA x x 
Platform 
technology 
Services  East Anglia South Western 
Scotland 
x x 
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APPENDIX 3.3: BIOTECH PRODUCT CHARACTERISTICS 
 
3.3.1 Location 
 
In relation to the products, around 44 percent of them had R&D that occurred in more 
than one location in the UK. The two main locations for R&D were East Anglia 
(23.6%) and Berkshire, Buckinghamshire and Oxfordshire (19.8%). Only three other 
locations had more than minimal levels; these were West Wales and the Valleys 
(5.7%), Inner London (5.7%), and Eastern Scotland (8.5%). In relation to the 
secondary R&D site, where relevant, the most significant sites were again East Anglia 
(21.3%) and Berkshire, Buckinghamshire and Oxfordshire (14.9%). Another four 
sites were also important: Kent (8.5%), Inner London (8.5%), Greater Manchester 
(6.4%) and Eastern Scotland (6.4%).  
 
A cross-tabulation of the primary and secondary R&D locations reveals that products 
from Berkshire, Buckinghamshire and Oxfordshire represent the most products with a 
secondary location (30.4% of the total). In these cases 85.7% of the time the primary 
location was also Berkshire, Buckinghamshire and Oxfordshire. As such the 
knowledge used in their development, whether internal or external, was locally based. 
This appears to be the same in most other regional cases, although East Anglia 
represented a popular secondary location across the board in that only 44% of the 
primary and secondary locations corresponded. 
 
3.3.2 Sector 
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Most of the 107 products were derived from only three sectors within the industry: (i) 
therapeutic, (ii) diagnostic and (iii) services (e.g. platform technologies). Just over a 
third were therapeutic products (35%), whilst another quarter (25%) were diagnostic 
and 17 percent were services. Apart from these three sectors, the only other sector 
represented above a minimal level was the agriculture sectors at nearly 6 percent of 
the total products.  
 
The three major sectors were concentrated in specific regions of the UK. The 
therapeutic products came from four regions, although the majority were concentrated 
in Berkshire, Buckinghamshire and Oxfordshire. The regions were Shropshire and 
Staffordshire (3 of 36), East Anglia (5), Eastern Scotland (3), and Berkshire, 
Buckinghamshire and Oxfordshire (12). In the services sector the products were 
concentrated in Kent (3 of 18), East Anglia (8), and Eastern Scotland (3). Finally the 
diagnostic sector was concentrated in West Wales and the Valleys (3 of 27), East 
Anglia (8), and Berkshire, Buckinghamshire and Oxfordshire (6). Of the less 
represented sectors, agriculture was concentrated in West Wales and the Valleys 
(50%) and bioinformatic was concentrated in Inner London (33%) and Berkshire, 
Buckinghamshire and Oxfordshire (33%). 
 
3.3.3 Launch Date 
 
The launch date of the products is sometimes difficult to discover; therefore some of 
the following is based on an assessment of when a firm started operating rather than 
an official launch date. Even with this caveat, there are only details for 91 products. 
The data shows that just over half (50%) of the products were launched between 1999 
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and 2002. Nearly 10 percent were launched in the 1980s, with the earliest being 1981. 
Between 1991 and 1998 another 32 percent were launched. Most of the products 
launched between 1999 and 2002 originated in either East Anglia (11) or Berkshire, 
Buckinghamshire and Oxfordshire (9). 
 
3.3.4 R&D Influence 
 
Around 45 percent of the products‟ R&D occurred in external institutions as well as – 
or instead of - the marketer, of which half occurred in either universities (45.8%) or 
public research organisations (PRO) (4.2%). Around 40 percent occurred in other 
firms and the final 10% occurred in multiple settings. Some of this externally 
conducted R&D also occurred in foreign countries. Around 20 percent of all the 
products had some form of R&D conducted overseas, with the majority of this taking 
place in the USA (47.6%) or EU (33.3%).  
 
3.3.5 Overall 
 
Most R&D occurred in two locations: East Anglia, and Berkshire, Buckinghamshire 
and Oxfordshire. Of these East Anglia appears to be the most open location since 
where Berkshire, Buckinghamshire and Oxfordshire was a secondary location it 
invariable relates to a product originating in the same location. East Anglia also 
represents a significant secondary location, ahead of Berkshire, Buckinghamshire and 
Oxfordshire, for other regions to draw upon. This may be an indication of the type of 
product in that therapeutic products predominantly came from Berkshire, 
Buckinghamshire and Oxfordshire, whilst research and diagnostic products came 
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from East Anglia. It is also significant to note that the products were launched 
relatively recently, over 50 percent since 1999. 
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APPENDIX 5.1: REGIONAL ORGANISATIONAL DISTRIBUTION 
NUTS2 FIRMS 
UNIVERSITY 
DEPTS 
SERVICE 
PROVIDERS PROs 
Tees Valley & Durham 4 4 0 0 
N‟ land, Tyne & Wear 6 9 6 0 
Cumbria 2 0 2 2 
Cheshire 10 0 8 0 
Greater Manchester 14 12 14 3 
Lancashire 1 3 2 0 
Merseyside 4 8 4 0 
East Riding  1 3 1 0 
N. Yorkshire 9 2 3 1 
S. Yorkshire 2 5 5 0 
W. Yorkshire 3 8 10 0 
Derbyshire & 
Nottinghamshire 7 9 8 1 
Leics, Rutland & 
Northampton 0 12 5 3 
Lincolnshire 1 0 0 1 
Herefordshire, 
Worcestershire & 
Warwickshire 2 0 3 1 
Shropshire & Staffordshire 4 3 1 0 
West Midlands 3 12 9 0 
East Anglia 65 13 49 15 
Bedforshire & 
Hertfordshire 9 3 21 5 
Essex 8 1 1 0 
Inner London 62 46 149 12 
Outer London 4 4 3 1 
Berks, Bucks & Oxon 68 14 50 12 
Surrey, E. & W. Sussex 22 6 22 5 
Hamps & Isle of Wight 9 5 5 2 
Kent 5 1 13 1 
Gloucs, Wiltshire & N. 
Somerset 6 12 13 5 
Dorset & Somerset 2 0 2 0 
Cornwall 1 0 0 0 
Devon 2 6 4 3 
W. Wales & the Valleys 11 6 6 6 
E. Wales 11 8 4 3 
N.E. Scotland 7 7 2 2 
E. Scotland 39 14 17 13 
S.W. Scotland 18 11 23 5 
Highlands & Islands 3 1 0 3 
N. Ireland 11 7 5 1 
Total 436 255 470 106 
Mean 11.8 6.9 12.7 2.9 
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ENDNOTES 
 
 
                                                          
i
 NUTS1 scales are used by the European Union (EU) to designate areas with between 3 million and 7 
million people http://ec.europa.eu/comm/eurostat/ramon/nuts/basicnuts_regions_en.html (accessed 
December 2006). 
ii
 It is also important to emphasise that Schumpeter positioned science and invention as exogenous 
influences on the firm during his earlier work (Rosenberg 1976; Freeman 1982). 
iii
 Some authors raise the obvious point that knowledge was crucial to the Industrial Revolution (e.g. 
Mokyr 2002) and therefore we could argue that knowledge has always been a central feature of 
economic development. However, the more relevant discussions around the knowledge economy also 
focus on specific features of economic change, such as the shift to service sector employment or 
growth in information technology, as specific features of current trends (e.g. Bell 1973; Castells 1996). 
iv
 Godin (2006) provides a list of 75 different „buzzwords‟ used between 1950 and 1984 to describe 
changing industrial structures in developed economies, including the „knowledge economy‟.   
v
 As a sidenote it is interesting to point out that Machlup was von Mises doctoral student and an active 
member of the Mont Pelerin Society, founded by Hayek and von Mises in 1947, along with Michael 
Polanyi who met Daniel Bell in the 1950s (Hull 2000). According to Hull (2000) the discussions 
around „knowledge‟ that the likes of Machlup, Polanyi and Bell engaged in were a direct response to 
their view of the dangers of totalitarian ideologies. However, the Mont Pelerin Society, Hayek, von 
Mises and others are also the forebears of what is now termed neoliberalism – i.e. the unfettered 
influence of markets on society – which has been identified as an ideology in its own right (Armstrong 
2001; Blyth 2002; Harvey 2005). 
vi
 This definition includes (1) new information technologies, (2) the importance of science, (3) 
globalisation, and (4) changing consumption patterns (DTI 1999c: 12). 
vii
 The relationship between the public science base and industry has also been problematised in 
research on conflicts of interest and bias in biomedical research (see Agryres and Liebeskind 1998). 
This has shown that academic-industry ties influence the likelihood to publish, intellectual exchange, 
and research agendas (Blumenthal et al 1986) and also that it influences the publication of data from 
clinical trials (Krimsky 2003). 
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viii
 The various functional, relational and associational features of the innovation process are illustrated 
in the Table below. As can be seen from the table, each aspect has unique properties that both 
precludes its designation as the „single‟ cause of innovation and precludes ignoring those aspects 
altogether. 
 
Table: The Functional, Relational and Associational Features of the Innovation Process 
 FUNCTIONAL RELATIONAL ASSOCIATIONAL 
Growth Conditions Material Social Interactional 
Market Advantage Comparative Competitive Complementary 
Agglomeration Economies Scale Scope Complexity 
Institutional Basis Hierarchy Market Network 
Knowledge Source Internal External Iteration 
Proximity Spatial Organisational Social 
 
ix
 It is important to note that the NIS literature is broadly speaking technologically determinist in that it 
ascribes to the long-wave model of technological change or the view that “Capitalism is characterized 
by unpredictable technological development paths” (Lagendijk 2006: 389). Consequently regions 
adjust to such changes as well as stimulate them.  
x
 The origins of „old‟ institutional economics are found in the late nineteenth and early twentieth 
century work of Thorstein Veblen (1857-1929) who critiqued the concept of „rational economic man‟ 
and argued that institutions represented a repressive force on human creativity (Foster 1991; Hodgson 
2005). The later work of John Commons (1862-1945) sought to address this initial negative view of 
institutions by suggesting that they enable humans to act collectively and therefore lead to economic 
growth and development; this in turn led to an evolutionary perspective that incorporated cooperation 
into economic action (Foster 1991; Hodgson 2005). Somewhat in contrast to this approach, „new‟ 
institutional economics developed around the work of Ronald Coase (b.1910) and his famous article on 
the firm (Coase 1937). This work was developed by Oliver Williamson – who coined the „new‟ 
definition – in the 1970s as an attempt to incorporate the rational actor into an institutional approach 
(Hodgson 2005) and concerns different modes of organising economic activity. 
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xi
 GREMI stands for Groupement Europeen des Milieux Innovateurs (Simmie 2005). 
xii
 The importance of „culture‟ has also been highlighted by a number of authors, particularly AnnaLee 
Saxenian (1994a, 1994b), whose research showed how Silicon Valley and Route 128 (Boston) had 
different corporate cultures that affected the development of both regions (see also Gertler 1997). 
xiii
 Even if wealth drives knowledge, as Sokol (2003, 2004) contends, we can still argue that the 
success of regional economies is dependent upon innovation, where innovation is conceived as a 
process of profit production – e.g. the search or construction of new markets through institutional 
change (see Birch 2007). 
xiv
 There has been a strong interest in value chains and similar approaches since the work of Porter, 
although often originating in very different fields. For example, there is considerable work on the idea 
of global commodity chains (GCC) which is derived from the World Systems theory (Hopkins and 
Wallerstein 1994) and propounded by the likes of Gary Gereffi (1994, 1996, 2001a, 2001b; Gereffi et 
al 2005). Other perspectives, such as global production networks (GPN) have come out of economic 
geography (Coe et al 2002; Ernst and Kim 2002; Henderson et al 2004). 
xv
 https://fame.bvdep.com/cgi/template.dll?product=1 (last accessed December 2006). 
xvi
 Through licensing Cohen and Boyer‟s patented rDNA technique earned over $200 million between 
1975 and 1997 for their two universities and themselves (Dutfield 2003: 138). 
xvii
 The dates for the foundation of the Biotechnology Directorate at SERC and Biotechnology Unit at 
the DTI vary across sources. 
xviii
 http://www.merlin-biosciences.com/People/VentureTeam.asp (last accessed December 2006). 
xix
 Because origin was based on marketing company, the development of the product could have 
occurred in a different country. 
xx
 Ernst and Young (2004: 17) claim that 50 percent of the 2003 sales of the top 13 blockbuster 
biologics “initially developed by biotech companies” accrued to „big pharma‟. 
xxi
 The first blockbuster biopharmaceutical (Bibby et al 2004). 
xxii
 Countries like Germany, Sweden and Denmark had such regimes (Senker et al 2000). 
xxiii
 It is important to note that whilst the number of pharmaceutical approvals has declined in recent 
years, the level of profit has not. McKinnon et al (2004: 3) showed that whilst the number of new drugs 
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has fallen by 33 % between 1998 and 2002, the “sales potential” of these new drugs has increased by 
57 % per drug. 
xxiv Berkshire, Buckinghamshire and Oxfordshire (9235 jobs), East Anglia (4654), Surrey, East and 
West Sussex (3721), Hampshire and Isle of Wight (2951), and Bedfordshire and Hertfordshire (2535). 
